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Upon translation into the endoplasmic reticulum (ER), ER resident proteins, and those destined 
for the secretory pathway, must be correctly folded into their native structure to be functional. 
During folding, many proteins must form disulphide bonds, a process facilitated by protein 
disulphide isomerase (PDI). Endoplasmic reticulum oxidoreductase 1 (Ero1) catalyses the 
formation of disulphides, using molecular oxygen as a terminal electron acceptor to drive the 
reoxidation of PDI. Ero1 must be tightly regulated to maintain the redox balance of the ER. One 
way in which this is achieved is by switching between an active or inactive state. Homocysteine, 
a precursor in the metabolism of cysteine and methionine, has been shown by the laboratory 
to induce the active form of Ero1α (OX1) in oesophageal cells. This finding was further 
investigated in this thesis using conformation-specific and anti-tag antibodies. Homocysteine is 
shown to induce an OX1 form in both transfected Ero1α and Ero1β. Ero1 OX1 was seen in 
multiple cell lines and in liver, but not pancreas tissue. This highlights the possibility that 
oxidative protein folding may be subjected to different regulation between tissues, depending 
on the redox poise. The site of homocysteine action, was investigated using Ero1α cysteine-to-
alanine and Ero1β structural mutants. The data suggest that Ero1α is indirectly post-
translationally modified by homocysteine at an antibody epitope site and not the CxxC redox-
active cysteine residues.  
 
The consequences of manipulating the oxidative folding environment were also examined by 
analysing a client protein, namely the MHC class II complex. These proteins are essential for 
the presentation of externally derived antigens to helper T cells.  The disulphide containing 
II 
 
MHC II molecules are folded in the ER, and the laboratory have previously shown that there 
are differences between the 3 isotypes (HLA-DR, DP and DQ) in their requirements to form 
stable dimers. Work in this thesis shows that the thermal stability of DPheterodimers is 
greater than that of DR heterodimers. However, homocysteine does not influence the 
ability of MHC class II molecules to form stable dimers.  
 
The studies presented in this thesis have implications for diseases such as cancer, where ER 
and oxidative stress may involve dysregulation of the oxidative folding machinery. High 
expression of Ero1α has recently been associated with cancers of the oesophagus and stomach, 
and low expression of Ero1 has been associated with poor prognosis of cancers such as 
osteosarcoma. Thus manipulating the ER redox poise through small molecules such as 
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1. General Introduction   
 
1.1 Protein folding  
 
The ability of denatured proteins, which have lost their native three-dimensional structure, to 
refold into a structure in which their original biological function is restored led to the idea that 
a proteins amino acid sequence holds all the necessary information for its correct folding 
(Anfinsen, 1973). In order to fold correctly, many proteins must form a compact structure 
where hydrophobic regions are buried within the structure and hydrophilic regions are 
accessible to solvents. When the secondary and tertiary structures have formed, and the 
protein has undergone any necessary processing and is able to function, it is said to be in its 
native state. According to Levinthal’s paradox, it is not possible to acquire a native protein 
structure, to be compatible with biological constraints, by randomly or systematically testing 
all of the theoretical conformations (Levinthal, 1968). As the native structures of proteins tend 
to be the most thermodynamically favoured, the native interactions between amino acids in 
an unfolded or incompletely folded protein will be more stable, and so more persistent, 
meaning that not all conformations need to be sampled by the protein as it folds (Wolynes et 
al., 1995). The route to the native state is further directed by temporal, spatial and physical 
constraints, such as pH, temperature and protein concentration. However, even when these 
constraints are accounted for, in vitro it takes denatured bovine pancreatic ribonuclease 10 
times longer to regain its native structure than it takes for the synthesis of this structure in vivo. 
Furthermore, the time taken to regain its native structure was increased and the misfolded 
protein load was increased when the concentration of denatured bovine pancreatic 
ribonuclease was folded in vitro at physiological concentrations (Goldberger, 1963). Thus, a 
number of strategies exist to optimise protein folding by preventing protein aggregation, 
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removing misfolded proteins and facilitating correct folding interactions. In the cell, these 
activities are governed by various folding factors, such as molecular chaperones, that start 
acting as soon as proteins are translated and continue until the protein has reached its 
intracellular or extracellular destination in a functional form. 
 
1.2 Protein folding in the ER 
 
There are two types of endoplasmic reticulum (ER). In the absence of bound ribosomes the ER 
is defined as smooth ER (sER), and is termed rough ER (rER) in their presence. sER is generally 
less common but can be found in abundance in certain specialised cells, especially those 
involved in lipid metabolism. In hepatocytes, for example, the sER contains the Cytochrome 
P450 family which are involved in metabolism and generally can detoxify a wide array of 
endogenous and exogenous compounds. Drug and cholesterol are examples of substances 
broken down by cytochrome P450s oxidative, peroxidative and reductive activities. The rER 
houses more translocation, folding and modification proteins (to be discussed further in 
sections 1.4, 1.5, 1.6 and 1.9) (Gilchrist et al., 2006). 
 
The rER is responsible for the folding and assembly of the majority of extraceullular, surface-
expressed, secretory and endosomal eukaryotic proteins. As a separate compartment in the 
cell, it is able to provide an environment that differs significantly from the rest of the cell. The 
compartment has high molecular crowding with 300-400gL-1 protein, which is 3-6x more than 
that of the cytosol (Braakman, 2013; Gidalevitz et al., 2013). The redox potential of the ER is up 
to 200x more oxidising than the cytosol, which facilitates disulphide bond formation and 
supports a specialised chaperone and protein modification machinery (discussed in sections 
1.4, 1.5, 1.6 and 1.9). 




The distinct environment formed by the ER favours certain types of structural protein folds, 
thus influencing the folds that predominate in secreted and cell surface proteins. There are 
several such folds which are much more frequent in secretory pathway proteins, like the 
immunoglobulin (Ig) fold which consists of a pair of β-sheets linked by a disulphide bond and 
hydrophobic interactions (Berg et al., 2002). The Ig fold is frequently used by proteins of the 
immune system and can be found in antibody molecules, the major histocompatibility complex 
(MHC) proteins, integrins and interleukin receptors, (Geierhass, 2004). Other domains which 
require disulphide bonds are seen much more frequently in ER folded proteins, for example 
epidermal growth factor (EGF)-like domains, which are not found in cytosolic proteins, contain 
three disulphides which stabilise its β-sheet and flexible loop (Campbell, 1993). The EGF-like 
domain can be subdivided into the “human” hEGF-like domain and the cEGF-like domain 
(named after its discovery in the complement serine protease C1r). EGF-like domains often 
occur as tandem repeats and the two subtypes are probably descended from an ancestral 4 
disulphide-containing domain (Wouters et al., 2005). 
 
Folding in the ER is not perfect with many proteins never reaching their native conformation. 
An example of this is coagulation factor VIII (FVIII) which is secreted 10-fold less than the 
homologous factor V (FV) (Marquette et al., 1995; Pittman et al., 1994). This is due to FVIII 
forming high molecular weight aggregates retained in the ER by the chaperones Binding 
immunoglobulin protein (BiP), calnexin and celreticulin (discussed in 1.4) (Swaroop et al., 1997; 
Tagliavacca et al., 2000). In addition to folding proteins destined for secretion, the ER will also 
fold viral gene products in virus-infected cells that are required for fusion of the viral envelope 
with host cell membranes. In contrast to the inefficient folding of FVIII, this process can be 
remarkably efficient; for example nearly 100% of influenza haemagglutinin is folded in 
influenza-infected cells (Braakman et al., 1991; Sanders and Myers, 2004). 




1.3 Protein entry into the ER 
 
To allow for proteins folded in the ER to reach their native state, they must first enter the ER 
lumen without prior folding elsewhere in the cell. A signal sequence of ~20 amino acids at the 
N terminus was first discovered when it was noticed that in vitro, the Ig light chain 
translational product was larger than that of the mature protein expressed in vivo (Blobel and 
Dobberstein, 1975). As this sequence emerges from the ribosome, it is bound by a signal 
recognition particle (SNP), made up of 6 polypeptides, which slows down translation and 
delivers the complex to the ER membrane by docking to the SRP-receptor (SR)(Wild et al., 
2004). 
 
Here the ribosome interacts with Sec61, through which the nascent protein enters the ER 
lumen. Sec61, the translocon, is a heterotrimeric integral membrane protein complex which 
forms a channel in which the traversing chain is protected from non-productive interactions 
(Brundage, 1990). In this channel folding is partially inhibited, likely due to the crowded 
conditions caused in part by the presence of many accessory proteins, but also by the channels 
diameter, which is not wide enough to allow efficient folding (Chen and Helenius, 2000).  The 
channel was claimed to be 40-60 Å at its widest (Hamman et al., 1997). However a structure of 
the evolutionarily conserved archaea SecY, solved by X-ray diffraction of the M.jannaschii 
protein, is not consistent with this and shows a diameter of 20-25 Å at the open cytoplasmic 
entrance of its hourglass shape (Van den Berg et al., 2004). Although the channel is not large 
enough to permit folding, its diameter is still relatively large so a gating mechanism is present 
to maintain the permeability barrier across the ER membrane and maintain critical ion 
gradients. 
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The gate on the cytoplasmic side of the translocon is guarded by 2 transmembrane helices 
(TM2b and TM7) of Sec61. TM2b and TM7, the conformation of which is controlled by binding 
of the signal sequences, facilitate the opening of the plug domain, another Sec61 helical 
domain which seals the pore (Reithinger et al., 2014; Van den Berg et al., 2004). 
 
On the luminal side of the translocon, BiP is the only soluble protein necessary and sufficient 
to seal the pore. BiP seals the pore in its ADP-bound conformation and requires 
conformational change, induced by ATP binding, to open the channel. BiP mutagenesis studies 
suggest that BiP binds to a membrane-bound J domain protein via its substrate binding domain 
to facilitate sealing of translocon pores (Alder et al., 2005). When a translocating protein 
reaches a threshold length of ~70 amino acids, it triggers the opening of the BiP mediated seal 
(Hamman, 1998). 
 
The signal sequence of an ER targeted protein is usually 20-25 amino acids in length and is 
cleaved co-translationally after the synthesis of ~140 amino acids; however, examples of post-
translational cleavage are known, such as the human immunodeficiency virus (HIV)-1 envelope 
glycoprotein (Land, 2003). Cleavage of the HIV-1 envelope glycoprotein occurs only after the 
formation of a set of unknown disulphide bonds and following slow folding (Land, 2003). In 
general, failure to cleave the signal sequence of a translocated protein can result in ER 
retention and misfolding (Shaw et al., 1988). The cleavage of signal peptides is controlled by a 
signal peptidase, although the sequence of the cleavage site varies significantly between 
proteins, it generally consists of a positively charged n-region, uncharged c-region and 
hydrophobic h region (Von Heijne, 1985). The nature of the signal sequence also determines 
the efficiency of protein targeting to the ER. Inefficient targeting can result in accumulation of 
proteins in the cytoplasm. Some of these proteins may be able to carry out their function here, 
whilst most others will be degraded (Karamyshev et al., 2014; Levine et al., 2005; Rane et al., 
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2010; Shaffer et al., 2005). For example, the inefficient translocation of the ER chaperone 
calreticulin means that it can become available for functional interaction with the 
glucocorticoid receptor and facilitate gene activation (Shaffer et al., 2005). Although cytosolic 
calreticulin can drive the expression of luciferase from a glucocorticoid receptor reporter gene, 
the full biological significance of the dual targeting of calreticulin remains to be established. 
 
1.4 ER Chaperones 
 
The process of folding in the ER begins as a protein is translated into the lumen. This places 
certain constraints on the protein precursors. The tethering of the termini of the nascent chain 
to the ribosome limits its diffusion into the ER, preventing aggregation and non-native 
interactions of unfolded proteins (Frydman et al., 1994). This also allows local folding to occur 
first as the amount of conformational space that the chain is able to sample is greatly reduced 
(Alexandrov, 1993). The ER is likely to be organised to position proteins which assist in early 
folding near the ER membrane to associate with translating and newly formed polypeptide 
chains, whereas those which assist with near-native structures are found deeper in the ER 
lumen (Jansens et al., 2002; Snapp et al., 2006). 
 
Molecular chaperones are proteins which aid other proteins in acquiring their native active 
conformation but are not part of the final protein structure (Ellis and van der Vies, 1991). They 
selectively interact with certain sequence and structural elements, such as hydrophobic 
regions, to prevent aggregation and facilitate folding by providing a protected environment. 
Within the ER, a classical heat shock protein (Hsp)70 chaperone (BiP), binds directly to the 
polypeptide chain (Haas and Wabl, 1983), and a carbohydrate-binding chaperone system 
(calnexin and calreticulin) interacts with hydrophilic glycan modifications (Slominska-
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Wojewodzka, 2015). These chaperone systems ensure that despite the large array of proteins, 
they are all chaperoned as they are modified and mature as they move through the ER 
(Braakman, 2013). 
 
1.4.1 Classical chaperones 
 
The classical chaperones found in the ER belong to the Hsp70 and Hsp90 molecular chaperone 
families, both regulated by adenine-nucleotide binding. They identify unfolded proteins by 
detecting exposed hydrophobic segments, which will be buried in the core of native proteins, 
thus protecting client proteins from aggregation. The Hsp70 family couples the binding and 
release of substrate proteins to ATP hydrolysis. The peptide binding cleft of the chaperone is 
opened by a conformational change prompted by the binding of ATP at the Hsp70 N-terminal 
ATPase domain. Following hydrolysis of ATP, the binding cleft closes leaving ADP bound Hsp70 
tightly interacting with the substrate (McCarty et al., 1995; Szabo et al., 1994). Hsp40 acts as a 
co-factor, retaining and targeting substrates to Hsp70. The Hsp40 family proteins are able to 
bind a diverse set of clients due to structural diversification, and the conservation of a J-
domain means they are still able to bind Hsp70. Hsp40 passes the substrate to Hsp70 with help 
from a nucleotide exchange factor which facilitates ATP hydrolysis, increasing the substrate 
affinity of Hsp70 which can now outcompete Hsp40 (Summers et al., 2009). 
 
The classical Hsp70 protein BiP binds to most proteins travelling through the ER at some point 
(Flynn et al., 1991) and, on average a protein is expected to contain a hydrophobic BiP binding 
region every 35 residues (Rudiger et al., 1997). BiP has been described as the master regulator 
of the ER, owing to its diverse set of roles involving assembly, transport and ultimately 
secretion of native proteins (Hendershot, 2004). During protein assembly, BiP is involved in 
facilitating insertion of precursor polypeptides into the translocon by gating the channel from 
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closed to open (Dierks, 1996). BiP acts as a molecular ratchet by binding the protein and 
preventing its movement back through the channel (Tyedmers et al., 2003). Another of BiPs 
many roles is at the end of a proteins life, where the solubility of misfolded protein aggregates 
is maintained by BiP to facilitate their disposal by the ER degradation machinery (Kabani et al., 
2003). 
 
The Hsp90 family has a varied set of functions with roles in cell cycle control as well as cell 
survival and cellular stress, Hsp90s also act as a hub for a complex chaperone machinery to 
interact with hundreds of substrate proteins, assisted by many co-chaperones such as CDC37 
and activator of 90 kDa heat shock protein ATPase homolog 1 (AHA1) that determine the rate 
of chaperone cycling and client recruitment (Zhang and Burrows, 2004). Hsp90 is a dimer. Both 
subunits consist of a N-terminal ATP-binding domain, a middle domain, and a C-terminal 
dimerization domain. Hsp90 exists in an open formation, in which its lid segment is 
repositioned upon binding to ATP and a Hsp70/Hsp40/substrate protein complex. Following 
another conformational change resulting in a closed structure, ATP is hydrolysed, the original 
open formation is regained, and the folded client released. A number of other proteins can 
inhibit or post-translationally modify Hsp90, for example by phosphorylation, acetylation, 
oxidation and ubiquitination (reviewed by (Li et al., 2012; Lorenz et al., 2014)). 
 
Glucose regulated protein (GRP) 94 belongs to the classical Hsp90 family and is one of the 
most abundant proteins in the ER; however, its client proteins are more restricted than those 
of other chaperones of a similar abundance. GRP94 appears to interact with substrates 
following their release from BiP and has a role in protein maturation (Melnick et al., 1994). The 
role of BiP and GRP94 is not limited to protein maturation. Both chaperones have been 
proposed to have diverse biological roles, with GRP94 able to induce T-cell immunity by 
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binding and delivering antigens to initiate an MHC class I-restricted T cell response (Li and 
Srivastava, 1993). 
 
1.4.2 Carbohydrate-binding chaperones 
 
Carbohydrate-binding chaperones, or lectin chaperones, are those that form hydrophilic 
interactions with N-linked glycans, rather than bind to the peptide backbone. Most proteins 
that pass through the secretory pathway are modified with the addition on N-linked glycans 
(to be discussed further in section 1.5), which are subsequently trimmed, allowing the binding 
of chaperones to N-linked glycans at trimming intervals (Helenius and Aebi, 2004). 
 
Calnexin and calreticulin are abundant lectin chaperones, binding monoglucosylated glycans 
(Kapoor et al., 2003). While calnexin binds to membrane proximal domain glycans, calreticulin 
interacts with those of ER luminal secretory proteins (Hebert, 1997). These chaperones 
perform largely the same function, giving the protein additional time and stability to fold into 
its native state, acting to prevent aggregation and recruiting protein disulphide isomerases like 
ER protein (ERp) 57 to promote disulphide bond formation and isomerisation. Following 
release from calnexin or calreticulin, substrate proteins are inhibited from rebinding to these 
chaperones, as the final glucose is removed by glucosidase II (Hammond, 1994). If a non-native 
conformation persists, the monoglucosylated state can be regenerated by the UDP-glucose: 
glycoprotein glucotransferase (GT). The level of misfolding determines whether reglycosylation 
occurs (Pearse et al., 2008), with GT detecting localised, disordered conformations and 
exposed hydrophobic patches of proteins with a nearly native conformation (Ritter and 
Helenius, 2000). Those proteins that can continue folding without the assistance of calnexin 
and calreticulin will be ignored by GT, as will those displaying major folding defects which 
instead attract BiP and are targeted for proteasome-mediated degradation (Hebert and 
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Molinari, 2007). Although primarily involved in carbohydrate binding, calnexin and calreticulin 
have been seen to bind and promote the folding of non-glycosylated proteins as well as 
preventing aggregation of non-glycosylated proteins (Danilczyk and Williams, 2001). Citrate 
synthase and malate hydrogenase are two non-glycosylated proteins which, when unfolded, 
interact with these lectin chaperones. Their folding is encouraged by retaining them in a 
conformation favourable for folding (Ihara et al., 1999; Saito, 1999). Examination of the 
binding specificity of calreticulin to non-glycosylated proteins shows a preference for 
hydrophobic peptides lacking acidic residues, and a minimum length of 10 residues (Jorgensen 
et al., 2000). 
 
A recently discovered ER chaperone called malectin was proposed to be the first chaperone 
able to interact with glycans following removal of the first glucose, whilst it is in the 
diglucosylated state. Malectin is expressed under several ER stress conditions where it 
modulates the secretion of misfolded proteins (Galli et al., 2011).  However, it has been 
proposed that malectin interacts with misfolded glycoproteins in a complex with ribophorin 1 
(Qin et al., 2012). Malectin may therefore provide an initial round of quality control prior to 
the engagement of the calnexin/calreticulin cycle (Tannous et al., 2015). 
 
1.4.3 Protein specific chaperones 
 
Certain proteins containing unique structures and those which are present in extremely high 
concentrations require substrate specific chaperones. Low-density lipoprotein receptors  (LDLR) 
is an example of this, where the LDL receptor-associated protein (RAP) provides additional 
support to allow its proper folding and prevent aggregation by preventing premature ligand 
binding. RAP binds to LDLR early in the secretory pathway, and the two proteins dissociate 
when they encounter the low pH of the Golgi (Li et al., 2002). Collagen, the most abundant 
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mammalian protein, interacts with many general chaperones, BiP and calnexin for example, 
but it also requires additional support from Hsp47 (Nagata, 1996). Hsp47 binds to procollagen 
upon formation of the collagen triple helix and facilitates further triple helix formation. Hsp47 
is indispensable and its mutation can cause osteogenesis imperfecta and other collagen-
related genetic diseases (Ishida and Nagata, 2011). 
 
1.5 N-linked glycosylation 
 
Upon entry to the ER most proteins undergo asparagine(N)-linked glycosylation at the acceptor 
site, Asn-X-Ser/Thr, with sequential processing of the N-glycan throughout the secretory 
pathway. A lipid anchor in the ER membrane provides an assembly point for the 
oligosaccharide substrate for N-glycosylation. Assembly of Man5-GlcNAc2 begins on the 
cytoplasmic side of the ER and is catalysed by glycosyltransferases using nucleotide activated 
monosaccharides. This oligosaccharide is translocated into the ER lumen and further 
glycosyltransferases add Glc3Man4 to the structure (Figure 1.1). The glycan can then be passed 
onto an asparagine residue by oligosaccharidetransferase (Schwarz and Aebi, 2011). N-linked 
glycans are frequently transferred co-translationally at ~13 amino acids into the ER lumen 
(Nilsson and Vonheijne, 1993). 
 
  





Figure 1.1. N-linked oligosaccharide structure  
The N-linked glycan is composed of two N-acetylglucosamines, nine mannoses and three 
glucoses. The terminal glucose is removed by glucosidase I following which the remaining 
two glucoses can be removed by glucosidase II. A glucose can be replaced by UDP-
glucose: glycoprotein glucotransferase. Mannosidase removes a terminal mannose. 




Following the addition of N-linked glycans to ER proteins, they are subsequently trimmed. The 
intermediate sugars guide protein secretion and assembly in different ways; initially they assist 
in proper protein folding and quality control, following this and further trimming they act as 
signals in intracellular transport and finally, after the final trimming, they form part of the final 
protein structure. Glucosidase I removes the outermost glucose residue. The remaining two 
glucose residues can then be removed by glucosidase II (Figure 1.1). Once removed, glucose 
residues can be replaced by GT taking the glucose from UDP-glucose that has been transported 
from the cytosol into the ER lumen. The efficiency of glucosidase II and GT is dependent on the 
number of mannose resides in the glycan; they become less efficient as the mannose residues 
are removed, which is catalysed by mannosidase enzymes (Grinna and Robbins, 1980) 
(reviewed by (Aebi, 2013)). GT will only interact with improperly folded glycoproteins 
displaying high-mannose glycans. Those glycoproteins with small folding defects and exposed 
hydrophobic residues tend to have the most efficient interactions (Ritter and Helenius, 2000). 
The glucose cycle allows proteins that remain unfolded following their release from calnexin 
and calreticulin to reattach to these chaperones for another attempt at folding. 
 
Glycoproteins that fail to fold are targeted for ER-associated degradation (ERAD) (discussed in 
section 1.7). The length of time a protein spends folding in the ER provides an indicator as to 
whether proteins are misfolded and subunits are unassembled or whether the proteins are 
present as folding intermediates. Glycoproteins are given reasonable opportunity to fold, with 
a lag period dependent on the protein and their number and location of glycans. The average 
lag time is 30-90 minutes, after which they are degraded, as shown in labelling studies with ER 
retention mutants (Mancini, 2003). The status of the N-linked glycan provides an indication of 
how long the protein has been folding for, with mannosidase slowly removing mannose 
residues, thus acting as a timer. If unfolded proteins do not interact with calnexin or 
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calreticulin during the lag period they are immediately targeted for ERAD. Those proteins that 
do interact with these chaperones are protected during this period, but upon mannose 
trimming the ERAD targeting ER degradation-enhancing α-mannosidase-like protein (EDEM) 
starts to compete with them (Molinari et al., 2003). EDEM becomes more likely to interact 
with the proteins as the mannose residues are trimmed and GT and glucosidase II become less 
efficient (Grinna and Robbins, 1980). EDEM also has the ability to act as a mannosidase and, 
independently of substrate demannosylation, act as a chaperone inhibiting aggregation of 
misfolded proteins upon release of the calnexin/calreticulin cycle. The concentration of EDEM 
is strictly regulated, increasing during ER stress (reviewed by (Slominska-Wojewodzka, 2015)). 
 
Not only does the addition of glycans recruit chaperones, but the folding, stability and 
maturation efficiency is increased by the altered physical properties of the protein, caused for 
example by the masking of hydrophobic stretches and proteolytic cleavage sites. These 
properties, along with the chaperones, help the protein reach its native state (Hanson et al., 
2009; Kundra and Kornfeld, 1999). The addition and modification of N-linked glycans to some 
proteins do not have an appreciable effect on their folding properties. These glycans can be 
modified by the cell to allow self-recognition and provide information on stages of 
differentiation and transformation (Lowe and Marth, 2003). 
 
About 90% of proteins that traverse the ER are modified with N-linked glycans (Apweiler et al., 
1999) and whilst some of them are necessary for function, others only facilitate folding and 
maturation. When the N-linked glycan sites of MHC class I are mutated, the resulting 
nonglycosylated MHC class I is functional but their cell surface expression is diminished 
(Miyazaki et al., 1986). Other N-linked glycans are completely dispensable; for example, 
elimination of glycans in influenza hemagglutinin affects only the folding rate, either speeding 
it up or slowing it down, and not the functional outcome of folding (Hebert, 1997). 




1.6 Other folding mechanisms 
 
Prolyl peptidyl cis-trans isomerases (PPIases) are important in protein folding.Proline residues 
are inserted into the ER in the ER trans conformation, PPIases can isomerise the conversion of 
these into the cis conformation, and back again depending on the requirements of the proteins 
native structure. Often the nature of the proline residue is changed multiple times before the 
portein is fully folded. The enzymatic activity of PPIases is a slow process and therefore rate-
limiting for folding in the ER (Reviewed in (Braakman, 2013)). 
 
For oligomeric proteins, protein folding can involve the assembly of subunits before they are 
able to leave the ER. In these cases, folding of the multiple subunits must be orchestrated to 
ensure they are able to assemble. Igs are an example of this; made up of 4 subunits composed 
of 2 Ig heavy chains and 2 light chains, the free heavy chains are stably bound by BiP which 
recognises the conformation of the substrate and retains it in the ER (Marcinowski et al., 2013). 
Light chains are required to remove BiP from the heavy chain, allowing it to fold and proceed 
with subunit assembly (Lee et al., 1999). Many other chaperones are involved in regulating 
levels of assembly of subunits, but no general mechanism has been described as to how free 
subunits are distinguished from those which are assembled. Other oligomer subunits contain 
ER retention signals, such as the C-terminal KDEL or the dibasic (KKXX) motif, which upon 
subunit assembly are hidden. This allows progression of the oligomer out of the ER. In the case 
in the G protein-coupled GABAB receptor, competition between 14-3-3 proteins and the coat 
protein I (COPI) retrieval machinery has been proposed to control ER retention and hence cell 
surface expression of this receptor (Brock, 2005).   Subunits which fail to assemble will not 
proceed out of the ER and will aggregate or become targeted for degradation. 




Unfolded protein O-mannosylation (UPOM), a much less studied protein modification, parallels 
N-linked glycosylation, with both structural and quality control roles. Like N-linked 
glycosylation, the mannosylated substrate is produced on the cytosolic side of the ER 
membrane and flipped into the ER lumen to where a single mannosyl group is transferred from 
the dolichol phosphate β-D-mannose donor (Haselbeck, 1983). UPOM was originally thought 
to occur only co-translationally, but more recently has been shown to occur co- and post-
translationally, to serine/threonine residues, with no sequence consensus yet known for this 
(Larriba et al., 1976; Loibl et al., 2014). As well as being structurally important UPOM has a 
broad role in protein quality control, with unfolded ER proteins becoming O-mannosylated. 
UPOM is not required for ERAD, and not related to the mannosylation that acts as a quality 
control marker for ERAD, but it enhances substrate solubility which is a prerequisite for ERAD 
(Harty et al., 2001; Nishikawa et al., 2001). Whilst mannosylation is required for degradation in 
some proteins it not always a signal for degradation, thus it operates as an independent 
quality control pathway for some proteins. Certain proteins require UPOM for ERAD, as has 
been demonstrated using KHN (a fusion construct of yeast hemagglutinin neuraminidase). 
Without UPOM, HMG-coA reductase degradation (Hrd1), one of the main ubiquitin ligases that 
function in ERAD does not target KHN, leaving KHN to accumulate in the ER. The O-
mannosylation of other substrates like the yeast Deg1-Sec62 model fusion protein does not 




Recognition of nonglycosylated proteins for ERAD occurs when ER chaperones detect unfolded 
regions. BiP, and its regulation by DnaJ family proteins are mainly responsible for this, however 
calnexin and celreticulin are able to bind some nonglycosylated proteins implicating them in 
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the early stages of the ERAD pathway. It is believed that ERAD cofactors, such as EDEM, are 
recruited upon prolonged retention of proteins by BiP and lead to the their retrotranslocation 
from the ER and subsequent ubquitination (Otero et al., 2010). Once ubiquitinated in the 
cytosol, misfolded proteins are directed to the proteasome or to ubiquitin ligases for 
degradation via homocysteine-induced ER protein (Herp) which acts as a bridge for partially or 
fully translocated proteins (Okuda-Shimizu, 2007). ERAD must recognise folding inaccuracies in 
ER folded proteins, including cytoplasmic, membrane and lumen regions. As this constitutes a 
wide range of ERAD substrates, a range of accessory factors exist to assist in recognition. The 
two central ubiquitin ligases, Hrd1 and glycoprotein (gp) 78,  are able to bind to these 
accessory factors, as well as others involved in substrate dislocation, allowing the coupling of 
substrate recognition and dislocation (Christianson et al., 2012). 
 
EDEM is best known for its role in glycoprotein degradation however, glycosylation and glycan 
trimming is not necessarily required for EDEM-mediated targeting of substrate proteins for 
degradation. EDEM has been found to bind, in a highly substrate dependant manner, to non-
native structures irrespective of their glycosylation status. EDEMs mannosidase-like domain, 
originally expected to be solely for substrate recognition, can bind to suppressor of Lin-12-like 
protein (SEL1L), a downstream ERAD machinery target containing 5 N-glycosylation sites. This 
suggests that it is not just the glycan status of substrates that is important, but also that of the 
ERAD machinery (Cormier et al., 2009). Three mammalian EDEM proteins have been 
characterised. Initially it was believed only EDEM3 possessed mannosidase activity, but further 
study showed that this activity could be induced by overexpression of EDEM1. This was 
determined by looking at mannose trimming of the ERAD substrate NHK in cells transfected 
with EDEM1, which showed an increase in N-glycans lacking terminal mannoses. No such 
increase in seen in transfected cells when EDEM1 was mutated at the proposed mannosidase 
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active site, or with EDEM 2 (Hosokawa et al., 2010). This work highlights that there are 
different EDEM functions which make up different ERAD pathways (Mast et al., 2005). 
 
The short-lived EDEM protein is localised in double-membrane buds outside ER exit sites 
where, at steady state, they are degraded. This allows for EDEM to become rapidly available to 
the ER, without the delay involved in transcriptional responses (Bernasconi and Molinari, 2011). 
EDEM is stabilised by binding the oxidoreductase ER DNA J domain-containing protein 5 
(ERdj5). This is the largest member of the PDI family at 90 kDa, and found at its highest 
concentrations in secretory tissues. It allows progression of misfolded proteins through ERAD 
by reducing disulphides in substrates. After disulphide bond reduction, the protein can now 
bind to BiP and dissociate from ERdj5, allowing BiP to target the protein for retrograde 
translocation (reviewed by (Okumura et al., 2015)). ERdj5 also aids retrograde translocation by 
preventing covalent interactions and aggregation which would make the substrate too large 
for the retrotranslocon channel (Ushioda, 2008). As well as this, ERdj5 can act as a chaperone 
by promoting productive folding following its reductase activity (Oka et al., 2013). 
 
Following recognition by ERAD, misfolded substrates are taken back across the ER membrane 
into the cytoplasm. Those proteins which are ER luminal proteins must be fully 
retrotranslocated, whereas certain domains of membrane proteins can diffuse through the 
membrane exposing them to the cystosol. Ubiquitination is coupled to retrotranslocation of 
membrane proteins but occurs late on in luminal protein retrotranslocation and allows ATP 
dependent extraction from the membrane and targeting to the proteasome. Valosin 
containing protein (P97) moves the substrates from the membrane to the cytosol. This ATPase 
is recruited by UBV domain containing protein (UBXD8), an ER membrane-embedded ERAD 
factor that has also been linked to the control of triacylglycerol synthesis and the turnover of 
RNA-protein complexes in the cytosol. P97 also binds other ubiquitin modifying enzymes such 
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as the de-ubiquitinating enzymes (DUB), which have been shown to be necessary for 
retrotranslocation. The need for DUBs suggests that cycles of ubiquitination and de-
ubiquitination exist. In support of this idea, substrates that are retrotranslocated but not 
ubiquitinated could indicate that factors other than the substrate are ubiquitinated (Bernardi 
et al., 2013; Ruggiano et al., 2014; Zhang, 2013). The ubiquitination is coordinated by a 
membrane associated ubiquitin ligase (E3 ligase) complex. The E3 ligase cofactors are likely 
needed to determine the specificity of the ligase (reviewed by (Ruggiano et al., 2014)), while 
others assist with the transfer of ubiquitin which must first be activated (E1) and conjugated 
(E2).  Ubiquitin, a small 76 amino acid protein, is recognised by and degraded by the 
proteasome. 
 
There is no definitive consensus as to the channel through which retrotranslocation occurs. 
Sec61 was first proposed as a retrotranslocon, backed up by findings that it interacted with 
ERAD substrates (Wiertz et al., 1996). These interactions were later found to be with proteins 
stuck on their way into the ER (Rubenstein, 2012). In addition, the pore diameter of Sec61 is 
unlikely to accommodate larger partially folded substrates. Subsequently, members of the 
Derlin family of membrane proteins, which have 4 membrane spanning domains, have been 
suggested to function as retrotranslocation channels, with their overexpression speeding up 
the degradation of ERAD substrates (Oda et al., 2006).  However, the crystal structure of 
rhomboid protease GlpG, a similar protein of the same family, lacked any membrane channels 
suitable for retrotranslocation. Instead, it is more likely that the derlins organise ERAD 
components and bind substrates as they enter the cytosol (Greenblatt, 2011). Following 
release into the cytosol, substrates for degradation are kept soluble and transferred to the 
proteasome by cystolic proteins, like Rad23, or shuttle factors chaperones such as the BAG6 
complex (Ruggiano et al., 2014; Xu, 2012). 
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Three ERAD sub-pathways have been described in S. cerevisiae based on the location of their 
degradation signal. These are ERAD-L (lumen), ERAD-M (membrane) and ERAD- C (cytosol) 
with each having its own E3 protein complex (Finley et al., 2012). Whether distinct 
subpathways exist in mammalian cells is unclear. Suggestions have been made that 
mammalian equivalents for the ERAD-L pathway exist. The mammalian Hrd1 E3 ligase is one of 
the most explored of the 6 described, and has been suggested to mediate the ERAD-L pathway 
(Ballar et al., 2011; Bernasconi et al., 2010). Overall, the data support the idea that distinct 
retrotranslocation pathways are present in the mammalian ER but these may not be as well 
defined as that in yeast (Okuda-Shimizu, 2007). 
 
Occasionally ERAD targets proteins in their native state. This is a highly regulated event only 
occurring in certain proteins and often working as a feedback inhibition system for specific 
purposes, such as maintaining sterol homeostasis and preventing accumulation of toxic 
intermediate sterol metabolites. Three-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), an 
enzyme in cholesterol synthesis, is one such protein. It is selectively targeted for ubiquitination 
to limit the rate of cholesterol production (Foresti, 2013; Song et al., 2005). Other proteins 
which, given the right circumstances, for example sufficient time, would fold properly can also 
be degraded. One of the best-known examples of this is the cystic fibrosis transmembrane 
conductance regulator (CFTR). CFTRs lengthy, inefficient, folding pathway leads to up to 80% 
being subjected to ERAD before it is able to fold (Cui et al., 2007; Lukacs et al., 1994; Lukacs 
and Verkman, 2012). 
 
Macromolecules with structural restraints such as aggregates and large proteins cannot 
traverse the retrotranslocation channel, thus another pathway must exist to remove them 
from the ER. One alternative route for these proteins is autophagy. Autophagy enables the 
degradation of cell compartments by packing the substrates for degradation into a double-
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membrane autophagosome and sending this to the lysosome, which is able to degrade large 
amounts of cellular material. The underlying mechanisms for this are largely unexplained, but 
one proposed method is that ER resident FAM134 reticulon protein family members facilitate 
autophagy by binding to autophagy modifiers microtubule-associated proteins 1A/1B light 
chain 3A (LC3) and gamma-aminobutyric acid receptor-associated protein (GABARAP). 
Subsequently, the ER becomes highly fragmented and degraded by the lysosome, as shown in 
experiments when the members of the FAM134 family are overexpressed (Khaminets et al., 
2015). Specifically, autophagy is used to clear the ER of accumulated partially folded human 
gonadotropin-releasing hormone receptor (GnRHR) (Houck et al., 2014). Other protein 
aggregates can escape recognition by molecular chaperones which detect hydrophobic 
sequences hidden upon aggregation (Kopito, 2000). Proteins could potentially be targeted for 
autophagy by a buildup of polyubiquitinated proteins however this could be a consequence of 
aggregation. There is crosstalk between proteasomal and autophagic degradation pathways, 
with proteins involved in both pathways and in activating them. One such pathway is activated 
by the proteasome inhibitor bortezomib (BZ). BZ induces, and requires, the stabilisation of 
ATF4, a member of the PERK (See section 1.8.2) pathway which is involved in proteasomal 
regulation, to bring about autophagy (Kawaguchi et al., 2011). 
 
1.8 Unfolded protein response 
 
A build-up of unfolded proteins can occur in many situations, including insufficient folding or 
degradation, paucity of chaperones when protein translation is increased, and changes in 
temperature or other stress conditions, which lead to unstable protein structures. Under these 
circumstances the unfolded protein response (UPR) is induced to adapt the ER to these 
conditions. Fluctuations in Ca2+, oxidative stress, hypoxia and energy depletion, to name a few, 
disrupt ER homeostasis and thus optimal folding conditions. Here, the UPR acts to tightly 
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regulate ER conditions. If the level of unfolded/misfolded proteins is too high and cannot be 
resolved, cell-death signalling pathways are activated (reviewed by (Cao, 2012)). Otherwise 
specific protein folding and ERAD genes are transcriptionally activated, whilst global protein 
translation is diminished to moderate the newly synthesised protein load which requires 
folding. 
 
The mammalian ER contains 3 transmembrane sensors to detect the folding capacity of the ER: 
inositol-requiring kinase 1 (IRE1), pancreatic ER elF2a kinase (PERK), and activating 
transcription factor 6 (ATF6). Each of these are at the start of a distinct UPR pathway (Figure 
1.2). 




Figure 1.2. The unfolded protein response pathways 
The three pathways detect a build up of unfolded ER proteins and activate transcriptional 
regulators. A. ATF6 travels to the golgi where it is cleaved by S1P and S2P to release its 
cytoplasmic transcription factor domain. B. PERK homodimerises and autophosphorylates 
allowing the phosphorylation of eIF2α which can prevent general protein translation, but 
increase the translation of the ATF4 transcription factor. C. IRE1 oligermerises and 
autophosphorylates causing the splicing of XBP1 mRNA, which allows the transcription 
regulator to be translated.  Adapted from (Walter and Ron, 2011). 





IRE1 is the most evolutionarily conserved branch of the UPR, and the only one that exists in 
yeast (Cox, 1993). Two mammalian homologs exist, IRE1α which is expressed ubiquitously 
(Tirasophon et al., 1998), and IRE1β found mostly in the intestinal epithelium (Bertolotti et al., 
2001). Under ER stress IRE1 dissociates from its partner, BiP, and homodimerises/oligermerises 
causing autophosphorylation. The phosphorylation induces the splicing of X-box binding 
protein 1 (XBP1) mRNA allowing translation of the DNA-binding domain (DBD) and 
transcriptional activation domain (AD) (Yoshida et al., 2001). The spliced XBP1 (XBP1s) protein 
travels to the nucleus where it upregulates the transcription of its target genes. Unspliced 
XBP1 (XBP1u) is constitutively translated. It was initially thought to be inactive and rapidly sent 
to the proteasome for degradation, however since then it has been shown to have a negative 
feedback regulatory function. XBP1u builds up in the recovery phase of ER stress and forms a 
complex with XBP1s which is rapidly degraded due to a degradation motif in the XBP1u version 
(Lee et al., 2003; Yoshida et al., 2006). How IRE1 detects ER stress has been questioned, 
although IRE1 could compete with unfolded ER luminal proteins for BiP binding. When BiP is in 
short supply, IRE1 would lose its bound BiP allowing its autophosphorylation (Kimata et al., 
2007). Alternatively, ER stress could be sensed by binding of unfolded proteins directly to 
IRE1α. Initially this was thought to be via a deep groove, ideal for ligand binding, formed when 
IRE1 dimerises (Creddle, 2005). A fuller structural picture of the luminal and cytosolic domains 
of IRE1 is being developed on the back of more recent crystal structures (Lee et al., 2008). 
 
An additional mechanism of IRE1 has been described in the UPR, with it promoting the 
degradation of other mRNAs, in addition to the splicing of XBP1, in order to reduce the ER 
protein folding load. IRE1 targets mRNAs, such as cCD59, with a CUGCAG consensus sequence 
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within its cleavage site making them substrates for exonucleolytic decay by the cytosolic 
exosome (Oikawa et al., 2010). 
 
IRE1 and XBP1 are not limited to the role described above, but also partake in other pathways 
influencing protein expression and cell fate. This is exemplified by the cross talk between 
inflammatory pathways and IRE1. Upon activation, IRE1 binds TNF receptor-associated factor 2 
(TRAF2) initiating the downstream NF-kB mediated proinflammatory cytokine production (Zha, 
2015). IRE1 has also been shown to have a crucial role in glucose and lipid metabolism, with 
prolonged IRE1 mediated c-Jun N-terminal kinase (JNK) activation contributing to insulin 
resistance, more so than lipid accumulation (Sun et al., 2015). Under extreme ER stress IRE1 
can bind the E3 ligase TRAF2 causing apoptotic signalling (Urano, 2000). These are just two 




The stress-sensing mechanism of PERK is very similar to that of IRE1 due to structural 
homology between their ER luminal domains. Again, activation of PERK occurs upon 
dissociation from BIP, followed by homodimerisation, autophosphorylation, activation and 
subsequent phosphorylation of eukaryotic initiation factor 2 (eIF2). eIF2α associates with the 
40S ribosomal subunit along with GTP, which is hydrolysed to GDP upon the addition of the 
large ribosomal subunit of the complex. The phosphorylation of eIF2α diminishes the 
conversion of GDP to GTP. Without the GTP eIF2 complex translocation cannot occur, 
alleviating the burden of additional protein synthesis (Ma et al., 2002). In general, 
phosphorylation of PERK and eIF2α reduce protein translation yet exceptions do exist in the 
form of the transcription factors ATF4 and ATF5, whose translation is facilitated. Transcription 
of genes concerned with amino acid metabolism and combating oxidative stress is increased 
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e.g. ATF4 (Harding et al., 2003) and TXNIP, which activates IL-1β and mediates ER stress-
mediated β cell death by ATF5 (Oslowski et al., 2012). In addition to its general role in the UPR, 
the PERK pathway is thought to be especially vital for pancreatic β cell function, as its absence 
leads to β cell loss and hyperglycemia (reviewed by (Lee, 2014)). Translational attenuation 
caused by PERK signalling is transient owing to the dephosphorylation of eIF2α by protein 
phosphatase 1 (PP1). This is important to allow for the production of mRNA associated with 




ATF6 is the principle sensor of the third UPR pathway and varies slightly from the other two. 
Like IRE1, its ER luminal domain senses ER stress by dissociating from BIP, which under normal 
conditions retains ATF6 in the ER. Without BIP bound, ATF6 travels to the golgi where it is 
cleaved by sphingosine-1-phosphate (S1P) and sphingosine-2-phosphate (S2P) releasing the 
cytoplasmic domain which forms a transcription factor. The cytosolic portion of ATF6 travels to 
the nucleus and induces transcription of its target genes. The transcriptional response overlaps 
with the response to XBP1 (reviewed in (Lee, 2014)). 
 
When the ER stress is chronic or severe, the UPR results in apoptosis, and the PERK pathway is 
the main driver of the apoptotic response. C/EBP homologous protein (CHOP) is one of the 
proteins upregulated by PERK. It is a proapoptotic factor but can also induce the 
dephosphorylation of eIF2α, which increases protein synthesis. If this occurs when protein 
folding is compromised, the increased unfolded protein load will cause further pro-apoptotic 
signalling; however, if the protein folding machinery has been largely restored, this allows the 
diversion from a cell death to a cell survival pathway (Marciniak, 2004; Zinszner et al., 1998). 
Under severe stress, IRE1 will also induce cell death by indiscriminately degrading ER-localised 
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mRNA, the signalling mechanism for which has not been described (Hollien et al., 2009). 
Recent evidence suggests that the cell determines whether it should initiate cell survival or 
apoptosis by the relative timing of IRE1 and PERK signalling (Walter et al., 2015). 
 
1.9 Disulphide bond formation in the ER 
 
The formation of disulphide bonds is highly favoured in the ER, due to its redox conditions. The 
ER is highly oxidising compared to the cytosol, reflecting the status of the extracellular space in 
which the surface and secretory proteins produced will be exposed to following departure 
from the ER, when they have reached their native state. Surface and secretory proteins often 
possess multiple cysteines, most of which must form structural and stabilising intra- and inter 
chain disulphide bonds before they can leave the ER. Disulphide bonds are covalent bonds 
generally formed by the coupling and oxidation of two thiol (-SH) groups. Despite the oxidising 
conditions of the ER, in most cases this is a reversible, enzymatically catalysed dithiol-
disulphide exchange with an electron acceptor with a disulphide bond that is subsequently 
reduced.  In the ER there is a relay of disulphide exchange reactions, beginning with molecular 
oxygen and ending with the substrate protein. Although many disulphide oxidoreductases are 
known, the most central and best characterised is protein disulphide isomerase (PDI), which 
works together with endoplasmic reticulum oxidoreductin 1 (Ero1). A reduced substrate 
protein passes electrons to PDI, leaving the substrate protein oxidised and with a disulphide. 
PDI is now reduced. PDI is reoxidised by Ero1, which transfers the electrons received from PDI 
onto molecular oxygen producing hydrogen peroxide (H2O2) (Figure 1.3). 
  





Figure 1.3. Thiol-Disulphide relay between Ero1 and target protein 
In the ER, molecular oxygen is a terminal electron acceptor. The subsequent disulphide 
formed in Ero1 is passed to PDI and on to the folding substrate protein. 





The Ero1 family is a highly conserved ER disulphide generating catalyst, found in in almost all 
eukaryotes. In mammals two paralogs exist, Ero1α (Benham et al., 2000; Cabibbo, 2000) and 
Ero1β (Pagani et al., 2000). Some differences exist between the 2 mammalian Ero1 isoforms; 
both are upregulated by ER stress but only Ero1α by hypoxia (Gess et al., 2003; Pagani et al., 
2000). The expression pattern of Ero1α and Ero1β also differs. Ero1α is universally expressed, 
with cell specific expression of Ero1β in the pancreas and stomach (Dias-Gunaseka, 2005). 
These differences suggest that the two isoforms may interact with specific PDI partners, and 
act in different ways. The enzymatic activity of Ero1β is about twice as fast as Ero1α, and 
regulation of Ero1β is much looser than in Ero1α, which is consistent with its location in 
secretory tissues, to give it more oxidative activity (Wang et al., 2011). 
 
The yeast Ero1p crystal structure (Figure 1.4) shows 10 α helices make up a single domain 
formed from the entire chain. Two extended loops after helix α1 are separated by a three-
stranded β sheet. This forms a flexible region, which holds a pair of cysteines called the shuttle 
cysteines. The following α helices form the core structure of the protein. The space in between 
α2 and α3 holds a Flavin adenine dinucleotide (FAD) cofactor. This buries the FAD isoalloxazine 
ring within the protein, positioning it next to the active-site cysteines (Cys351-Cys355) (Figure 
1.5). No clear channel is seen in this crystal structure for oxygen to reach this ring. It was 
suggested that, due to the lack of a visible O2 channel, a gating system may exist (Gross et al., 
2004). Two cysteine pairs are involved in thiol-disulphide exchange with PDI, both of which are 
conserved in the mammalian Ero1α and Ero1β proteins (Bertoli et al., 2004). The Ero1α Cys94-
Cys99 pair is found on the flexible loop, the interaction of the loop with PDI allows a 
conformational change which brings Cys94-Cys99 into contact with the Cys394-Cys397 pair, 
thus they are known as the shuttle cysteines (Figure 1.5). The Cys394-Cys397 disulphide forms 
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an active-site near the FAD isoalloxazine ring (Inaba, 2010). Another disulphide is formed 
between the cysteine pair Cys85-Cys391. This has a structural role, and its absence by 
mutation leads to a destabilised Ero1α structure which has an abnormal gel migration 
(Benham et al., 2000). 
 
The human Ero1α protein has also been crystallised to 2.35Å (Inaba, 2010) and has overall 
similarities to the yeast protein. The shuttle loop of Ero1α, which accepts electrons from PDI, is 
composed of a co-factor binding, four-helix bundle core region found next to the Cys-X-X-Cys 
active site. The binding of PDI allows a conformational change, which brings this loop into 
contact with the other functional region. 
 
For each disulphide produced by Ero1α, one molecule of H2O2 is created. This potential 
reactive oxygen species can generally be dealt with by the cells antioxidant systems and in 
some cases is utilised or acts as a messenger in other pathways (Veal, 2007). H2O2 becomes a 
potential problem when its amount exceeds the cells ability to deal with it and leads to 
harmful ER oxidative stress. Due to increased capacity for disulphide production, the 
overexpression of Ero1p in yeast shows amplified H2O2 production. 
 
  





Figure 1.4. Structure of Ero1p 
A. Ero1p α helices and β strands, represented by cylinders and arrows respectively, 
numbered from N to C terminus. The FAD cofactor is represented by gold ball-and-stick and 
cysteine residues by green and yellow balls. B. Ero1p α helices and β strands are 
represented by ribbons and arrows respectively. The cysteine residues are labelled, 
numbered and represented by green and gold balls. FAD is labelled and represented by 
green, red, blue and purple balls. Adapted from (Gross et al., 2004) 





Figure 1.5. Comparison of the disulphide bond arrangements in Ero1p, Ero1α and 
Ero1β 
Cysteine residues are labelled according to amino acid position. Those forming 
regulatory disulphide bonds are coloured in purple, the inner active sites are in green, 
the shuttle cysteines are in red and the structural cysteines or those with unknown roles 
are in brown.   
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Disulphide bond production must be controlled by the ER environment to prevent 
hyperoxidation and the oxidative stress associated with excess H2O2. Although the oxidising 
capacity of the ER can be controlled by modifying gene expression levels of Ero1, this is a 
relatively slow process. A much more rapid system exists at the level of protein modulation. 
This is in the form of a feedback mechanism within the Ero1 protein, which senses the ER 
redox status and modifies Ero1 activity appropriately, preventing futile cycles and hyper 
oxidation. A change in the positioning of an Ero1 disulphide acts as a switch, allowing it to exist 
in an active or inactive state. This was first found in Ero1p, which was proposed to have two 
catalytic (Cys352-Cys355 and Cys100-Cys105) and two regulatory (Cys150-Cys295 and Cys90-
Cys349) cysteine pairs. When the ER environment is overly oxidising, a disulphide bond is 
formed between the regulatory cysteines which reduces the activity of the catalytic cysteines. 
The opposite occurs in relatively reducing ER conditions, with the regulatory cysteines reduced 
and the catalytic ones active (Sevier, 2007). In the yeast system, PDI1p is the main regulator of 
activation of Ero1p. It reduces Ero1p regulatory bonds thus causing Ero1p activation (Kim et al., 
2012). 
 
The existence of regulated Ero1α forms in mammals was implied from observations of 
monomeric Ero1α, which appeared as three bands on a non-reducing gel: a reduced form 
(Red), an oxidised form (OX1) and a compact form (OX2), with the Red form migrating the 
slowest, and the OX2 form the fastest. The faster migrating OX2 form was favoured under 
oxidising conditions, and the Red form was apparent when Ero1α was fully reduced (Anelli et 
al., 2002; Benham et al., 2000). An Ero1α/PDI complex was also seen by SDS-PAGE when 
transfected cell lysates were subjected to alkylation along with other high molecular weight 
complexes. The switch mechanism in Ero1α was later identified as a regulatory disulphide 
formed between Cys94 and Cys131, which blocks the catalytic Cys94-Cys99 disulphide 
(Appenzeller-Herzog et al., 2008; Chambers et al., 2010). The Cys131 residue competes with 
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PDI for the interaction with Cys94. A high presence of PDI in reducing conditions would 
outcompete the Cys131 residue, allowing the activity of Ero1α to be re-established (OX1). In 
oxidising conditions, Cys131 would not have as much competition and so interacts with Cys94, 
inactivating Ero1α (OX2) (Appenzeller-Herzog et al., 2008) (Figure 1.6).  The regulatory 
disulphides can be reoxidised by molecular oxygen, however this is a relatively slow compared 
to catalysis by oxidised PDI (Sheperd, 2014). 
 
The interaction of Ero1α and PDI was initially thought not to be solely dependent on inter-
molecular disulphide bonds, since PDI devoid of all of its active site cysteines is still able to 
induce the OX1-OX2 conversion of Ero1. An additional noncovalent interaction between the 
two proteins has been suggested, with PDIs redox dependent conformation exploited to 
optimise delivery of oxidative equivalents (Otsu et al., 2006). More recent studies have shown 
that a single catalytic domain of PDI, or an octapeptide containing the PDI active site, is 
sufficient to regulate the activity of Ero1. This regulation is abolished by an active site 
modifying PDI inhibitor (Zhang, 2014). Zhang also noted that the conformational flexibility of 
the loop between the regulatory cysteines increases following their reduction, which would 
allow hydrophobic interactions with PDI. 
 
  





Figure 1.6. ER redox conditions regulate Ero1α outer active site/shuttle cysteines 
A. Under reducing ER conditions PDI exists in the reduced form and interacts with the 
Ero1α cys94, preventing the interaction between the Ero1α active site and regulatory 
cysteines. The intermolecular disulphide is exchanged, leaving PDI oxidised. B. Under 
oxidising ER conditions PDI exists in the oxidised form and does not compete for the 
Ero1α outer active site disulphide bond; therefore the Ero1α active site cysteines 
preferentially interact and form a disulphide bond with the regulatory cysteines. Adapted 
from (Appenzeller-Herzog et al., 2008).  




The regulatory disulphides are conserved between Ero1α and Ero1β. However, Ero1β does 
contain an extra cysteine, Cys262, which was proposed to engage with Cys100 to form a 
regulatory bond (Wang et al., 2011). However, molecular modelling of the Ero1β structure 
showed the Cys262 side chain to be completely buried. Furthermore, mutation of Cys100 or 
Cys130 hyperoxidises both ERp57 and ER-localised glutathione (GSH) sensors, implicating them 
as regulatory disulphide bond forming cysteines. As the Ero1α and Ero1β regulatory 
disulphides are likely to be shared, it can not explain the loose regulation of Ero1β compared 
to Ero1α. Instead, this has been explained by the inner active site sequence of Ero1β, Cys-Asp-
Lys-Cys, which when mutated into Ero1α in place of its active site Cys-Phe-Lys-Cys substantially 
increases the oxidase activity of Ero1α (Hansen, 2014). 
 
Another level of control has been described in the reoxidation of yeast Ero1p by molecular 
oxygen, suggesting that this reaction is conditional on the levels of free FAD. Ero1p tightly 
bound to FAD can undergo numerous rounds of reduction and oxidation. Despite this, high 
levels of free FAD stimulate the oxidation of Ero1p whilst low levels hinder it. Free FAD is 
unlikely to act as a terminal electron acceptor; instead a low affinity Ero1p binding site could 
bind FAD and act as a sensor, modulating the strongly bound FAD, which couples reoxidation 
of Ero1p to the reduction of oxygen (Tu, 2002). The ER FAD concentration is determined by the 
cytosol, with an FAD equilibrium existing between the two compartments. Such a dependence 
on free FAD could link disulphide production to the metabolic or nutritional status of the cell. 
No such level of control has been seen in mammalian Ero1α, the reason for which is unclear 
(Sheperd, 2014). 
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Ero1p maintains its ER localisation via a 127-amino acid terminal extension whilst the plant 
Ero1 found in the developing endosperm of rice has a rER membrane targeting signal at the N-
terminal region (Onda et al., 2009). No such targeting signal exists in Ero1α or Ero1β. Instead 
the interaction with PDI is required for the ER retention of mammalian Ero1 proteins. Other 
protein-protein interactions also facilitate the secretory pathway localisation of mammalian 
Ero1, for example interactions with the PDI homolog ERp44. It is the C-terminal RDEL motif of 
ERp44 that helps to prevent Ero1 secretion (Anelli et al., 2003; Otsu et al., 2006). Although 
ERp44 and ERp57 appear to form complexes with Ero1, much evidence has been provided to 
suggest that PDI is its main interactor: the amount of PDI that co-immunoprecipitates with 
Ero1 is higher than any other protein, and on western blots PDI is the predominant complex 
formed with Ero1. As well as this, unlike other ER interacting proteins, PDI is required for ER 
reoxidation after Dithiothreitol (DTT) treatment and its depletion and over-expression regulate 
the activity status of Ero1α (Appenzeller-Herzog et al., 2010), although this was later disputed 
when individual over expression of PDIp, P5, ERp46 or ERp57 was shown to accelerate the 
inactivation of Ero1α in vitro. This means that Ero1α is controlled by the redox balance of an 
ensemble of PDIs, which is especially important as it indicates that many PDIs with differential 
expression in particular cell types can also control Ero1α (Zhang, 2014). Regulation is also vital 
in preventing a build-up of misfolded and misoxidised proteins. An uncontrolled system would 
result in hyper oxidising conditions with PDI unavailable to perform its role in isomerisation 
and reduction of misoxidised proteins. 
 
1.9.2 PDI structure 
 
There are over 20 members of the PDI family, most having between one and three redox 
active sites and all with at least one thioredoxin (trx) domain (Kozlov et al., 2010). Thioredoxins 
are small reductases made up of five central β-sheets surrounded by four α helices with a 
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conserved –CGPC- active site motif at the N-terminal of α2 (Eklund et al., 1991). The founding 
member of the family, PDI, is composed of four trx domains, a-b-b’-a’, with an interdomain of 
19 residues (x-linker) between the b’ and a’ domain (Figure 1.7). 
 
The b’ domain forms a hydrophobic pocket where the specificity for oxidation by Ero1α lies 
(Denisov et al., 2009; Inaba, 2010). Some PDIs, such as ERp57, differ in their b’ domains, where 
they have different protein surface and electrostatic potentials. These differences result in 
ERp57 having an intrinsically low reactivity for Ero1α which can be greatly increased by the 
substitution of its b’ domain with that of PDI. Consistently, the replacement of the b’ domain 
of PDI with that of ERp57 resulted in extremely slow oxidation of Ero1α. The b’ domain is PDIs 
main binding site for substrate proteins, however the other domains are also involved in 
binding larger proteins.  This hydrophobic pocket accommodates the protruding -hairpin of 
Ero1α and upon removal of the  -hairpin by mutation the interaction between PDI and Ero1α 
is substantially impaired (Inaba, 2010). Upon formation and cleavage of redox active 
disulphides within PDI, there is a change of conformation which results in at least a 10 fold 
lower affinity for Ero1α. This allows PDI to be efficiently cycled as an oxidised PDI will 
dissociate and not readily bind to ERO1α (Masui, 2011). 
 
As well as binding to Ero1, PDI must also bind effectively to a variety of substrate proteins and 
release them upon oxidation. The large size of the binding pocket allows this by having a low 
degree of specificity for hydrophobic ligands, facilitating release upon acquisition of the native 
structures with fewer hydrophobic residues exposed (Denisov et al., 2009). 
  





Figure 1.7. Schematic of PDI domain structure 
PDI is made up of two a domains, a and a’, and two b domains, b and b’. a’ and b’ are 
connected by an X linked, and a KDEL ER retention motif is found at the C terminal end.   




Initial nuclear magnetic resonance (NMR) studies of individual PDI domains demonstrated that 
the b and b’ domains show little identity in structure to the a and a’ domains; despite this, the 
trx fold is preserved whilst the active site it lost along with the cis-proline residue located near 
the active sites which forms an active site stabilising cis peptide bond (Kemmink et al., 1999). 
 
The redox potential of purified PDI was originally calculated to be E0' = -175 +/- 15 mV, using a 
defined GSH redox buffer, and is thus a good oxidant of protein thiols (Lundstrom and 
Holmgren, Biochemistry 1993).  The a and a’ domain hold active sites and individually have 
similar redox potentials, however the active site in a’ is preferentially oxidised than that in the 
a domain. When the positions of these 2 domains are switched, it is the a domain that is more 
active, therefore the differences in oxidation can be attributed to the active site next to the C-
terminal of b’ being favourably oxidized by Ero1α (Wang et al., 2009). 
 
In its reduced state, the interface between a’ and b’ created by extensive packing shields parts 
of the substrate binding sites, with the hydrophobic residues found here being characteristic of 
ligand binding. Upon oxidation of the a’ active site, its compact conformation is loosened to 
expose the substrate binding sites. This provides a model helping to explain the activity of PDI. 
It is believed that Trp-396, which is adjacent to the a’ active site and interacts with the b’ 
domain when PDI is reduced, senses the redox change and has an important role in triggering 
a conformational change, upon which Trp-396 is exposed (Wang et al., 2012). 
 
The ability of PDI to undergo redox-regulated conformational changes is dependent on the 
presence of the x linker proceeding an active trx-like domain. When mapped out biochemically, 
b’xa’ is the minimal structure required for the conformational change caused when PDI is 
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oxidised by Ero1α. Although PDI has 4 separate trx-like domains, crystal structures show that 
they tightly pack to form one compact structural entity integrated by the x linker (Wang et al., 
2012). 
 
1.9.3 PDI functions 
 
Oxidative folding is not perfect and errors are often made. A common mistake made by the ER 
machinery is to create a disulphide too early in the folding of a protein. These are often non-
native and cause further misfolding, as cysteines that form bonds in the native structure are 
forced out of range. Unless such mistakes are corrected, the misfolded proteins are either 
degraded or aggregate. Oxidoreductases help prevent this from happening as they have the 
capacity to reduce or isomerise non-native disulphides (Kojer and Riemer, 2014). 
 
Other than its oxidoreductase role, PDI also acts as a chaperone and targets misfolded proteins 
for ERAD. The catalytic cysteines of PDIs active sites are not involved in the chaperone activity, 
and so PDI can assist in the folding of model proteins lacking disulphides like GAPDH, citrate 
synthase and alcohol dehydrogenase (Cai et al., 1994; Primm et al., 1996; Quan et al., 1995). 
 
PDI also engages in other functional protein interactions. For example, PDI acts as a subunit to 
prolyl-4-hydroxylase (involved in collagen modification and quality control) and triglyceride 
transferase, stabilising these complexes and localising them to the ER (Bottomley et al., 2001; 
Pihlajaniemi et al., 1987; Wetterau et al., 1990). PDI also forms aggregates with other 
chaperones allowing networks to be created before they bind unfolded proteins, rather than 
assembling on these proteins (Meunier et al., 2002). Chaperone complexes containing PDI are 
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also found in the ER lumen and at the cystolic face of Sec61 where proteins being translated 
acquire the correct topology (Stockton et al., 2003). 
 
PDI has been implicated in certain neurodegenerative and protein misfolding diseases. In 
Parkinson’s and Alzheimer’s disease, a nitric oxide group is added to both the PDI a and a’ 
domain active site cysteines, although only a small fraction is modified, it affects their function, 
and disables the protection PDI provides against the accumulation of protein aggregates. This 
results in a sustained and non-resolving UPR (Uehara et al., 2006). 
 
Although PDI is found mainly in the ER, where is can reach milimolar concentrations (Hillson et 
al., 1984; Lyles and Gilbert, 1991),  PDI is occasionally found in other compartments such as 
the cell surface, cytosol and at mitochondrial associated ER membranes (MAMS), where it 
accumulates in neurons when mutant misfolded huntingtin proteins are expressed. In these 
circumstances, PDI could trigger apoptotic cell death via mitochondrial outer-membrane 
permeabilisation. In contrast, inhibiting PDI in rodent brain cells alleviated the toxicity of 
mutant huntingtin, suggesting that PDI could be therapeutically targeted in neurological 
diseases like Huntington’s chorea (Hoffstrom et al., 2010). On the cell surface, PDI modulates 
free thiols on activated platelets influencing platelet aggregation (Burgess, 2000). Although 
there is a growing body of literature to support the recruitment of PDI to plasma membranes, 
the mechanism by which this is achieved and controlled has remained elusive. 
 
The diversity of the PDI family (21 members in humans) allows them to perform a wide array 
of specific functions owing to different arrangements of their Trx-like domains (Benham, 2012). 
ERp44 possess an a domain endowed with a CRFS motif, followed by the inactive b and b’ 
domains and a carboxy-terminal ER retrieval signal. The CRFS motif reduces its efficiency as an 
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oxidoreductase, but means that disulphides are longer lived due to the absence of the second 
cysteine, making it especially efficient at its role in quality control and protein transport in the 
secretory pathway (Anelli et al., 2003). ERp44 possesses another role as a redox sensitive 
modulator of inositol 1,4,5-triphosphate receptor type 1 (IP3R1) channel proteins that mediate 
Ca2+ release from the ER. ERp44 binds IP3R1, inhibiting its channel activity and modifying the 
generation of Ca2+ signals from the ER (Higo, 2005). 
ERp57 is a close homologue of PDI, with 33% amino acid sequence identity. It differs at the 
substrate binding b’ domain, where it has diverged to preferentially interact with calnexin and 
calreticulin allowing the promotion of oxidative folding of newly synthesised glycoproteins 
(Araki and Nagata, 2011; Frickel et al., 2004). ERp57 also forms part the core of the MHC class I 
peptide loading complex along with tapasin with which it forms a covalent interaction 
accounting for the stability of the complex (Dick et al., 2002). ERp57 is required for proper 
functioning of tapasin whose function involves peptide loading and editing functions (Dong et 
al., 2009). As with ERp44, another of ERp57s roles is in maintaining ER calcium levels. The Ca2+ 
pump sarco ER calcium ATPase (SERCA), is involved with the reuptake of Ca2+ into the ER. 
ERp57 binds and oxidises SERCA when the ER Ca2+ stores are full; the resulting disulphide bond 
inhibits the activity of the pump. When Ca2+ stores are low ERp57 dissociates, leaving behind 
the reduced, more active, SERCA (Li and Camacho, 2004). 
 
PDIp is one of the few PDI family members with specific tissue distribution. Originally throught 
to be only found in the pancreas and involved in proenzyme folding, it was later found in other 
tissues, mainly in digestive enzyme-secreting cells, suggesting its expression and function is 
limited (Desilva, 1997). However, PDIp has a broader role than originally thought, and is 
especially involved in folding secretory digestive enzymes with high expression levels in gastric 
chief cells as well as pancreatic acinar cells (Fu et al., 2009).  




PDILT is another PDI member with specific localisation (Van Lith et al., 2007). Found in the 
post-meiotic germ cells of the testis, it interacts with the testis-specific calreticulin-like 
chaperone, calsperin, and with the calnexin homolog calmegin, to mediate the quality control 
of disintegrin and metalloprotease domain 3 (ADAM3), required for sperm migration and zona 
pellucida binding. With only one cysteine in the two a domain active sites, PDILT is not 
involved in disulphide bond oxidation or reduction, but is likely to have a chaperone or 
scaffolding function (Tokuhiro, 2012). 
 
1.9.4 Reactive oxygen species 
 
One molecule of H2O2 is generated for every disulphide produced and molecular oxygen 
consumed by Ero1α. If kept at sufficiently low concentrations (submillimolar), H2O2 has been 
shown to refold model proteins, meaning two disulphides could be produced from molecular 
oxygen without harmful by products. This refolding could occur directly by the peroxide, or via 
PDI (Nguyen et al., 2011). Despite this potential for recycling H2O2, and although other 
mechanisms exist to offset this H2O2 production, if disulphide production is not regulated, 
excess H2O2 produced is detrimental to the cell. However, such regulation also has to maintain 
the ER redox conditions and optimise oxidative folding of native disulphide bonds, so the 
regulation of the Ero1α cycle is not necessarily solely designed to minimise H2O2 production. 
There is some evidence to suggest that disulphide bond formation, and the resulting reactive 
oxygen species (ROS), does not induce oxidative stress per se; rather it is misfolded proteins, in 
conjunction with resulting ROS, which is responsible for oxidative stress (Malhotra et al., 2008). 
This means that effective systems to offset the production of H2O2 must be present. There are 
three peroxidases within the mammalian ER that may do this, namely peroxiredoxin IV (PrxIV), 
GSH peroxidase 7 (GPx7) and GSH peroxidase 8 (GPx8). There are 8 members of the human 
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GPx family, and despite their name suggesting they are catalysts in a reaction between 
peroxide and reduced GSH, the 2 ER resident GPx members (GPx7 and GPx8) lack the GSH 
recognising residues and GPx catalytic residues found in the other GPx family members. They 
instead are members of the GPx-like peroxidase (TGPx) family with PDI peroxidase activity. 
Their expression increases the activity of 4 out of 5 PDI family members tested in vitro. ERp57, 
whose activity was not increased by GPxs, differs in its substrate specificity and b’ binding site. 
This may provide an explanation as to why GPx7 and GPx8 does not increase the activity of 
ERp57 (Nguyen et al., 2011). GPx7 (and probably GPx8) is able to offset the production of H2O2 
by H2O2 oxidising Cys57 to a sulfenic acid, leaving H2O to be released. Cys86 then attacks Cys57 
or the PDI a active site cysteine forming an inter- or intra-molecular disulphide; again this 
releases an H2O molecule. The disulphide is now transferred to the PDI active site to leave PDI 
oxidised and GPx7 reduced (Figure 1.8). In vitro, GPx7 interacts with the a domain of PDI whilst 
Ero1α does so with the a’ domain in a sequential manner. Consequently, it has been suggested 
that GPx7 may also be transiently close to PDI during the oxidative folding cycle (Wang, 2014). 
 
There is some evidence from bimolecular fluorescence complementation (BiFC) to suggest that 
GPx7 and GPx8 can physically and functionally interact with Ero1α. GPx8 (and presumably 
GPx7) associates with an Ero1α molecule, stabilising the 32 amino acid loop region between 
Cys208 and Cys241. Mutation of this region in Ero1α led to a decreased BiFC signal. This 
position puts GPx8 in close proximity to the site of peroxide exit from Ero1α allowing the 
peroxide to be utilized immediately (Nguyen et al., 2011; Ramming et al., 2015). Gpx8 is 
predicted to be a type 1 transmembrane protein, with its catalytic domain in the ER and a 
short N-terminal cytoplasmic region. 
  





Figure 1.8. Catalysis of disulphide bond formation by GPx7 and PDI from H2O2 
H2O2 oxidises GPx7, with Cys57 forming a sulfenic acid and releasing H2O. Another H2O is 
released upon forming a disulphide between GPx7 Cys57-Cys86, which is passed onto 
Cys57-PDI through thiol-disulphide exchange (shown on left). Alternatively, upon release of 
the second H2O, a disulphide is formed directly between Cys57-PDI (shown on the right). 
Finally the intermolecular disulphide bond is passed onto PDI to form an oxidised PDI 
active site.  Adapted from (Wang, 2014). 




Knockdown of GPx8 causes an elevation of the UPR and antioxidant response markers as well 
as increasing oxidation of the cytosol. Knockdown of PrxIV does not induce the same response, 
suggesting that there is some functional separation between the two proteins, with PrxIV 
targeting H2O2 of an unknown origin and only reacting with H2O2 produced by Ero1α when it is 
at high concentrations. It is likely that the interaction between Ero1α and Gpx8 prevents PrxIV 
from gaining access to Ero1α derived H2O2 (Ramming et al., 2014). Further to this, GPx8 is 
potentially stabilised by its interaction with Ero1α. Such a reliance may provide further 
evidence for a functional separation (Ramming et al., 2015). 
 
Another method of disulphide generation is via the VKOR enzyme. VKOR is a transmembrane 
protein with two conserved cysteine pairs, which catalyse the reduction of vitamin K epoxide 
to vitamin K hydroquinone, an activity that is crucial for the function of blood clotting factors. 
Homologues of the human VKOR enzyme have been described as an alternative oxidiser of PDI 
in humans and is present in numerous other organisms, such as bacteria, including 
cyanobacteria, and mammals (Schulman, 2010; Singh et al., 2008). Oxidised VKOR is able to 
exchange its disulphide with trx-like oxidoreductases. When VKOR or Ero1 is knocked down 
alone in HepG2 cells, the effects are minimal, but when both genes are ablated in combination, 
disulphide bond formation in the model protein albumin is delayed (Rutkevich and Williams, 
2012). 
 
The presence of multiple oxidative folding pathways, which are independent of Ero1 is implied 
by mice with complete loss of function of Ero1. Although these mice have an enhanced load of 
unfolded protein intermediates and are subjected to the UPR, along with other abnormalities, 
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they are still viable (Zito et al., 2010). The same loss of function is fatal in C. elegans, suggesting 
that the presence of extra oxidative pathways is exclusive to mammals. 
 
1.9.5 ER oxidising equivalents 
 
The oxidising conditions in the ER must be maintained for optimal disulphide bond formation. 
GSH plays a huge part in ensuring redox homeostasis by acting as a redox buffer. GSH is a low 
molecular weight thiol synthesised in the cytosol, where it is maintained in its reduced form by 
GSH reductase. This maintains the reducing conditions in the cytosol, meaning disulphides are 
rarely formed here (Hwang et al., 1992). GSH is delivered into the ER where it serves as a 
reducing equivalent and balances oxidation by Ero1. Once in the ER, part of the GSH pool 
becomes oxidised and this GSH disulphide (GSSG) can no longer diffuse out of the ER (Banhegyi 
et al., 1999). Under reducing conditions, GSSG can oxidise reduced PDI, which in turn regulates 
Ero1 activity. Although disulphide formation can occur in the absence GSH and GSSG, it is 
thought that they still play an important role in the ER, with low GSH levels accelerating non-
native disulphide formation (Chakravarthi and Bulleid, 2004). Furthermore, GSH levels rise 
during oxidative stress and help eliminate ROS, indicating that GSH has both protective and 
disulphide bond forming roles (Chakravarthi et al., 2006).  However, a more recent study 
shows that depletion of GSH does not have measurable effects on ER disulphide bond 
formation and thus is not needed to maintain thiol redox or folding homeostasis (Tsunoda et 
al., 2014). This questions the importance of GSH in ER redox and suggests that other small 
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1.10 The MHC 
 
Oxidative protein folding in the ER introduces disulphide bonds into client or substrate 
proteins, and the main client to be considered in this thesis is the Major Histocompatibility 
Complex (MHC). The MHC is a family of genes that play a significant role in the immune system 
by presenting peptide antigens to T cell receptors. The MHC proteins are synthesised in the ER 
and therefore a knowledge of their disulphide bond formation and ER quality control is 
important for understanding susceptibility to infection, autoimmunity and immune disease.  In 
humans the genes for the MHC, called human leukocyte antigens (HLA), encompasses about 
3.6 megabase pairs and is found on the short arm of chromosome 6 at 6p21.3 (Fernando et al., 
2008).  The HLA gene cluster is divided into three regions, encoding class I, II and III genes.  
Class I and II are classical HLA genes, the proteins they code for bind peptides intracellularly 
and present them at the cell surface to provide a means of self-identification for subsequent 
immune recognition. 
 
1.10.2 MHC class I 
 
MHC class I molecules are found on nearly all nucleated cells (Ploegh et al. 1981). These 
transmembrane heterodimers and are composed of a highly polymorphic heavy (α) chain 
composed of three domains, α1, α2 and α3. Domains α1 and α2 make up the antigen binding 
site, and α3 associates with the light chain β2 microglobulin (Figure 1.9). The MHC class I 
molecule binds intracellular peptides (e.g. those derived from viruses) that have been 
transported from the cytosol into the endoplasmic reticulum. The process of MHC class I 
assembly and binding to high affinity peptides requires the assistance of a set of the ER 
chaperones including calnexin, calreticulin and ERp57 (previously discussed in sections 1.4) 
which make up the peptide loading complex (PLC). This is responsible for recognising and 
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loading of peptides onto the MHC class I- β2 microglobulin heterodimer. The PLC begins to 
form following the synthesis of the heavy chain, which interacts with BiP and calnexin. The 
light chain attaches to this complex prompting calreticulin to replace calnexin and stimulating 
the recruitment of the other PLC components, namely tapasin, ERp57 and TAP (the peptide 
antigen transporter). Upon completion of peptide loading, the removal of a last glucose 
residue allows MHC class I trafficking and progression through the secretory pathway. Quality 
control mechanisms prevent MHC class I molecules which are unstably bound to peptide from 
exiting the ER; these molecules are re-glycosylated and given another opportunity to bind high 
affinity peptides (reviewed in (Hulpke and Tampe, 2013)). Recently Ero1α has also been 
described to have a role in the correct formation of the PLC. MHC class I has two disulphide 
bonds in the α2 and α3 domains which must be created before interaction with the MHC class 
I light chain. Whilst the heavy chain is complexed with calnexin, it has been proposed that 
Ero1α associates with the heavy chain through calnexin and, via PDI, mediates heavy chain 
oxidation (Kukita et al., 2015). 
 
The MHC class I molecule traffics to the cell surface once a high affinity peptide has been 
bound. Here CD8+ T cell receptors recognise antigen derived peptides in the context of MHC 
class I, causing them to proliferate and induce the destruction of the cell that is presenting a 
“foreign” peptide (Madden, 1995). 
 
1.10.1 MHC class II 
 
MHC class II molecules present peptides from extracellular material to T-cells to initiate an 
immune response. They present the peptide in such a way that they can be bound by specific T 
cell receptors on the surface of CD4+ T cells. This activates further downstream effects, such as 
T-cell proliferation, antibody production and effector T-cell function, which help form an 
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immune response to eliminate the pathogen (Berger and Roche, 2009). These transmembrane 
glycoproteins are able to bind a vast array of peptides due to their highly variable peptide-
binding site. This is formed by the interaction of the two chains of the MHC class II molecule. 
This heterodimer consists of a 33-35 KDa α chain and a 26-28D Kd β chain, both of which have 
a transmembrane region, a cytoplasmic unit and two extracellular domains (named α1/α2 in 
the α chain, and β1/β2 in the β chain). The peptide binding site is formed by β-pleated strands 
and α helical formations made by the α1 and β1 domains (Marsh, 2000)(Figure 1.9). 
 
In humans, three different loci encode class II MHC molecules: HLA-DP, DR and DQ. Although 
these isotypes are about 70% similar to each other the proteins have different stabilities and 
requirements for their intracellular assembly (discussed in 1.10.4). Variation in the repertoire 
of peptides able to bind to MHC class II molecules is not only created by the different isotypes, 
but also by the great level of polymorphism seen within them, most of which is concentrated 
in, or around, the peptide-binding site. MHC class II molecules are co-dominantly expressed, 
which increases the range of presented peptides that CD4+ T cells are able to respond to. 
 
MHC class II molecules are found in professional antigen presenting cells (APC) (Hitbold, 2002). 
Professional APCs include dendritic cells, macrophages and B-lymphocytes. These are cells 
whose specialized function is to acquire, process and express exogenous antigens at the cell 
surface in the context of MHC class II. In general, CD4+ cells, which are only able to recognise 
peptides presented by MHC class II molecules, are either activated or induced to become 
regulatory cells according to the affinity of the presented peptide and the nature of the local 
cytokine environment. The ligation of co-receptors provides co-stimulatory signals for 
activation, with T cell receptors such as CD28 interacting with CD80 or CD86 in APCs. Their 
expression of MHC class II may differ as they develop and their role changes, for example, 
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dendritic cells show a rapid increase in MHC class II transcription following maturation 
(Landmann et al., 2001). 




Figure 1.9. Comparison of MHC class I and II molecules 
MHC class II mollecules are composed of an α chain (composed of α1 and α2) and a β chain 
(composed of β1 and β2). α1 and β1 make up the peptide binding site which binds 
exogenous peptides and presents them to CD4 T cells. MHC class I molecules are 
composed of three α domains, α1, α2, and α3, of which α1 and α2 make up the peptide 
binding site, and α3 associates with β2 microglobulin. They bind endogenous peptides 
which are presented to CD8 T cells.  
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1.10.3 MHC class II assembly 
 
The trafficking of MHC class II molecules is slightly more complicated than MHC class I as they 
must be prevented from binding cytosolically derived peptides following biosynthesis in the ER, 
where the α and β chain join to form a heterodimer. To prevent the loading of ER localised 
peptides into the MHC class II peptide binding site, the invariant chain (Ii) associates with this 
groove. By preventing premature peptide binding, Ii allows the MHC class II molecules to 
continue assembling and folding correctly. 
 
The mechanism by which the MHC class II subunits assemble with Ii is still open to question. 
MHC class II α and β chains are able to efficiently form dimers however these tend to be 
misfolded, resulting in lost epitopes and inefficient transport through the secretory pathway, 
as found from experiments using conformation specific antibodies (Anderson and Miller, 1992). 
Ii acts as a chaperone, promoting effective association and folding of the α and β chain. Four 
forms of Ii exist, all synthesised from the same precursor mRNA by alternate splicing (Strubin 
et al., 1986). The two short versions, p41 and p43 have low expression levels and a protease 
inhibitory domain, whereas the 2 most predominant ones, p33 and p35, have a ER retention 
sequence in an extended N-terminal cytoplasmic domain (reviewed in (Cresswell and Roche, 
2014)). p33 and p35 can form mixed trimers via the Ii trimerisation domain, that acts as a 
scaffold for the attachment of 3 MHC class II αβ pairs. The trimer is retained in the ER by a 
retention signal in p35; the ability to leave the ER may be attained by a change in conformation 
in the cytoplasmic tail, or by the masking of the retention signal by the α and β chains (Lamb, 
1992). This model has been questioned recently by the idea that Ii matches the αβ pairings by 
binding only one α chain in the scaffold which it then matches to a β chain (Koch, 2007, 2011). 
Although Ii nonamers have been demonstrated for HLA-DR1, it is not clear whether HLA-DP 
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or HLA-DQ class II molecules are assembled by the same route, or whether all HLA-DR allelic 
variants require nonamer formation for their onward transport. 
 
A leucine-isoleucine motif found in the cytoplasmic tail of Ii targets the Iiαβ trimer to a late 
endosomal compartment known as the MHC class II compartment (MIIC), thus Ii also acts as a 
trafficking protein (Pieters J, 1993). In order to reach the MIIC, MHC class II travels through the 
endosomal-lysosomal pathway. Here the compartments become increasingly acidic, activating 
various cathepsin proteases which start to break down Ii into a small fragment, Class-II-
associated invariant chain peptide (CLIP), found in the peptide binding groove of the MHC class 
II αβ heterodimer. CLIP is exchanged for antigenic peptides in a process mediated by the MHC 
class II chaperone HLA-DM (Figure 1.10). 
 
Unlike the classical HLA molecules, such as HLA-DP, DR and DQ, DM is not expressed on the 
cell surface but assists in antigen presentation. HLA-DM binds directly to the αβCLIP complex 
in the MIIC, releasing CLIP from the peptide-binding site, and allowing peptide exchange. There 
is a vast array of peptides in this compartment originating from internalized exogenous 
molecules. These travel through the endocytic membrane transport pathway where they 
encounter resident proteases and are broken down into short peptides, to which MHC class II 
molecules are able to bind. The exchange of these peptides is catalysed until a stable 
αβpeptide complex is formed by an incorporated, generally high affinity, antigenic peptide 
(Busch et al., 2005). Peptide loaded MHC class II molecules are presented at the cell surface 
after the membrane fusion of complexes from endosome derived vesicles (Hitbold, 2002). 
 
  





Figure 1.10. MHC class II trafficking 
MHC class II heterodimers assemble in the ER. The binding of Ii at the peptide binding site 
prevents premature binding to antigenic peptides, stabilises the dimer, and targets it for 
the endosomal pathway. Caspases in the early endosome cleave Ii into CLIP, which is 
removed with the assistance of HLA-DM allowing MHC class II to bind protein antigens, 
which have been internalised and broken down. The peptide-MHC class II complex is then 
trafficked to the plasma membrane. 
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1.10.4 MHC class II haplotypes 
 
Although the three haplotypes, HLA-DP, DR and DQ, perform the same general function of 
presenting peptides to CD4+ T lymphocytes, the properties of individual allelic variants and the 
peptides they are able to present differ. DR and DQ have been studied more extensively than 
DP and, in comparison, much more is known about these two isotypes. The differences 
between the three isotypes infer differences in their selectivity in binding peptides. DR 
molecules are most likely to shelter aromatic and hydrophobic residues in the conserved 
peptide binding pockets whilst DQ prefers relatively short side chains (Raddrizzani et al., 1997). 
These differences allow a large repertoire of peptides to be bound and presented by HLA 
molecules. However, DP molecules are only able to bind a much more limited set of peptides 
in comparison with DR and DQ (Sidney et al., 2010). 
 
Cell surface expression of DP molecules is significantly less than that of DR and DQ (Diedrichs 
and Schendel, 1989). This has implications for the level or nature of immune responses they 
are able to initiate, with the possibility that alterations in expression level could lead to 
associations with disease. Unusually high expression of certain DP alleles, such as DPB1*01:01, 
may provide a functional basis for increased susceptibility to chronic hepatitis B virus (Thomas 
et al., 2012). 
 
As well as there being variability in the binding of peptides between the three classical MHC 
class II molecules, there are also differences in their assembly and stability requirements. 
Although all three isoforms require Ii for their targeting to endosomal compartments, a 
portion of DP molecules can form a stable dimer in its absence (van Lith, 2010). The three MHC 
class II molecule types also differ in their requirement for HLA- DM. DP and DQ can form stable 
dimers without DM, however the amount of dimer always increases when DM is introduced. 
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The ability of DP to form stable dimers without Ii and DM may indicate that other, unknown, 
accessory factors may help stabilise DP dimers. It is not known whether these dimers are 
stabilised by ER derived peptides or whether DPcomplexes are intrinsically more stable 
than their DR or DQ counterparts. 
 
Although MHC class II molecules are highly specialised and their function closely regulated, 
they are often linked to immune diseases. Different HLA- DP alleles are often protective 
against, or make an individual more susceptible to, immune dysfunction and autoimmune 
diseases. The potential of there being different accessory factors involved with DP could 
provide an explanation as to why certain diseases, like chronic hepatitis B, are linked to DP 
(Kamatani et al., 2009). Often it is unknown why certain MHC class II molecules are associated 
with disease, but sometimes this can be explained by inefficient interactions with peptides or 
accessory proteins. Examples of this include the possibility that different alleles are less 
susceptible to cathepsins which reduce Ii to CLIP (Hsing and Rudensky, 2005), that different 
alleles have lower or higher affinities for CLIP (Busch et al., 2005), or that different class II-
peptide complexes have different susceptibilities to the action of HLA-DM. Often the “classical” 
HLA molecules are associated with protection against diseases, and in some of these cases the 
expression of certain genes is linked with an increase in the levels of HLA-DM. This results in 
increased stability of MHC class II molecules, leading to an elevated immune response. An 
example of this is in acute myeloid leukemia where a good clinical outcome is associated with 
a chromosomal abnormality, bringing the ETV6 and AML1 genes together. This rearrangement 
increases the expression of HLA-DR and HLA-DM (Jastaniah et al., 2006). 
 
Certain HLA-DR or DQ molecules associated with autoimmune diseases may bind inefficiently 
to Ii, for example in rheumatoid arthritis (Patil et al., 2001). Whether this kind of inefficient 
binding in relation to DP molecules would also initiate an autoimmune response is 
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questionable due to its ability to form stable dimers without Ii. Although less is known as to 
how DP contributes to immune dysfunction, it is known that DP is associated with hepatitis B 
(Kamatani et al., 2009), and beryllium disease. In beryllium disease, DP molecules with a 
glutamic acid at position 69 have been linked with susceptibility (Richeldi et al., 1993). This 
glutamic acid may change the conformation of a pocket within the peptide binding groove, 
making it larger and allowing access to beryllium. Additionally, a solvent-exposed pocket 
amino acid may also favour beryllium binding. It is the increased affinity for and subsequent 
binding of beryllium that triggers an adverse immune response to the heavy metal in the 
environment (Silveira et al., 2012). Further investigation into DP folding and quality control 
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1.11 Thesis aims 
 
Both Ero1a and Ero1b are tightly regulated in the ER. This allows the introduction and 
isomeration of native disulphide bonds by PDI whilst also maintaining the ER redox balance. 
This thesis aims to investigate Ero1 and its putative substrate MHC class II by:  
 
Gaining a better understanding of how Ero1 activity is controlled, and how Ero1 structures are 
affected and contribute to the impact of homocysteine treatment. 
 
Investigating the difference between the control of Ero1α and Ero1β and whether this changes 
in different cell types. 
 
How changes in Ero1 activity affect the ER folded MHC class II, as well as factors influencing 
the stability of MHC class II. 






2. Materials and Methods 
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2. Materials and Methods 
 
2.1 Cell culture  
 
The human melanoma MelJuso cell line and the human fibrosarcoma HT1080 cell line were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, ThermoFisher Scientific), 
and the human cervical carcinoma HeLa cells in Minimum essential medium (MEM, Gibco, 
ThermoFisher Scientific). The media was supplemented with 2mM glutamax (Gibco, 
ThermoFisher Scientific), 8% foetal calf serum (Sigma), 100 Units ml-1 penicillin and 100 
micrograms ml-1 streptomycin (Sigma). The human monocytic leukemia THP-1 cell line and the 
human lower esophageal  adenocarcinoma OE33 cell line were maintained in RMPI 1640 
(Gibco, ThermoFisher Scientific) supplemented with 2mM glutamax, 100 Units ml-1 penicillin, 
100 micrograms ml-1 streptomycin, and 10% foetal calf serum. All of these cultures, except 
THP-1 cells, were passaged every 48-72 hours, when at about 90% confluent. To passage the 
adherent cells, they were washed twice with phosphate buffered saline (PBS) (Sigma) and 
trypsinised using 0.05% trypsin (Gibco, ThermoFisher Scientific) for 5 minutes at 37ᵒC until the 
cells lost their attachments to the dish. The cells were resuspended in fresh media, and diluted 
1:10 into fresh media for reseeding onto 10cm dishes or flasks. The THP-1 cell line was 
passaged by spinning down at 218 g for 4 mins, washing with PBS and resuspending. The 
media was refreshed once a week. All cells were free from mycoplasma and maintained at 5% 
CO2 and 37 








2.2 Tissue samples 
 
Tissue samples were obtained from FVB or C57BL/6 mice by dissection after schedule 1 killing. 
Liver and pancreas tissue samples were either cut into small pieces and snap frozen placed in 
liquid nitrogen, or placed into a vessel containing PBS on ice for immediate usage. Single cell 
suspensions were made by passing tissue through a 40 m cell strainer (BD biosciences) in PBS. 
The suspended cells were pelleted at 400g for 5 min and resuspended in complete media. 
HT1080 cells were trypsinised, washed in PBS, and resuspended in complete media to make 
single cell suspensions.  
 
2.3 Antibodies  
 
The polyclonal rabbit antisera against PDI was generated by immunising rabbits with a purified 
rat PDI protein preparation, as described (Benham et al., 2000). The polyclonal D5 antiserum 
against Ero1α was raised in rabbits against a purified MBP-Ero1α fusion protein (Mezghrani et 
al., 2001). The monoclonal antibody 2G4 was raised against recombinant Ero1α and was a kind 
gift from Prof. Roberto Sitia. The polyclonal antibody against Ero1β (4131) was raised against a 
unique internal peptide YTGNAEEDADTKTLL and generated for the laboratory by Sigma 
Genosys (Dias-Gunasekara, 2005). 
 
The mouse monoclonal antibody raised against βactin (Abcam, ab8224), the mouse 
monoclonal antibody raised against myc (antigen EQKLISEEDL, Cell Signalling, 9B11), the 
mouse monoclonal antibody raised against HA (antigen YPYDVPDYA, Cell Signalling, 262K), the 
mouse monoclonal antibody raised against V5 (antigen GKPIPNPLLGLDST, Invitrogen, 46-0705), 
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and the mouse monoclonal antibody raised against TLR3 (Imgenex, 40C1285.6) were 
commercially available.  
 
The mouse monoclonal antisera HC10, raised against free MHC class I B and C allele heavy 
chains (Stam et al 1986), the mouse monoclonal 1B5, which was raised against the C-terminus 
of the MHC class II DRα heavy chain, the rabbit polyclonal antisera raised against the MHC 
class II DP, which recognises the DPβ and weakly recognises the DPα when DPαβ are co-
expressed, and the rabbit polyclonal antisera raised against the MHC class II DRβ and DP, 
which primarily recognises the DPβ chain, but also faintly detects DPα chain, were kind gifts 
from Prof. J. Neefjes, Netherlands Cancer Institute, The Netherlands.  The concentrations or 




For leupeptin and NH4Cl treatments, cells were incubated with complete media containing 15 
nM leupeptin, 20 mM NH4Cl or mock treated with complete media only for 1 hour. Cells were 
washed with PBS and analysed by immunofluorescence. 
 
Homocysteine and cystathionine treatments were carried out by incubating cells with 0, 0.1, 1 
or 10 mM homocysteine or cystathionine in complete media for 1 hour. Cells were then 
washed and lysed for protein analysis. 
 
  




Table 1- Antibody concentrations and dilutions used for western blotting and 
immunofluorescence 
Antibody  Application  Dilution  
Anti-PDI (pAb) WB 1:1000 
D5 (pAb) WB 1:1000 
Anti-actin (mAb) WB 1:1000 
Anti-myc (mAb) WB 1:1000 
Anti-HA (mAb) WB 1:2000 
Anti-V5 (mAb) WB 1:500 
Anti-TLR3 (mAb) WB 1:500 
Anti-TLR3 (mAb) IF 1:25 
HC10 (mAb) WB 1:200 
Anti-DRβ (pAb) WB 1:1000 
Anti-DP (pAb) WB 1:1000 
Anti-DP (pAb) IF 1:200 
1B5 (mAb) WB 1:1000 
1B5 (mAb) IF 1:200 
4131 (pAb) WB 1:200 
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Ascorbic acid treatments were carried out alongside 0, 1 or 10 mM homocysteine incubations, 
as described above. Zero, 10, 100 µM or 1 mM ascorbic acid was mixed with each 
concentration of homocysteine in complete media prior to application, and the cells were 
incubated with these reagents for one hour. After incubation, cells were lysed for protein 
analysis. 
 
The single cell suspensions were treated with either 10 mM homocysteine or 10 mM DTT in 
complete media, or mock treated with complete media alone for 1 hour with agitation. Cells 
were lysed and the lysates taken for protein analysis, as previously described.   
 
ER Tracker or Lyso Tracker (both Invitrogen) were applied to cells at a 1:2000 or 1:5000 
dilution respectively, 10 mins prior to imaging cells. 
 
The chemicals used were obtained from Sigma unless otherwise stated.  
 
2.5 RNA extraction 
 
To obtain nucleic acids from tissue culture cells, the cells were washed twice with PBS and 
lysed in 250μl TRI-reagent (Sigma). After the addition of 50μl chloroform, the lysates were 
vortexed and centrifuged for 15 mins at 4°C at 16,100 g in a bench-top centrifuge (Eppendorf). 
The top phase was removed, added to 125μl isopropanol, vortexed, left on ice for 10 mins and 
then centrifuged for 10 mins at 16,100 g. The supernatant was removed and the pellet was 
washed with 400 μl 75% ethanol, vortexed and spun at 7,600 g for 5 mins. The supernatant 
was removed, pellets air dried and resuspended in 10 μl nuclease free water. 






Spectrophotometry was used to determine the concentration of extracted RNA using a 
spectrophotometer (ND-1000 LabTech international). Samples were diluted to 50 ng/μl for RT-
PCR. An AccessQuick RT-PCR kit (Promega) was used to subject 50 μg RNA to RT-PCR.  The 
cycling protocol used for RT-PCR was 45 °C for 1 hr, 94 °C for 2 mins, (94 °C for 30 secs, 60 °C 
for 1 min, 72 °C for 1 min) 30 times, then 72 °C for 5 mins with the PCR being held at 4°C upon 
completion of the cycle. Resulting cDNA was run on 1% agarose gel (1% agarose w/v made up 
in 120 ml of TE buffer and 5.5 µl ethidium bromide (Fisher Scientific), to stain the gel) at 100 
mV for about 40 mins. The DNA was visualised by exposure of the agarose gel to UV light and 
the gel photographed on a Uvidoc system. The primers designed and used in this study are 
shown in Table 2. 
 
2.7 Cell lysis for protein analysis 
 
Cells in tissue culture were washed twice with PBS and lysed for subsequent protein analysis at 
4°C in MNT lysis buffer (1% Triton-X100, 20 mM MES, 30 mM Tris-HCl, 100 mM NaCl, pH 7.4 
and the protease inhibitors cystatin, leupeptin, antipain and pepstatin A at 1 microgram/ml). 
Unless stated, lysis buffer was supplemented with 20mM N-ethylmaleimide (NEM) to prevent 
disulphide bond rearrangement. Lysates were centrifuged at 16,100 g for 10 minutes at 4°C to 
remove nuclei. The post nuclear supernatants were either snap frozen in liquid nitrogen or 
taken forward for further analysis by sodium dodecyl sulfate (SDS) -PAGE. 
 
  




Table 2- RT-PCR primers 
mRNA Target Product size Direction  Primer 
β-actin 823 Forward  CCACACCTTCTACAATGAGC 
-actin Reverse  ACTCCTGCTTGCTGATCCAC 
TLR3 749 Forward  CACGCAAACCCTGGTGGTCCC 
TLR3 Reverse  ACACCCGCCTCAAAGTCCCT 
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2.8 Determination of protein concentration 
 
Protein concentration of cell lysates was carried out using the Biorad DC Protein Asssay kit, an 
assay based upon the colour change of a Coomassie Brilliant Blue G-250 dye in response to 
different protein concentrations. Twenty µl of each protein sample was mixed with 100 µl of 
the dye reagent, vortexed and incubated at room temperature for 5 mins. Absorbance was 
measured at 595 nm using an Eppendorf Biophotometer. A blank was made with lysis buffer. 
Protein standards from 0.2-0.9 mg/ml were made with Bovine Serum Albumin (BSA) and used 




Prior to analysis, lysates were prepared by the addition of 2x Laemmli loading buffer (4% SDS, 
20% glycerol, 120 mM Tris-HLC pH 6.8, 0.02% bromophenol blue) and where stated, 50mM 
DTT was added to the samples to reduce disulphide bonds. Samples were boiled for 5 mins at 
95°C unless otherwise stated, and spun down for 1 min at 16,100 g. Samples were run on 12% 
SDS-PAGE gels (Running gel: 24% ProSieve 50 acrylamide solution (Lonza), 600 mM Tris pH 8.8, 
0.1% SDS, 0.1% ammonium persulfate (APS) and 0.04% N,N,N’,N’-Tetramethylethylenediamine 
(TEMED, Sigma). (Stacking gel: 5% ProSieve 50 acrylamide solution, 130 mM Tris pH 6.8, 0.1% 
SDS, 0.1% APS and 0.075% TEMED). The running gel was cast and left to polymerise for ~40 
mins topped with 500 l of water. The water layer was removed, the stacking gel was cast on 
top of the running gel, a 10 or 15 well comb was placed in the stacking gel and the stack was 
left to polymerise for ~20 mins. Once the gel had polymerised, cell lysates in Laemmli sample 
buffer were loaded alongside a protein marker (Fermentas or Biorad) and the gel was run in 
Tris-Glycine-SDS running buffer (Biorad) for ~1 hour at 50mA. After SDS-PAGE, the gels were 
either stained using Coomassie blue or taken for western blotting.  




2.10 Comassie staining 
 
Following electrophoresis, the gel was fixed for 30 minutes in fixing solution (Sigma). The fixing 
solution was removed and the gel was covered in working solution (4 parts Brilliant blue G-
colloidal concentrate (Sigma), 1 part methanol (Fisher Scientific)) and stained overnight with 
constant agitation. The gel was then destained with 10% acetic acid (Fisher Scientific) in 25% 
methanol for 60 seconds, washed with 25% methanol, and destained in 25% methanol for up 
for 24 hours with constant agitation. The gel was then dried on a SICE-PLAS gel drier. 
 
2.11 Western blotting 
 
Following electrophoresis, the proteins on the gels were transferred to polyvinylidene 
difluoride (PVDF) membranes which had been primed in methanol for 20 seconds. Transfer 
took place in transfer buffer at 4 oC (25 mM Tris, 1.5 M Glycine and 20% methanol), either for 2 
hr at 150 mA or overnight at 30 V. Membranes were blocked overnight in 4% w/v milk powder 
dissolved in Tris buffered saline (TBS) (10 mM Tris pH 8, 150 mM NaCl) with 0.1% Tween (TBST). 
Membranes were incubated with primary antibody diluted to the appropriate concentration 
(see Table 2) in 1% milk in TBST for between 40 mins and 1 hr, then washed four times for 5 
mins with TBST. Following this, membranes were incubated with the corresponding secondary 
antibody, either goat anti-mouse HRP or swine anti-rabbit HRP (both DAKO) diluted to 1:3000 
in 1% w/v milk powder in TBST for 40 mins, and again washed four times for 5 mins in TBST. 
The membranes were visualised by the application of 500 μl ECL (GE Healthcare) which was 
prepared from mixing equal parts of luminol solution and peroxide solution. The ECL mix was 
applied to the membrane for 1 min under Saran wrap, to ensure even distribution of the fluid. 
Following this step, excess ELC was removed, and the membranes wrapped in fresh Saran 
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wrap. The membrane was exposed to photographic film (Kodak,) which was developed using 
an X-ray developer machine (XOMAT). 
 
2.12 Immunofluorescence  
 
Cells in tissue culture were grown on cover slips distributed into 6 cm dishes or 6 well plates. 
The cover slips were treated with 10% poly-l-lysine for 10 mins and washed with sterile PBS. 
After cell adherence and growth in tissue culture medium, the cells were washed twice with 
PBS fixed with 4% paraformaldehyde for 15 mins and washed in PBS++ (PBS with 1 mM CaCl2 
and 0.5 mM MgCl2). Free aldehyde groups were quenched with PBS++ containing 50 mM 
NH4Cl2, and cells were again washed three times in PBS++. Cells were permeabilised with 0.1% 
Triton x 100 in PBS++. Following a wash in PBS++, and two washes in PBS++ with 0.2% BSA, 
coverslips were incubated in 20 μl primary antibody diluted to the appropriate concentration 
(see Table 2) in PBS++ with 0.2% BSA for 20-40 mins in a dark moist chamber. Primary antibody 
was washed off with three washes of PBS++ with 0.2% BSA, and coverslips were incubated 
with the corresponding fluorescent conjugated secondary antibody, either goat anti-mouse 
Alexa Fluor 488 (green), donkey anti-rabbit Alexa Fluor 488 (green), and donkey anti-rabbit 
Alexa Fluo594 (red) (all from Molecular Probes), diluted to a concentration of 1:1000. 
Coverslips were washed twice with PBS++ with 0.2% BSA, twice with PBS++, once with PBS++ 
containing 1x DAPI (Invitrogen) to counter stain the nuclei, and once with water to remove 
excess PBS. The coverslips were mounted onto slides by inverting them onto a drop of 
mountant containing ant-fade (Vectashield) and secured with nail varnish. The coverslips were 
imaged using either an inverted UV microscope (Zeiss) or a laser scanning confocal SP5 
microscope (Leica). 
 




2.13  Live cell imaging 
 
Live cell imaging was used to investigate the ER of tissue culture cells. Cells were grown on 35 
mM glass-bottomed -dishes  (Ibidi). Ten minutes prior to treatment, cells were incubated 
with ER tracker (Invitrogen ThermoFisher). Cells were treated with 10 mM homocysteine in 
complete media, 10 mM DTT in complete media, or mock treated, and immediately imaged. 
Images were taken every 10 minutes for an hour using an Andor Revolution XD spinning disk 
confocal microscope with Olympus 60x UPlanApo lens. The collected images were converted 
to a movie format using ImageJ software. 
 
2.14 Immunoprecipitation  
 
Cell lysates were incubated with antibody (see Table 2 for dilutions used) immobilised on 
Protein A sepharose beads in 1.5 ml eppendorf tubes. The primary antibodies were mixed with 
50µl of a 20% suspension of beads in lysis buffer (without NEM or CLAP) and rotated in a fridge 
for 2 hours at 4°C. Beads bound with antigen-antibody complexes were washed 3 times in lysis 
buffer (without NEM or CLAP); they were collected in between washes by centrifugation for 1 
min at 8,000g at 4oC. After washing, the beads were resuspended in Laemmli sample buffer, 
boiled for 5 mins in the presence or absence of 50 mM DTT, centrifuged for 2-3 mins at 16,100 








2.15 Transformation and Transfection 
 
Plasmid cDNAs (shown in Table 3) were used to transform DH5α E.coli bacteria. One µg 
purified plasmid DNA was preincubated at 42°C for 1 minute, followed by addition of 50 µl 
competent bacteria which were heat shocked by a further incubation at 42°C for 1 minute. 
Nine hundred µl LB media was added to the bacteria and the mixture was incubated at 37°C 
for 45 min. The bacteria were pelleted by centrifugation at 218 g for 1 min. The pellets were 
resuspended in 100 µl LB media, spread on to LB-agar plates supplemented with 0.1 mg/ml 
ampicillin and incubated overnight in a 37 oC incubator. After overnight growth, individual 
colonies were picked and were resuspended in 5 ml LB media supplemented with 0.1 mg/ml 
ampicillin and incubated overnight. Plasmid DNA was purified from the cultures using QIAprep 
Spin Miniprep Kit (according to manufacturers instructions). The overnight culture was 
pelleted, resuspended and lysed for 5 mins after which a neutralisation buffer was added and 
centrifuged for 10 mins at 16,100 g. The supernatant was applied to the QIAprep spin column 
where a silica membrane absorbs the DNA. The column was centrifuged at 16,100 g for 30 secs, 
and washed twice with wash buffer to remove impurities. The DNA was eluted by the addition 
of elution buffer, incubating for 1 min, and centrifuged for 1 min at 16,100g. 
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Table 3- Plasmid cDNA 
Plasmid Full plasmid name Source 
Ero1α WT  pcDNA3.1 Ero1a-myc  Sitia laboratory 
Ero1α C104A/C131A  pcDNA5 Ero1a C104A/C131A-V5-His  Bulleid laboratory 
Ero1α C391A  pcDNA3.1 Ero1a C391A-myc  Benham laboratory 
Ero1α C394A/C397A  pcDNA3.1 Ero1a C394A/C397A-myc  Benham laboratory 
Ero1α C391A/C394A/C397A  pcDNA3.1 Ero1a C391A/C394A/C397A-myc  Benham laboratory 
Ero1β WT  pcDNA3.1Ero1b-myc  Sitia laboratory 
Ero1β H254Y  pcDNA3.1 Ero1bH254Y-myc  Benham laboratory 
Ero1β G252S  pcDNA3.1 Ero1bG252S-myc  Benham laboratory 
HLA-DRα  pcDNA3.1 DRA*0101  Neefjes laboratory 
HLA-DRβ  pcDNA3.1 DRB*010101  Neefjes laboratory 
HLA-DMα  pcDNA3.1 DMA-HA  Benham laboratory 
HLA-DMβ  pcDNA3.1 DMB-myc  Benham laboratory 
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For transfection, cells were grown to ~80% confluency in 6 cm dishes. Transfections were 
either with Superfect transfection reagent (QIAGEN) or Lipofectamine 3000 (Invitrogen 
ThermoFisher). For transfections with Superfect, 1 µg DNA and 5µl Superfect were added to 
400 µl serum free media, vortexed and incubated at room temperature for 5-10 minutes. This 
mixture was added to washed cells, along with 1.5 ml supplemented media (as described in 
the cell culture section). The cells were incubated for 2-3 hours, washed and the spent media 
was replaced with fresh media. Lipofectamine was used according to manufacturers 
instructions for 6-well use. Unless stated, where 7.5 µL volumes was used, 3.75 µL 
Lipofectamine 3000 reagent was diluted in 125µL Opti-MEM media. One µg DNA was added to 
125 µL Opti-MEM media and 5 µL P300 reagent. The diluted DNA was added to the diluted 
Lipofectamine and incubated at room temperature for 5 mins, after which it was added to the 
cells, along with 1.75 mL complete media. 
 
2.16  Differentiation and activation of macrophages  
 
THP-1 cells in 252 cm flasks were treated with 50 nM phorbol myristate acetate (PMA) in 
complete media to differentiate them into adherent cells with a macrophage-like phenotype. 
When differentiated, as determined by adherence, cells were mock treated or treated with 10 
µg/ml lipopolysaccharide (LPS) in complete media for 4 hours. Cells were washed with PBS 
twice and lysed for protein analysis (by SDS-PAGE) or RNA analysis (by RT-PCR). For activation 
by polyinosinic:polycytidylic acid (Poly(I:C)), cells were washed with PBS and incubated with 
complete media containing 10 or 50 µg/ml Poly(I:C) for 6 hours, washed in PBS twice and RNA 
extracted for analysis by RT-PCR. 
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2.17  Temperature treatments of cell lysates 
 
As described in the SDS-PAGE section, 2x Laemmli loading buffer was added to post-nuclear 
supernatants from cell lysates. These mixtures were then heated in a heating block to 60°C, 
90°C or left at room temperature (20°C) for 5 minutes. The samples were spun down at 16,100 
g for 5 min at room temperature and run on a 12% SDS-PAGE gel. Western blotting was used 
to determine the amount of stable MHC class II heterodimers (see western blotting section). 
 
 
2.18 Endo H treatments  
 
Lysates were denatured with 10x glycoprotein denaturing buffer at 100°C for 10 minutes. The 
lysates were either mock treated or digested with 5% endoglycosidase H (EndoH) enzyme 
(New England Biolabs) and 1x G5 Reaction Buffer (0.5 M Sodium Citrate, pH 5.5) at 37°C for 1-2 
hours. Post digestion, the lysates were mixed with reducing 2x Laemmli sample buffer, boiled 
for 5 min, centrifuged for 1 min at 16,100g at room temperature, and subjected to analysis by 
SDS-PAGE. 
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Homocysteine is a sulphur containing amino acid precursor and although non-protein forming, 
it is an intermediate in the remethylation and transsulphuration metabolic pathways (Figure 
3.1) with respective end products methionine and cysteine (Selhub, 1999). Remethylation 
involves the transfer of a methyl group to homocysteine. N-5-methyltetrahydrofolate is the 
main donor with the reaction being vitamin B12 dependant. This process is reversible, with 
some of the methionine being converted by ATP activation into S-adenosylmethionine, a 
methyl donor. Homocysteine is regenerated when S-adenosylhomocysteine (SAH), the by-
product of these methylation reactions, is hydrolysed. The hydrolysis is reversible and favours 
SAH. 
 
The alternative pathway for homocysteine is transsulphuration. Cystathionine β-synthase 
catalyses the irreversible condensation of homocysteine with serine to form cystathionine, 
which is hydrolysed by γ-cystathionase to form cysteine and α-ketobutyrate. Excess cysteine 
can be excreted in the urine or can be oxidized to taurine or inorganic sulphates, thus excess 
homocysteine can be removed via transsulphuration. When one of these pathways is 
disrupted there is a build-up of homocysteine which is transferred into the blood, although this 
removes the potential of toxicity from the cell, this risk is passed onto vascular tissue. 
 
 3. Induction of Ero1α OX1 by homocysteine 
80 
 
The pathway that is taken in humans is thought to be nutritionally regulated with an increase 
in dietary methionine resulting in an increased use of the transsulphuration pathway and less 
remethylation cycling.  SAM is thought to play a part in this regulation as an activator of 
cystathionine β-synthase. 
 
Excess intracellular homocysteine can be toxic, so along with its catabolism, a cellular export 
mechanism assists its removal from the cell. This export results in a small amount of 
homocysteine in the plasma. When a disruption in homocysteine metabolism occurs, the 
resulting built-up homocysteine is deposited by the export mechanism into the blood. 
Hyperhomocysteinemia generally results from a deficiency in the vitamins involved in 
homocysteine metabolism or defects in the enzymes involved in homocysteine metabolism. 
Severe hyperhomocysteinemia, an elevation in total plasma homocysteine, can result in 
plasma homocysteine concentrations of up to 400 µM, but even an increase to 5 µM increases 
the risk of coronary heart disease by 60-80%. 
  





Figure 3.1. The methylation and transsulphuration pathways of homocysteine 
metabolism 
In the Methylation pathway the vitamin B12 dependant transfer of a methyl group to 
homocysteine forms Methionine, which is subsequently activated by ATP to form the 
methyl donor SAM. SAM transforms to SAH by donating its methyl group to a 
methylation substrate. Homocysteine is regenerated upon hydrolysis of SAH. 
In the Transsulphuration pathway homocysteine is condensed with serine to form 
cystathionine through the action of Cystathionine β-synthase. Cystathionine is 
hydrolysed to Cysteine which is excreted or oxidized to taurine or inorganic sulphates. 
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Hyperhomocysteinemia is associated with an increased risk of vascular disease, stroke, 
infarction and potentially a number of other disorders implicated by the development of these 
conditions, such as Alzheimer’s disease (Boushey et al., 1995; Seshadri et al., 2002). 
Homocysteine damages  the endothelium (McCully, 1969),  in particular causing structural and 
functional disruption  of cerebral blood vessels through oxidative stress. Homocysteine has 
been shown to increase lipid peroxidation and oxidation of proteins, explained by increases in 
ROS generated by homocysteine autoxidation (Derouiche et al., 2014). However, the 
underlying pathophysiological mechanisms of homocysteine-mediated vascular damage are 
not well understood (Akalin et al., 2008; Faraci and Lentz, 2004). 
 
The production of NO within the endothelium acts as a relaxing factor to vessel walls. 
Hyperhomocysteinemia impairs endothelium dependant relaxation and in addition to this, it 
also elevates the levels of peroxynitrite, reactive nitrogen species and potent oxidants in the 
vessel wall. This happens upon the reaction of NO with superoxide and has numerous 
detrimental effects (as does superoxide) at the vessel wall, as well as being an activator of poly 
(ADP-ribose) polymerase, a mediator of vascular dysfunction (Soriano et al., 2001). It may also 
divert the formation of NO in favour of  superoxide (Faraci and Lentz, 2004).  
 
3.1.2 What is already know about Ero1α and homocysteine? 
 
Battle et al (2013) have previously looked into the relationship between Ero1α and 
homocysteine in OE33 oesophageal cells, which in the gastrointestinal epithelia would be 
exposed to homocysteine in the diet. Ero1α, which was strongly expressed and mainly in the 
OX2 state, could be post translationally regulated, with homocysteine causing a 25 fold 
increase of Ero1α in the OX1 state (Battle et al., 2013) (Figure 3.2, compare lanes 3 and 4).  




This effect of homocysteine was reversible as upon removal of homocysteine, and when 
normal conditions were restored, the OX1/OX2 balance returned to that of before treatment 
within 60 minutes. Titration experiments showed that 1 mM homocysteine induced OX1 
strongly, whereas 100 µM homocysteine also induced OX1 but to a lesser extent. 
Homocysteine was not acting as an indiscriminate reductant as there was no change to other 
proteins sensitive to ER redox conditions upon treatment with homocysteine. Other 
antioxidants and redox active metabolites such as N-acetylcysteine and riboflavin did not have 
the same effect; riboflavin, like homocysteine, is found in the diet, and so also potentially 
influences the GI epithelia. As it seemed Ero1α appeared to be detecting the presence of 
homocysteine, amino acids downstream of homocysteine, (methionine and cysteine) which 
are also sulphur containing, were also applied to OE33 cells in culture (Battle et al., 2013). 
Treatment of cells with excess methionine and cysteine did not initiate any change in Ero1α 
Ox1 levels, suggesting that Ero1α sensing might be restricted to a control point or points in the 
synthesis of sulphur containing amino acids. 
 




Figure 3.2. Homocysteine induces Ero1α OX1 
Ero1α exists in three states, active (OX1), inactive (OX2) and reduced (R). When analysed 
by SDS-PAGE and immunoblot with the αEro1α antibody D5, the three states can be seen. 
OX1 is induced upon treatment with homocysteine (HC), and R is seen under reducing SDS-
PAGE. Adapted from (Battle et al., 2013).  
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3.1.3 Ero1α mutants  
 
The mutation of regulatory and structural Ero1α cysteines is a useful tool for investigating its 
function. The Ero1 C104A/C131A mutant is unable to form the regulatory bond Cys94-Cys131 
which keeps Ero1α in its inactive OX2 form, thus this is a constitutively active mutant, with 
oxygen consumption assays confirming that it is more active than the WT, leading to hyper 
oxidation of PDI (Araki and Nagata, 2011; Baker et al., 2008). When transfected with this 
mutant, cells undergo transcriptional changes to 159 genes, most of which are related to the 
UPR resulting in UPR target protein levels similar to that when treated with inducers of UPR. 
This apparent UPR response may be due to proteins misfolded by sulph(i/o)nylation which is 
mediated by H2O2 (Hansen, 2012). 
 
Whilst the Ero1α WT migrates entirely in the OX2 form on a western blot, the C104A mutant 
migrated mostly as OX2 with a tiny amount of OX1, unable to form Cys99-Cys104, Cys94-
Cys131 is believed to be destabilised and lost. When Cys104-Cys131 is lost in C131 mutants 
there would not be a noticeable shift in the OX1 band if Cys99-Cys104 is also lost. It is 
therefore unclear whether Cys99-Cys104 is also lost. 
 
The Ero1α C85/C391 double mutant migrates as 2 bands, one at a molecular weight between 
that of OX1 and OX2; this is thought to contain the Cys94-Cys131 disulphide bond. The other 
band migrates at a weight the same as that of when Ero1α is fully reduced, R. In this form 
Cys94-Cys131 has been destabilised. Again, it is unclear whether Cys99-Cys104 is also 
destabilised (Hansen, 2012).   
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Ero1α is normally retained in the ER, but is in part secreted when over expressed, possibly due 
to the localization mechanism being saturated (Anelli and van Anken, 2013). When misfolded, 
Ero1α forms high molecular weight aggregates which do not pass ER quality control and so are 
not secreted. The lack of any such aggregates suggests that these mutants are still able to fold 
into the correct formation, further evidence of this is provided by the presence of the OX1 and 
OX2 forms in various mutants. These mutants are still able to interact with PDI, with only slight 
variations in molecular weight due to changes in the molecular weight of Ero1α.  
 
3.1.4 Ascorbic acid 
 
Ascorbate, or vitamin C, is an abundant anti-oxidant and cofactor for enzymatic reactions, like 
collagen crosslinking, which underlies the pathogenesis of scurvy.  Despite this, its function is 
not restricted to collagen crosslinking, and deficiency also leads to ER stress and an unfolded 
protein response.  An ascorbic acid deficiency can be due to a lack or ascorbate in the diet or 
its cellular consumption in excess. Excess consumption can occur if a free cysteine is not 
converted quickly enough to a disulphide. In this case the free cysteine interacts with and 
mops up ROS with H2O2, being oxidised to sulphenic acid. Sulphenic acid can go down one of 
two pathways: it can be reduced to a disulphide, creating a disulphide relay, or it can be 
reduced and return to a free thiol with the conversion of ascorbic acid to the chemically 
unstable dehydroascorbate. If this occurs in excess the consumption of ascorbic acid leads to 
its deficiency. Such consumption is unlikely when PDI is present in the reduced form as the PDI 
quickly converts free cysteines into disulphides (Zito et al., 2012).  
 
Any altered kinetics of disulphide bond formation may affect ER function as it provides a delay 
sufficient to expose free thiols. Such a disturbance can be seen in In Ero1α knockout mice 
where the lack of Ero1α results in a 5 fold lower procollagen 4 hydroxyproline content, whose 
 3. Induction of Ero1α OX1 by homocysteine 
87 
 
formation is ascorbate dependant, depleting collagen maturation. No other severe 
abnormalities are seen as disulphide bond formation can continue at the expense of ascorbate 
(Zito et al., 2012). However, dehydroascorbate has also been argued to be an electron 
acceptor for reduced PDI, and has been shown to result in a decreased protein thiol 
concentration when given to human liver microsomal vesicles. The rate of thiol oxidation was 
30% less than that when ascorbate was used instead, with much reduced thiol consumption 
upon the inhibition of ascorbate oxidation. All the tested means to curtail ascorbate oxidation 
resulted in a decrease in thiol oxidation. This is due to the need for ascorbate to be oxidised to 
dehydroascorbate before it can act as an electron acceptor (Csala et al., 1999).  Ascorbate 
oxidation occurs in the cytoplasm, as only ascorbate in its oxidised form can be transported 
into the ER (Banhegyi et al., 1998). This could mean that in the absence of Ero1α, PDI is 
oxidised by dehydroascorbate with H2O2 produced by ascorbate oxidase enzymes (Szarka and 
Lorincz, 2014).  
 
3.1.5  N-Ethylmaleimide  
 
Protein thiols are extremely sensitive to their redox environment and any changes in this 
environment are reflected in their oxidation state. The redox status of thiols and disulphides 
can be trapped chemically to prevent changes during cell lysis and analysis. This procedure 
must be quick to prevent changes in equilibria and to prevent the action of redox active 
enzymes that can rearrange disulphides. It must also be irreversible to further prevent 
rearrangement. NEM achieves this quenching by thiol alkylation (Hansen and Winther, 2009). 
It reacts with sulfhydryls to form stable thioether bonds. NEM can only react with available 
thiols, thus those buried in the three-dimensional structure will not be quenched. If the three-
dimensional structure is lost, these free thiols will be exposed and subject to potential 
rearrangement.   







3.2.1 Detecting Ero1α in cells treated with homocysteine   
 
Previous observations show changes in the Ero1α oxidation state upon treatment with 
homocysteine (Battle et al., 2013). As the regulation of disulphide bond formation and the 
oxidative status of Ero1α at steady state differs between cell types (Benham et al., 2013), here 
it is first investigated whether such changes could be replicated in cell lines other than the 
oesophageal cancer cell line OE33 which was originally used. To compare with the OE33 cells, 
which have high levels of Ero1α expression, the human cervical carcinoma cell line, HeLa, and 
the immortalised fibrosarcoma cell line, HT1080, were used. 
 
Previous experiments have shown that the oxidation status of Ero1α can be regulated by the 
addition of as little as 100 µM homocysteine, but more noticeably, 1 mM homocysteine to the 
cell. Using the same method of treatment, the conditions used in Battle et al (2013) were 
replicated, but rather than using the D5 polyclonal antiserum to detect Ero1α, the 2G4 
monoclonal antibody was used. HT1080 and HeLa cell lysates were analysed by non-reducing 
SDS-PAGE and a western blot was probed with the 2G4 antibody (Figure 3.3A and C, lanes 1,3 
and 5). The result shows that Ero1α exists in a fast-migrating and likely inactive (OX2) form at 
steady state, consistent with previous data (Benham et al., 2013). By using non-reducing 
conditions, disulphide bonds were preserved, allowing disulphide-dependent conformations to 
be observed. Upon addition of DTT to the cell lysates the Ero1α band shifts up to a higher 
molecular weight, meaning it is fully reduced (Figure 3.3A and C, compare lanes 1 and 2; 3 and 
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4; 5 and 6). Although OX2 is present, the change to Ero1α OX1 upon homocysteine treatment 
could not be seen. Unlike D5, the polyclonal antibody previously used in Figure 3.2 (Battle et 
al., 2013), the monoclonal antibody 2G4 did not appear to detect the OX1 form of Ero1α, 
which is expected to start appearing upon treatment with 1 mM homocysteine (Figure 3.3A 
and C, lane 5) and to form a clear band with 10 mM homocysteine (Figure 3.3A and C, lane 7).  
The complete disappearance of an Ero1α signal (Figure 3.3A, lane 7) suggests either that Ero1α 
is not present in this sample or that Ero1α exists in a form that is unrecognisable to the 2G4 
antibody. Under reducing conditions OX2 Ero1α should be completely reduced as seen with all 
other homocysteine concentrations in this experiment. However, there was no reduced Ero1α 
signal upon treatment with 10 mM homocysteine (Figure 3.3 A, lane 8). The HC10 antibody, 
which recognises free MHC class I heavy chains, was used to reprobe the membranes for MHC 
1 (Figure 3.3 B and C). The reprobe with HC10 showed equal loading between the lanes and 
that there was protein present in lanes 7 and 8, where there was an absence of signal for 
Ero1α. The apparent molecular weight of the MHC class I heavy chain changed between NR 
and R lanes (1 and 2, 3 and 4, 5 and 6, 7 and 8) as the disulphides were broken, providing 
further evidence that the change in Ero1α molecular weight is due to the reducing conditions.  
 
The homocysteine treatments were performed on both the HT1080 and HeLa cell line to see 
whether the disappearance of Ero1α at 10 mM homocysteine in the HT1080 fibrosarcoma cells 
was cell specific. Ero1α could not be detected in either cell line after 10 mM homocysteine 
treatment (Figure 3.3A and C, lanes 7 and 8), further suggesting that OX1 was not detected by 
the 2G4 antibody. Using the MHC 1 antibody HC10 as a positive control (Figure 3.3 B and C, 
lanes 7 and 8), it was confirmed that 10 mM homocysteine resulted in a loss of detection of 
Ero1α by the 2G4 antibody in both cell lines (Figure 3.3C lanes 7 and 8). 
 
 






Figure 3.3. Homocysteine prevents the detection of Ero1α by the 2G4 monoclonal 
antibody 
HT1080 (A,B) and HeLa (C,D) cells were treated with 0, 0.1, 1 and 10 mM homocysteine 
for 1 hour then lysed in MNT buffer. Cell lysates were then subjected to reducing (R) or 
non-reducing (NR) SDS-PAGE and subsequent western blotting with the monoclonal 
antibodies 2G4 (A,C) and HC10 (B,D). Reduced (*) and non-reduced (**) forms of Ero1α 
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3.2.2 Induction of Ero1α OX1 by homocysteine in cells transfected with WT Ero1α 
 
In order to determine whether the lack of Ero1α signal in the previous experiments (Figure 3.3) 
was due to homocysteine causing the removal of Ero1α from the cell or due to the antibody 
not detecting Ero1α, the homocysteine treatments were repeated on HT1080 cells transfected 
with myc tagged wild type (WT) Ero1α. These lysates, alongside mock transfected cell lysates 
treated with 0, 1 or 10 mM homocysteine, were analysed by SDS-PAGE and western blotting. 
Again, only 1 oxidation state (OX2) was present and there was no signal upon 10 mM 
homocysteine treatment when using the 2G4 antibody (Figure 3.4A), meaning that the 
homocysteine treatments had the same effect on transfected cells. In this figure, 2G4 detected 
the endogenous Ero1α, which is present in all samples, as shown by its presence in mock (M) 
transfected cells (Figure 3.4A lane 1). When the lysates were probed for PDI, each lane had an 
equal amount of PDI showing that all samples contained protein (Figure 3.4B). 
 
The transfected lysates were probed with the D5 antibody (Figure 3.4D) used by Battle et al 
(Battle et al., 2013). The results show that it was possible to see the change in Ero1α OX state 
from OX2 to OX1 upon the addition of homocysteine (compare lanes 2 3 4), first reported by 
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Figure 3.4. Induction of OX1 by homocysteine in cells transfected with WT Ero1 
Following transfection with wild type (WT) Ero1α or mock transfection (M), HT1080 cells 
treated with 0, 0.1, 1 and 10 mM homocysteine for 1 hour were lysed in MNT buffer. Cell 
lysates were then subjected to non-reducing (NR) or reducing (R) SDS-PAGE and 
subsequent western blotting with the antibodies αMyc (C and E), αPDI (B), 2G4 (A) or D5 
(D). Ero1α monomer oxidation states are labelled OX1, OX2 or reduced (Red). The upper 
band in C and E is a non-specific protein reacting with the anti-myc antibody that acts as a 
loading control. Background bands are indicated (*). 
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When the lysates were probed with αMyc (Figure 3.4C), there was no signal in mock 
transfected cells as there was no myc tagged protein present (Figure 3.4C, lanes 1 and 2). As 
there was no signal in the mock sample and there was a signal in the transfected samples 
(Figure 3.4C, lanes 3, 4 and 5), it can be concluded that the signal was the myc tagged Ero1α. 
The addition of the myc tag on Ero1α increases its apparent molecular weight, explaining the 
difference in size when comparing the transfected Ero1α detected by αMyc (Figure 3.4C), and 
the endogenous Ero1α detected by 2G4 (Figure 3.4A). The transfected Ero1α was not detected 
by 2G4 in this experiment, as shown by the absence of a heavier molecular weight Ero1α in 
Figure 3.4A. Myc tagged Ero1α was present in the OX2 form (Figure 3.4C lanes 3, 4, and 5), 
confirming the findings that Ero1α OX2 is present in cell samples when probed with the anti-
myc antibody. When treated with 10 mm homocysteine (Figure 3.4C lane 5) most of the OX2 
changed to OX1; when the equivalent sample was probed with the D5 antibody (Figure 3.4D 
lane 4) all of the OX2 signal was lost in favour of OX1. This change from OX2 to OX1 could be 
an explanation for the loss of Ero1α signal seen with 2G4. If 2G4 was not able to detect Ero1α 
in the OX1 form, no Ero1α would be detected in Figure 3.4A lane 5, as at this level of 
homocysteine only the OX1 exists. However, this explanation should also account for the 
disappearance of the fully reduced Ero1α after 10 mM homocysteine treatment (Figure 3.3A 
lane 8). Analysing the transfected lysates under reducing conditions, resulted in a single 
reduced Ero1α band, showing that the shift in the molecular weight of myc-tagged Ero1α 
under non-reducing conditions was a result of disulphide bond formation, not degradation. 
The addition of DTT eliminated the OX1 form (which 2G4 does not appear to detect) and 
reduces Ero1α-myc into the same reduced state as seen with lower concentrations of 
homocysteine treatments (Figure 3.4E). Taken together, the results in Figures 3.3 and 3.4 
suggest that the loss of Ero1α signal when probing with 2G4 could be due to covalent 
modification of Ero1α by high concentrations of homocysteine, which renders it unavailable to 
detection by 2G4. 
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By transfecting cells with tagged WT Ero1α, and probing for the tag, it was possible to see all 
forms of Ero1α, unlike probing with 2G4. The αMyc analysis showed a change in Ero1α 
oxidation state, with the ratio of OX1:OX2 moving from OX2 being favoured at low 
concentrations of homocysteine to OX1 being favoured at higher concentrations. This was a 
trend seen over many repeats, and although the OX2:OX1 ratio varied slightly between 
experiments, there was a clear trend towards Ero1α becoming more, what appears to be, 
“active” upon treatment of homocysteine with increasing concentrations. The average 
OX2:OX1 ratio over 6 experiments was 27.6:1 at 0 mM, 4.7:1 at 1 mM and 0.2:1 at 10 mM 
homocysteine. These results reinforce those done previously, showing that the control of 
Ero1α activation status by homocysteine can be replicated in multiple cell lines. Figure 3.4 also 
highlights the inability of 2G4 to effectively detect the Ero1α OX1 state. Interestingly the 
results show that 2G4, a monoclonal antibody, is able to detect a modification of Ero1α by loss 
of binding. 
 
 To further investigate the effects on the oxidative folding machinery induced by homocysteine, 
the homocysteine treatments were repeated on HT1080 cells. Following cell lysis, the lysates 
were analysed by SDS-PAGE and western blot with the 2G4 (Figure 3.5A, lanes 1, 2, 3 and 4) 
and αPDI (Figure 3.5B) antibodies, or used in an immunoprecipitation with an αPDI antibody 
and then analysed by western blotting (Figure 3.5A, lanes 5, 6, 7 and 8). Figure 3.5A shows that 
Ero1α co-immunoprecipitated with PDI at the same quantity when treated with 0, 0.1 or 1 mM 
homocysteine. As there was no immunoprecipitated Ero1α signal at 10 mM homocysteine, 
Ero1α was either not immunoprecipitating with PDI or if they are co-immunoprecipitating, the 
interaction did not protect Ero1α from the homocysteine induced modification which is 
prevented 2G4 from detecting Ero1α. The signal of the antibody used in the 
immunoprecipitation (Figure 3.5 A, lanes 5, 6, 7 and 8) acts as a loading control. Reprobing the 
membrane with the αPDI antibody (Figure 3.5B) shows that there was a similar level of PDI 
protein in all samples.  











C Figure 3.5. Detection of Ero1α PDI complexes in homocysteine treated cells 
HT1080 cells treated with 0, 0.1, 1 and 10 mM homocysteine (HC) for 1 hour were then 
lysed in MNT buffer. Cell lysates were immunoprecipitated with αPDI and subjected to 
reducing (R) SDS-PAGE and subsequent western blotting with the antibody 2G4 (A). Cell 
lysates were subjected to reducing (R) SDS-PAGE and subsequent Western blotting with 
the αPDI antibody (B). The reduced Ero1α monomer is labelled Red. Background bands 
are indicated (*). 
 
B 
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3.2.3 The effect of homocysteine on Ero1α in cells transfected with the mutant Ero1α 
C104A/C131A 
 
The oxidation state of Ero1α is dependent on the formation of a disulphide bond between 
Cys94-Cys99, the outer active site, which can be transferred to PDI and makes it oxidised (OX1) 
(Figure 3.6A and B). The formation of Cys94-Cys131 blocks Cys94 making it unavailable for 
interaction with Cys99, and forming the inactive (OX2) Ero1α. Homocysteine appears to push 
Ero1α into the OX1 form. It is unknown whether this effects the regulatory control mechanism 
depicted in Figure 3.6A and B. To investigate how homocysteine mediates its effects, HT1080 
cells were transfected with a constitutively active mutant Ero1α to see if homocysteine directly 
regulates Ero1α through partial reduction.  
 
The Ero1α C104A/C131A mutant is constitutively active as the regulatory disulphide Cys94-
Cys131, which blocks the catalytically essential shuttle Cys94, is absent (shown schematically in 
Figure 3.6 C). This leaves the Cys94 to form a disulphide with Cys99, and interact with PDI 
under all conditions; this form is Ero1α in OX1.  
 
HT1080 cells transfected with a V5 tagged C104A/C131A Ero1α mutant were lysed and the 
lysates were probed with αV5 antibody (Figure 3.7A). The transfectants expressed Ero1α only 
in a state which appear to be OX1, regardless of treatment, or non-treatment, with 
homocysteine. The addition of DTT to samples in Figure 3.7B caused a shift in molecular weight 
of these bands to the fully reduced form and shows that the Ero1α in Figure 3.7A was in the 
oxidised state.  The addition of homocysteine to the transfected cells did not affect the 
migration of tagged C104A/C131A Ero1α, as OX1 was evident and OX2 absent at all 
concentrations. Homocysteine appears to push WT Ero1α into the OX1 form, however 
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C104A/C131A Ero1α exists in this form under all conditions, and no change was observed in 
this experiment.  
 
As with the detection of the myc tag (used in Figures 3.4B and C), the antibody against the V5 
tag used in Figure 3.7A and B detected Ero1α OX1 at a higher molecular weight than expected 
for non-tagged Ero1α. This was due to the tag increasing the molecular weight of the protein. 
This result can be compared with Figure 3.7C, where the OX2 form of Ero1α recognized by 2G4 
was considerably lighter than the OX1 recognized by anti-V5 (Compare Figure 3.7A and C). OX2 
Ero1α was present in the samples as it is the endogenous pool which was not constitutively 
active, and not V5 tagged. The disappearance of this OX2 Ero1α upon treatment with 10 mM 
homocysteine acts as a positive control, confirming that the homocysteine treatment had 
worked. Probing the samples again with αPDI showed equal levels of endogenous protein 
between samples, and that there was protein loaded in the 10 mM homocysteine treated 
sample (Figure 3.7D).  
 
  













Figure 3.6. Schematic representation of Ero1α regulation 
Schematic representation of cysteines and their disulphide links in OX1 (A) OX2 (B) and the 
OX2 Ero1α mutants C104A C131A (C), C391A (D), C394A C397A (E), C391A C394A C397A (F) 
Ero1α. 
 







Figure 3.7. Induction of OX1 by homocysteine in cells transfected with C104A/C131A 
Ero1α 
Following transfection with Ero1α V5 tagged C104A/C131A, HT1080 cells were treated 
with 0, 0.1, 1 and 10 mM homocysteine for 1 hour then lysed in MNT buffer. Cell lysates 
were then subjected to non-reducing (NR) or reducing (R) SDS-PAGE and subsequent 
Western blotting with the antibodiess αV5 (A,B), αPDI (D) or 2G4 (C). Ero1α monomer 
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3.2.4 The effect of homocysteine on Ero1α in cells transfected with the mutant Ero1α C391A 
 
A structural disulphide bond connecting Cys85 and Cys391 is thought to bring together the two 
active sites of Ero1α, thus facilitating electron transfer between them. On SDS-PAGE, the 
C391A mutant Ero1α runs at a molecular weight intermediate to the OX1 and R form, as 
without the long range disulphide its structure is a lot more similar to that of the completely 
reduced form (Benham et al., 2000). It is not known if the Cys85 is able to form a bond with 
another free Cys in the absence of Cys 391 (shown schematically in Figure 3.6D).  
 
Figure 3.8A shows that in HT1080 cells transfected with the myc tagged C391A mutant, Ero1α 
existed as 2 partially oxidised forms. The lower mobility form migrated the same as the 
reduced form seen in Figure 3.8B, making it likely that the bands seen in Figure 3.8A were OX1-
like and reduced-like forms of Ero1α. Despite the shift in molecular weight, due to the loss of 
the long range disulphide, there was still the same pattern of change with the addition of 
homocysteine. From this we can conclude that the homocysteine induced change in the 
structure of Ero1α was not due to a change in the regulatory bond between Cys85 and Cys391. 
Ero1α is still able to function as an oxidoreductase in this form, however the lack of the 
regulatory bond means that oxidative folding via Ero1α is less efficient (Mezghrani et al., 2001). 
 
The 2G4 antibody was used again to ensure that the change in compactness of the C391A 
mutant was due to homocysteine treatment. The absence of signal upon 10 mM homocysteine 
treatment showed that the homocysteine treatment had led to the disappearance of the 2G4 
epitope (Figure 3.8C). Probing for PDI showed the presence of endogenous protein in all 
samples (Figure 3.8D). 
 











Figure 3.8. Induction of OX1 by homocysteine in cells transfected with C391A Ero1α 
Following transfection with myc-tagged Ero1α-C391A, HT1080 cells were treated with 0, 
0.1, 1 and 10 mM homocysteine for 1 hour then lysed in MNT buffer. Cell lysates were then 
subjected to non-reducing (NR) or reducing (R) SDS-PAGE and subsequent western blotting 
with the antibodies αMyc (A,B), 2G4 (C) or αPDI (D).  Ero1α monomer oxidation states are 
labelled OX2, OX1-Like (OX1-L), reduced-like (Red-L) or reduced (Red). Background bands 
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3.2.5 The effect of homocysteine on Ero1α in cells transfected with the “active site” mutants 
Ero1α C394A/C397A and C391A/C394A/C397A 
 
Cys394-Cys397 make up the inner active site of Ero1α. Mutation of Cys394 or Cys397 inhibits 
oxidative folding (Mezghrani 2001), as the inner active site cannot form and regenerate 
disulphides to pass on to the outer active site (shown schematically in Figure 3.6E). This leaves 
the outer active site without a source of disulphide bonds, making it redundant. 
 
HT1080 cells transfected with myc tagged C394A/C397A Ero1α showed an increase in OX1-like 
levels of Ero1α that lacked the inner active site (Figure 3.9A). This is consistent with other 
studies where mutation of Cys394 or Cys397 causes an increase in OX1-like compared to OX2 
Ero1α (Appenzeller-Herzog et al., 2008). In Figure 3.9A upon the addition of homocysteine, 
Ero1α was further converted into an apparent OX1 state, as was previously seen with WT 
Ero1α. This would suggest that the homocysteine effect is independent of the inner active site 
Cys394-Cys397. This result does not rule out the possibility that homocysteine is taking its 
affect via the outer active sites Cys94-Cys99, and inducing OX1 regardless of whether Ero1α is 
able to take part in oxidative folding.  
 
To analyse whether the absence of both the long range disulphide and the ‘inner’ active site 
influenced the response of Ero1α to homocysteine, a myc-tagged triple mutant was used 
(C391A/C394A/C397A). When HT1080 cells were transfected with this mutant, two bands, 
likely OX1-like and reduced-like Ero1α, existed in similar amounts prior to treatment with 10 
mM homocysteine (Figure 3.9C). Unlike the Ero1α WT and the individual C391A and 
C394A/C397A mutants, the amount of the upper band, here reduced-like, did not increase 
when cells were treated with homocysteine, however the lower band was still lost at 10 mM 
homocysteine. This result can be attributed to the combination of mutating the active site and 
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the long range disulphide, as the constant upper band size was not seen with C394A/C397A 
Ero1α. Figures 3.9B and D show these samples having been probed with PDI as a loading 
control. Probing the lysates used in this experiment with the 2G4 antibody proved inconclusive, 
meaning it was not possible to tell if the triple mutant had lost the 2G4 epitope.  
  











Figure 3.9. Induction of OX1 by homocysteine in cells transfected with C394A/C397A or 
C391A/C394A/C397A Ero1α 
Following transfection with C394A/C397A (A,B) or C391A/C394A/C397A (tri) (C,D), HT1080 
cells were treated with 0, 0.1, 1 and 10 mM homocysteine for 1 hour then lysed in MNT 
buffer. Cell lysates were then subjected to non-reducing (NR) SDS-PAGE and subsequent 
Western blotting with the antibodies αMyc (A,C) or αPDI (B,D).  Ero1α monomer oxidation 
states are labelled OX1 or OX2, OX1-Like (OX1-L) or reduced-like (Red-L). Background 
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3.2.6 Homocysteine and the interaction between Ero1α and PDI  
 
Ero1α and PDI interact which, when visualised via western blot, gives a complex of about 120 
kDa (Benham 2000). Whilst investigating the impact of homocysteine on the oxidation state of 
Ero1α, changes in the Ero1α/PDI complex were observed. In Figure 3.5, for example, the co-
immunoprecipitation of Ero1α and PDI could no longer be seen after cells were treated with 10 
mM homocysteine. To investigate the interaction between Ero1α and PDI more closely, a 
further series of experiments were performed. When analysed under non-reducing conditions, 
HT1080 cell lysates appeared to show no change in their Ero1α/PDI complex when treated 
with 0, 0.1 or 1 mM homocysteine and probed with the 2G4 antibody (Figure 3.10A, lanes 1-3). 
Upon the addition of 10 mM homocysteine, as previously seen (Figure 3.1) Ero1α monomers 
disappeared (Figure 3.10A, lane 4). Here, the Ero1α/PDI complex also disappeared, which is 
probably a result of it not being recognised by 2G4 (Figure 3.10A, lane 4).  
 
When these samples were probed with αPDI under non-reducing conditions (Figure 3.10B) the 
Ero1α/PDI complex appeared at the same molecular weight as that seen upon probing with 
2G4, but only upon treatment with 0 or 0.1 mM homocysteine. The PDI/Ero complex 
disappeared with the addition of 1 or 10 mM homocysteine. Note that the anti-PDI antibody 
recognised another double band at a higher molecular weight. This doublet was relatively 
resistant to the effects of homocysteine, and may represent an interaction between PDI and a 
client protein.  
 
With the transfection of cells with myc tagged WT Ero1α it was possible to investigate the 
behaviour of the PDI/Ero1α complex by identifying it using an αmyc antibody (Figure 3.10C and 
D). The band representing the Ero1α/PDI complex in Figure 3.10C became much narrower with 
10 mM homocysteine.  As there was a bigger pool of OX1-like Ero1α at high concentrations of 
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homocysteine it might be expected that this would provide a larger available pool to interact 
with PDI; this, however, does not appear to be the case. The loss of the 120 kDa complex was 
observed over many repeats of this experiment, as well as other experiments where cells were 
transfected with WT or mutant Ero1α. The loss of the 120 kDa complex was seen for both 
endogenous and tagged/transfected Ero1α. In general when western blotted lysates were 
probed with αPDI, the Ero1α/PDI complex completely disappeared at 10 mM homocysteine, 
but often started to disappear at 1 mM homocysteine. 
  









Figure 3.10. The effect of homocysteine on PDI/Ero1α complexes  
Following transfection with Ero1α WT (C and D) HT1080 cells, as well as untransfected 
HT1080 cells (A and B) were treated with 0,1 and 10 mM homocysteine for 1 hour then 
lysed in MNT buffer. Cell lystaes were then subjected to non-reducing (NR) or reducing (R) 
SDS-PAGE and subsequent Western blotting with the antibodies 2G4 (A), αPDI (B) or αMyc 
(C and D). Ero1α monomer oxidation states are labelled OX1, OX2 or reduced (Red). PDI-
Ero1α complexes (PDI/Ero1 α) and PDI-client complexes (PDI-C) are labelled . Background 
bands are indicated (*). 
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3.2.7 Homocysteine and the interaction between PDI and the mutant Ero1α C104A/C131A, 
C391A, C397A/C397A and C391A/C394A/C397A 
 
It has been demonstrated that PDI-complexes are diminished upon the addition of 10 mM 
homocysteine (Figure 3.10). To investigate whether the diminishing complexes are due to the 
change in Ero1α activity status or due to the method by which homocysteine has its effect, the 
previously used Ero1α mutants (3.2.2.3-3.2.2.5) were looked at further. 
 
Cells transfected with the Ero1α mutants C104A/C131A, C391A, C394A/C397A or 
C391A/C394A/C397A were subjected to non-reducing SDS-PAGE and subsequent western 
blotting with αtag antibodies. No PDI complex could be detected between V5-tagged Ero1α 
C104A/C131A and PDI under non-reducing conditions (data not shown). 
 
The Ero1α C391A mutant, (Figure 3.11A, a repeat of Figure 3.8A showing the PDI/Ero1α 
complex) had the same pattern of change in  what appears to be Ero1α OX1 and OX2, as seen 
in the wild type (Figure 3.10). There was also a similar pattern of PDI/Ero1α complex loss, with 
most of the complex lost with 10mM homocysteine treatment. The bands representing the 
Ero1α complex in Figure 3.11A spanned a greater range of molecular weights than that seen in 
the wild type. The loss of the regulatory disulphide Cys391-Cys85 and subsequent loss of 
structure may cause complexes of different sizes to be formed, or free cysteine residues 
resulting from the mutation may interact with PDI or other proteins to form complexes of 
different weights.  
 
 This pattern seen in Ero1α C391A was also seen in the Ero1α C394A/397A mutant in Figure 
3.11B, which showed a larger range of molecular weights than seen in Figure 3.9A. The 
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PDI/Ero1α complex spanned a greater range of molecular weights than the wild type, and the 
lower molecular weight bands diminish at 10 mM homocysteine, with the band resolving into 
2 separate bands. The change in molecular weight of these bands could suggest that the 
complexes are pushed into different conformations upon homocysteine treatment. 
 
A faint band or bands were formed at about 120 kDa in Ero1α triple mutant 
(C391A/C394A/C397A) in the absence of homocysteine treatment. These disulphide-
dependent complexes became slightly fainter when cells expressing Ero1α were treated with 
homocysteine, however it is not clear which bands represent the Ero1α/PDI complex  (Figure 
3.11C). The PDI/Ero1α complex may only exist in small quantities in cells expressing this 
mutant.   
 
The PDI/Ero1α complex diminished upon 10mM homocysteine treatment in cells transfected 
with wildtype Ero1α, but also when cells were transfected with mutant Ero1α which showed 
the same pattern of Ero1α OX1-like/OX2 change as the wild type.  
  








Figure 3.11. The effect of homocysteine on PDI/mutant Ero1α complexes  
Following transfection with Ero1α mutants C391A (A), C394A/C397A  and (B), 
C391A/C394A/C397A (C) HT1080 cells were treated with 0, 0.1, 1 and 10 mM 
homocysteine for 1 hour then lysed in MNT buffer. Cell lysates were then subjected to 
non-reducing (NR) SDS-PAGE and subsequent Western blotting with the αMyc antibody. 
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3.2.8 NEM and Ero1α disulphides 
 
We have seen that homocysteine alters the activation state of Ero1α and the PDI/Ero1 
complex, both of which are controlled by disulphide bonds. Homocysteine also affects Ero1α 
mutants which have altered disulphides. To investigate whether homocysteine exerts its effect 
by altering the availability of free –SH groups, cells were lysed with or without the thiol-
alkylating agent NEM. All of the experiments carried out so far have used lysis buffer 
containing NEM which is often used to prevent disulphide rearrangement by blocking the –SH 
groups, and is particularly effective as it is very quick to permeate cell membranes. 
 
Under reducing or non-reducing conditions, lysates were subjected to SDS-PAGE and western 
blot with 2G4 (Figure 3.12). In the absence of homocysteine, Ero1α from HT1080 cells existed 
in the OX2 form both in the presence and absence of NEM under non-reducing conditions 
(Figure 3.12A lanes 1 and 2). With the addition of 1 mM homocysteine Ero1α existed in the 
OX2 form. The shadow band (*) previously observed (Figure 3.4A) can also be seen, however in 
the presence of homocysteine, there was another band with a slightly higher molecular weight 
(**) than the shadow band which was not observed when NEM was present. This suggests that 
the addition of homocysteine reduces an –SH group that becomes available for disulphide 
rearrangement after lysis or that Ero1α favours rearrangement to an already existing –SH 
group in the presence of homocysteine. When the homocysteine concentration was increased 
to 10 mM, Ero1α OX2 disappeared; however the additional band in the absence of NEM, as 
seen in lane 3, remained. When the samples were analysed under reducing conditions, all 
Ero1α existed in the reduced form. Like the previous treatments with 10 mM homocysteine, 
the Ero1α signal completely disappeared, but without the addition of NEM (Figure 3.12A, lane 
11) the reduced Ero1α remained. This signal could be the same as the reduced form of the 
band recognised in lane 5. 




When the same lysates were probed with an αPDI antibody under non-reducing conditions, 
the PDI/Ero1α complex was not detected in either the NEM or non-NEM lysed cell lines with 
10 mM homocysteine. This would suggest that the less compact Ero1α protein found in Figure 
3.12A lane 5 was not able to bind PDI. The PDI/Ero complex could be seen with all other 
combinations of homocysteine and NEM tested (Figure 3.12B lanes 1, 2, 3 and 4). A higher 
molecular weight complex ~160kDa could also be seen, which increased in intensity with the 
addition of homocysteine in the presence of NEM.  
 
 When the same experiment was carried out in the OE33 cell line using 2G4 to detect Ero1α in 
cell lysates +/- NEM (Figure 3.12C), the same results were seen, with a slower migrating, partly 
reduced higher molecular weight Ero1α band appearing in the presence of homocysteine and  
in the absence of NEM. This suggests that homocysteine partially reduces Ero1α and that as 
the Ero1α protein becomes partially reduced, it exposes a sulhydryl group that is accessible to 
alkylation by NEM, resulting in loss of the 2G4 epitope. What is seen in HT1080 is not cell 


















Figure 3.12. NEM effect on disulphide bonds in homocysteine treated cells 
HT1080 (A and B) and OE33 (C) cells were treated with 0, 1 and 10 mM homocysteine for 1 
hour then lysed in MNT buffer in the presence (+) or absence (-) of 50 mM NEM. Cell 
lysates were then subjected to non-reducing (NR) or reducing (R) SDS-PAGE and 
subsequent Western blotting with the antibodies 2G4 (A and C) or αPDI (B). Background 
bands are indicated (*)(**). 
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3.2.9 Cystathionine does not impact the oxidation state of Ero1α 
 
To further investigate how homocysteine mediates its effect on Ero1α, cells in culture were 
treated with an intermediate in the homocysteine metabolism pathway, cystathionine. Battle 
et al (Battle et al., 2013) observed that the control of Ero1α by homocysteine did not extend to 
the amino acids cysteine and methionine in OE33 cells. By using cystathionine, the product of 
the first step in the metabolism of homocysteine to cysteine, it is possible to deduct whether 
homocysteine directly effects Ero1α or if it is working through cystathionine in this pathway.  
 
The conditions of the cystathionine treatments were the same as that for homocysteine, using 
concentrations up to 10 mM since all Ero1α existed as OX1 at this concentration of 
homocysteine. Neither HT1080 nor OE33 cells showed a change in oxidation state upon 
treatment with cystathionine (Figure 3.13A and B respectively). There also appeared to be no 
change in the migration or level of the PDI/Ero1α complexes (Figure 3.13A), disregarding a 
small decrease in the band intensity for the PDI/Ero1α complex in 1 mM cystathionine treated 
HT1080 cells (Figure 3.13 A lane 4), which was most likely due to sample loading variation. The 
experiments suggest that it is not the cystathionine intermediate in the homocysteine 
metabolic pathway which mediates the homocysteine effect. 
 
  








Figure 3.13. Cystathionine does not change the recognition of Ero1α by the 2G4 antibody 
or increase Ero1α OX1 
HT1080 (A) and OE33 (B) cells were treated with 0, 0.1, 1 and 10 mM cystathionine for 1 
hour then lysed in MNT buffer. Cell lysates were then subjected to reducing (R) or non-
reducing (NR) SDS-PAGE and subsequent Western blotting with the monoclonal antibody 
2G4. Ero1α monomer oxidation states are labelled OX2 or reduced (Red). Background 
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3.2.10 Ascorbic acid does not impact the oxidation state of Ero1α or its recognition by 2G4 
 
Despite the Ero1α in cell lines existing predominantly in the OX2 state, different cell types vary 
in their OX1:OX2 ratios under normal conditions. This is likely due to differences in their 
secretory load, and thus the amount of protein they are responsible for folding. However in 
culture, cell lines thrive and thus are maintained in different media compositions, including 
differing amounts of ascorbic acid. Ascorbic acid may contribute to the redox poise of the cell, 
particularly when the normal Ero1-PDI pathway or ER redox conditions are perturbed. 
Whether ascorbic acid, or the lack of it, has an effect on the Ero1-PDI axis and homocysteine 
control was therefore investigated. 
 
OE33 and HT1080 cells were treated with increasing concentrations of ascorbic acid (AA; 0 µM, 
10 µM, 100 µM and 1 mM; an appropriate range to induce cellular changes (Blaschke et al., 
2013; Minor et al., 2013)) with or without either 1 or 10 mM homocysteine. No change was 
seen in the ability of 2G4 to detect Ero1α in any of the treatment combinations. When treated 
with ascorbic acid alone (Figure 3.14 A, B, D and E, lanes 3, 5 and 7) there was no change in 
Ero1α OX2. As this band also did not appear to change upon the addition of 1 mM 
homocysteine, the homocysteine effect was not enhanced by ascorbic acid. If such an effect 
did exist there would be a potential shift towards the Ero1α OX1 state, as seen with 10 mM 
homocysteine, at higher ascorbic acid concentrations. Consistent with previous results, the 
Ero1α band disappeared with 10 mM homocysteine in both HT1080 and OE33 cells (Figure 
3.12B and E). There was no recovery of signal when homocysteine-treated cells were co-
incubated with ascorbic acid. This suggests that ascorbic acid neither enhances nor diminishes 
the effects of homocysteine on Ero1α. 
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Despite there being no change to Ero1α monomers, in OE33 cells treated with ascorbic acid, a 
change was seen in the bands seen above the PDI/Ero1α complexes at about 140 kDa, which 
increased with the addition of ascorbic acid (Figure 3.14F). The addition of 1mM homocysteine 
prevented this increase. A similar pattern is seen in HT1080 cells, with the exception of lane 5, 
where an air bubble may have blocked the signal (Figure 3.14C). 
  























   
E 
Figure 3.14. Ascorbic acid does not affect the recognition of Ero1α by 2G4 
HT1080 (A, B and C) and OE33 (D, E and F) cells were treated with 0, 1 and 10 mM 
homocysteine in combination with 0, 10 100 µM and 1 mm ascorbic acid (AA) for 1 hour 
then lysed in MNT buffer. Cell lysates were then subjected to non-reducing (NR) SDS-PAGE 
and subsequent Western blotting with the monoclonal antibody 2G4 (A, B, D, E) or αPDI (C 
and F). Ero1α monomer oxidation state labelled OX2. PDI-Ero1α complexes (PDI/Ero1 α) 
and PDI-client complexes (PDI-C) are labelled . Background bands are indicated (*). 
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3.2.11 Homocysteine does not cause gross changes in ER morphology  
 
To further characterise how homocysteine influences Ero1α, and the general effects of this 
molecule on the ER, HT1080 cells were mock treated or treated with homocysteine or DTT and 
subjected to live cell imaging at 10 minute intervals (Figures 3.15, 3.16 and 3.17). A blue/white 
ER tracker was used to visualise the ER. The morphology of the ER did not change over the 
course of 50 minutes in the untreated cells (Figure 3.15). The ER had a characteristic 
perinuclear appearance.  Although the signal from the ER tracker became progressively 
brighter with time, the morphology remained consistent. HT1080 cells treated with 
homocysteine presented a very similar picture, with a perinuclear staining of similar size and 
density (Figure 3.16). In contrast, when cells were treated with DTT, changes to the ER occured 
very quickly, in the time between cell treatment and the first image being taken (Figure 3.17). 
The perinuclear staining was different to that seen in Figure 3.15 and 3.16, with gross changes 
occurring and smaller vesicles becoming visible. The addition of DTT to the ER makes it much 
more reducing thus preventing proper protein folding, inducing oxidative stress and eventually 
causing cells to detach and die.  
 
Taken together these experiments suggest that, unlike DTT, homocysteine does not have a 
general reducing effect on the ER and lay the groundwork for live cell imaging of ER proteins 
involved in oxidative protein folding. 
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Figure 3.15. ER morphology in untreated HT1080 cells 
HT1080 cells were incubated with ER tracker for 10 minutes. Following this cells were 
imaged, and imaged again every 10 minutes. 0 minutes (A), 10 minutes (B), 20 minutes (C), 
30 minutes (D), 40 minutes (E), 50 minutes (F). Red scale bar=10 microns. Yellow arrow 
indicates an example of ER perinuclear staining. 
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Figure 3.16. ER morphology in homocysteine treated cells 
HT1080 cells were incubated with ER tracker for 10 minutes. Following this, cells were 
treated with 10 mM homocysteine and imaged, and imaged again every 10 minutes after 
this. 0minutes (A), 10 minutes (B), 20 minutes (C), 30 minutes (D), 40 minutes (E), 50 
minutes (F). Red scale bar=10 microns. Yellow arrow indicates an example of ER 
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Figure 3.17. ER morphology in DTT treated cell 
HT1080 cells were incubated with ER tracker for 10 minutes. Following this, cells were 
treated with 10 mM DTT and imaged, and imaged again every 10 minutes after this. 0 
minutes (A), 10 minutes (B), 20 minutes (C), 30 minutes (D), 40 minutes (E), 50 minutes (F).  
Red scale bar=10 microns. Yellow arrow indicates an example of ER perinuclear staining, 











Ero1 has a complex system of control which is highly regulated and although a mechanism 
exists to explain this control, much remains to be known about its regulation. By looking at 
homocysteine, which has previously been shown to influence the oxidation state of Ero1α, it is 
possible to explore novel ways in which Ero1α is controlled. Investigating how, and at what 
point, homocysteine takes an effect would give insight into this. 
 
As well as the change in oxidative state previously seen with homocysteine (Figure 3.2), here 
another change is seen in the disappearance of Ero1α signal when using the monoclonal 
antibody 2G4 (Figure 3.3A and C). There was no Ero1α OX1 signal seen in any cell type when 
lysates were probed with 2G4, so although the antibody could potentially not detect Ero1α in 
its OX1 form, the lack of signal upon reduction of Ero1α suggests that it is not the oxidative 
state of Ero1α per se that prevents it from being bound by 2G4. As a monoclonal antibody, 2G4 
recognises a specific Ero1α epitope. The data in this chapter suggest that this site is no longer 
accessible to the 2G4 antibody when the protein is both non-reduced and reduced. There is a 
possibility that homocysteine induces some form of post translational modification which 
prevents 2G4 from binding to Ero1α. As the epitope of the 2G4 antibody has not yet been 
mapped, it is difficult to establish the nature of any potential modification. However, the 
experiments with Ero1α mutants in this chapter suggest that it is not the active site or 
regulatory disulphide that are important for 2G4 recognition of Ero1α. These experiments 
could be followed up with the analysis of Ero1α truncation mutants. Were such a post 
translational modification to be found, it could be a molecular switch for instigating the 
activation of Ero1α OX1, or eradicating the OX2 form. Although Ero1α may exist in the OX1 
form when the protein is analysed by SDS-PAGE, it does not necessarily mean it is functional. 
Thus further experiments to determine whether homocysteine may perturb the function of 
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purified Ero1α may be warranted. This potential for regulation of Ero1α by homocysteine is 
shown by the decrease in Ero1α/PDI complexes (Figure 3.10). This loss of complex may 
correlate with a decrease in disulphide transfer to PDI, or to client proteins. However, certain 
Ero1α mutants with altered structural cysteines bind less PDI than the WT whilst retaining 
functional activity, showing that Ero1α can still retain some function, with lower levels of PDI 
binding.  
 
By using cells transfected with tagged Ero1α it was possible to replicate the Ero1α OX2 to OX1 
change seen upon the addition of homocysteine, using a different antibody to that originally 
used (D5). As well as this, the experiments presented in this chapter have shown that the 
homocysteine effect occurs in transfected Ero1α, and not only with endogenously expressed 
Ero1α, allowing the investigation of mutant Ero1α, via transfection, to proceed.  The Ero1α 
mutants C104A/C131A, C391A, C394A/C397A and C391A/C394A/C397A exist at different 
oxidation states in the cell when untreated but, like the WT, these mutants all appear to be 
pushed into a more reduced state, with the complete disappearance of OX2 at 10 mM 
homocysteine. Some of these mutants, such as Ero1αC391A, lack compact structure, due to 
the loss of a structural cysteine. Others, such as the “active site” mutants, may not be able to 
complete a full cycle of electron transfer, due to loss of active site cysteine’s. This means the 
homocysteine effect is not reliant on complete electron transfer, nor on the compact Ero1α 
structure. 
 
Differences in the Ero1α/PDI complex are observed between Ero1α mutants. The experiments 
in this chapter suggest that the complex formation between PDI and Ero1 is not affected by 
low concentrations of homocysteine, but can be manipulated by higher concentrations.  The 
Ero1α C391A and C394A/C397A mutants form a disulphide-bonded complex with PDI and 
possibly other proteins which when represented in Figure 3.11A and B, appears to span a 
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range of molecular weights. This band is likely to be made up of a number of merged bands, 
which become more discrete upon homocysteine treatment. The narrowing in size of this band 
could be due to Ero1α losing the ability to bind PDI, or PDI losing its interactions with Ero1α in 
order to form another interaction.  In an Ero1α C391A/C394A/C397A mutant, the Ero1α PDI 
complex diminished to a smear of much less abundance than seen in the other mutants (Figure 
3.11C); even less of the complex is seen upon addition of homocysteine, where it almost 
disappears. It seems unlikely that this change in complex is due to the homocysteine, as such 
small concentrations of homocysteine have not been seen to have an effect in other 
experiments, however structural change caused by the C391A/C394A/C397A mutation could 
open up the structure and potentiate the effect of homocysteine.   
 
Treatment of cells with cystathionine (Figure 3.13), and as previously shown methionine and 
cysteine, does not impact the oxidation state of Ero1α. Cystathionine, cysteine and methionine 
are downstream of homocysteine in the sulphur amino acid biosynthetic pathway (Battle et al., 
2013). Thus it does not appear to be the case that Ero1α can detect high levels of sulphur 
through cystathionine, which could potentially act to alert the ER to oncoming elevated 
protein synthesis and trigger the activation of Ero1α as a precautionary measure for an 
increased folding load.  In situations of high cysteine concentrations, methionine catabolism is 
reduced in a process called “methionine sparing”. This process also does not appear to affect 
the control of Ero1α directly. 
 
The level of Ero1α expressed differs between cells (Battle et al., 2013). The reason for such 
variation is yet to be fully determined, however it may be a consequence of the function of the 
cell type. It would be expected that cells with a high secretory, and thus high folding capacity 
would have high levels of Ero1α. Previously, the effect of homocysteine has only been shown 
on a gastro-intestinal adenocarcinoma cell line, which may have elevated Ero1α due to factors 
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including dysregulation of gene expression and increased translation induced by hypoxia. 
Furthermore, this cell type would be expected to have greater exposure to homocysteine in 
the diet. By looking at other cell lines, this study has established that homocysteine influences 
the behaviour of Ero1α in disparate immortalised cancer cell types (fibrosarcoma and cervical 
cancer), which may not be exposed to homocysteine in the diet, but may have changed 
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There are two different human Ero1 paralogs. Ero1α and Ero1β are regulated differently with 
both upregulated by ER stress, whereas only Ero1α is regulated by hypoxia (Gess et al., 2003; 
Pagani et al., 2000). They also have tissue specific expression where there are potentially 
differences in their roles. Whilst Ero1α is universally expressed, Ero1β is found in the stomach 
and pancreas (Dias-Gunasekara, 2005). As Ero1β is found in secretory cells, further studies of 
Ero1β could improve the understanding of how proteins secreted by these cells fold, and allow 
the manipulation of Ero1β to improve protein folding. This would be valuable for proteins such 
as Insulin. Insulin is secreted by beta-cells, which are the most common cell type in the 
pancreatic islets of Langerhans (Brange and Langkjoer, 1993). Whilst Ero1β promotes the 
folding of the disulphide linked chains of insulin, its expression is decreased in diabetic mice 
which have impaired insulin secretion, and increased ER stress upon overexpression (Awazawa 
et al., 2014).   
 
4.1.1 Ero1β mutants 
 
The FAD binding site is conserved between Ero1α, Ero1β and Ero1p. The α2 and α3 helices of a 
4 α helix bundle hold the FAD cofactor between them, where is it positioned next to the 
CXXCXXC active site (Figure 4.1).   





Figure 4.1. Ero1 active site 
FAD is held between the α2 (left) and α3 (right) helices, shown as dark blue. Inner active 
site and regulatory cysteines are labelled. The Ero1α structure is adapted from (Inaba, 
2010). The Ero1β structure has not yet been solved. 
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Two Ero1p mutations positioned near residues forming contacts with FAD impair the enzymes 
function (Frand and Kaiser, 1998; Pollard et al., 1998). The single amino acid substitution 
G229S results in a protein that has temperature sensitive maturation defects and ER retention 
of the disulphide containing secretory proteins carboxypeptidase Y and Gas1p, whereas the 
Ero1p-H231Y mutant yeast strain showed a slight UPR up regulation under normal conditions 
and was overly  sensitive to DTT (Gross et al., 2004). By aligning the FAD binding regions of the 
Ero1 protein from S. cerevisiae and H. sapiens, it was possible to determine the equivalent 
Ero1 residues, G252 and H254, respectively (Dias-Gunasekara, 2006).  
 
The Ero1β G252S and H254Y mutants do not undergo gross conformational changes and 
protein biosynthesis appears normal. They are also still able to form non-covalent interactions 
with PDI; however, covalent interactions with PDI (mediated by disulphide bridges) are 
disrupted in Ero1β G252S. The Benham laboratory has previously shown that unlike the Ero1β 
wild type protein, which is mostly reduced and loses most of its disulphide dependant 
interactions upon in vivo treatment with DTT, Ero1β-H254Y complexes are not easily reduced 
by DTT and the G252S mutant counter-intuitively forms a greater number of higher molecular 
weight complexes. Incubation of cells transfected with the Ero1β wild type at temperatures of 
24⁰C and 42⁰C had no effect on Ero1β misfolding, whereas at 24⁰C both Ero1β mutants lose 
their disulphide complexes and at 42⁰C they are both misoxidised. Gunasekara et al (Dias-
Gunasekara, 2006) suggested that disruption of contacts with FAD in these mutants may result 
in loss of FAD binding, or result in a loss of structural stabilisation that makes the protein prone 
to misoxidation during stress. As well as this, there may be disruption to the charge of the FAD 
binding fold, resulting in defects in electron transfer. Under such conditions normal disulphide 
dependant interactions cannot be maintained, and so it has been proposed that this more 
readily exposes thiols to form aberrant disulphide bridges (Dias-Gunasekara, 2006). Given the 
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laboratories background in the biology of Ero1β, it was decided to use Ero1β as a tool to 
further understand the effect of homocysteine on the oxidative protein folding machinery. 
 
  





4.2.1 Initial transfection analysis of Ero1β  
 
To better understand the control of Ero1 proteins by homocysteine, Ero1β was investigated to 
determine whether mutations that had a known effect on protein conformation and function 
were also subject to homocysteine modulation. If there is a similar affect on Ero1 and β, the 
affect homocysteine has is likely to be a result of conserved sequences between the two 
proteins. 
 
Ero1β is not expressed in immortalised cell lines. In the absence of a cell line with sufficiently 
high expression of Ero1β to be examined, Ero1β-HA was transfected to explore its behaviour. 
This meant that Ero1β was expressed in the same cell line(s) and thus subjected to the same 
conditions as for Ero1α, explored in the previous chapter. The transfected HT1080 cells were 
lysed and the cell lysates subjected to SDS-PAGE and immunoblotting using the anti-HA mAb 
and the polyclonal anti-Ero1β serum 4131 (Figure 4.2). Initially, the transfected cells did not 
express the wild type Ero1β-HA. The αHA antibody detected a large amount of non-specific 
binding, with no additional specific bands in the transfected cells when compared to the mock 
transfected cells (Figure 4.2A, compare lanes 1 and 2). When the samples were run next to a 
mouse pancreatic tissue lysate, which expresses Ero1β, and probed with pAb 4131, it was clear 
that Ero1β had not been transfected successfully (Figure 4.2B, lanes 1 and 3). The pancreatic 
lysate showed two bands, a lower one of the expected weight of Ero1β OX2, and a higher 
reduced band running at ~75 kD.  To optimise the transfection, HT1080 cells were compared to 
HeLa cells, which are easier to transfect. As well as transfecting the cells using the original 
concentration of transfection reagent, the amount was doubled (see methods chapter).  
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Protein expression and complex formation was analysed by reducing and non-reducing SDS-
PAGE followed by Western blotting (Figure 4.2C). When equal amounts of cell lysates from the 
transfectants were compared using the anti-HA antibody, the transfection of HeLa cells 
appeared to be more efficient, with a band representing Ero1β appearing at ~55 kDa at both 
transfection reagent concentrations (Figure 4.2C, lanes 5, 6, 11 and 12). In HT1080 cells, Ero1β 
was only weakly visible under reducing conditions at the higher concentration of transfection 
reagent (Figure 4.2 C, lane 9), with a possible background band appearing at the lower 
concentration under non-reducing conditions (Figure 4.2 C, lanes 2 and 3). The increase in 
molecular weight seen in Ero1β under reducing conditions (Figure 4.2 C, compare lanes 3 and 9, 
5 and 11, 6 and 12), and the absence of signal in the mock transfections (Figure 4.2 C, lanes 1 
and 7) provides evidence that the signal is specific to Ero1β. As the transfection efficiency of 









Figure 4.2. Detection of Ero1β in transfected cells  
A. and B. Following transfection with Ero1β or mock transfection (M), HT1080 cells were 
lysed in MNT buffer and the resulting cell lysates, and pancreas tissue lysate (B), subjected 
to non-reducing (NR) SDS-PAGE and subsequent Western blotting with the αHA (A) or 
4131 (αEro1β) (B) antibodies. C. HT1080 and HeLa cells were mock transfected or 
transfected with Ero1β using the initial amount, 3.75 µL, of transfection reaction (Ero1β) 
or double the original amount, 7.5µL (Ero1β 2). These cells were then lysed in MNT buffer 
and the resulting cell lysates subjected to non-reducing (NR) SDS-PAGE and subsequent 









4.2.2 The effect of homocysteine on Ero1β in cells transfected with the WT and mutant Ero1β 
H254Y and G252S 
 
The Ero1β G252S and H254Y mutants misoxidise at 42oC and upon mild DTT stress (Dias-
Gunasekara, 2006). Such responses are not seen in the wild type and do not occur with other 
stresses such as hydrogen peroxide challenge or glutathione deprivation.  The misoxidation of 
Ero1β in these mutants affects its capacity to build disulphide bonds with PDI. As a loss of PDI 
interactions has been seen with Ero1α when cells are treated with homocysteine, there could 
be the same effect on wild type Ero1β, which may or may not be influenced by the G252S and 
H254Y mutants.  
 
To investigate Ero1βs interaction with PDI, and whether homocysteine has the same capacity 
to reduce the Ero1β monomer, HeLa cells were transfected with wild type, G252S or H254Y HA 
tagged Ero1β. The transfected cells were subjected to homocysteine treatment. When the cell 
lysates were analysed by SDS-PAGE under non-reducing conditions, there was a shift in the 
monomer to a slightly higher molecular weight when cells were treated with 10 mM 
homocysteine (Figure 4.3A, compare lanes 3 and 4, 5 and 6, 7 and 8), suggesting that 
homocysteine had the same reducing effect on Ero1β monomers as it did on Ero1α. This shift 
could be seen in both the wild type and the mutants. The difference disappeared when the 
protein was analysed under reducing conditions (Figure 4.3B). This is because Ero1β was fully 
reduced by DTT in the sample buffer, thus proving that the change in molecular weight was 
due to changes in disulphide bonds.  
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Ero1β/PDI complexes are expected to appear at ~130 kDa. In the wild type transfectants, there 
were two high molecular bands,  of which the ~130 kDa one is likely to be the Ero1β/PDI 
complex (Figure 4.3A, lane 3). Since Ero1β is known to form homodimers (Dias-Gunasekara, 
2005), the lighter band of ~120 kDa could be an Ero1β/Ero1β disulphide linked complex. The 
wild type Ero1β protein showed disulphide dependant complexes, which were dispersed when 
the proteins were reduced by DTT in vitro (Figure 4.3A and C, lanes 3 and 4), and were reduced 
to a single complex present at a much lower intensity, upon addition of homocysteine to the 
living cells (Figure 4.3A, lane 4). Both the G252S and H254Y Ero1β mutants formed a ladder of 
complexes, as expected from previous work in the laboratory (Figure 4.3A, lanes 5, 6, 7 and 8). 
Both of the Ero1β FAD mutants lost the highest molecular band with the addition of 
homocysteine. Compared with Ero1β G252S, the Ero1β H254Y mutant lost more disulphide-
dependent interactions after homocysteine treatment, reminiscent of the result obtained 
when cells transfected with these mutants were challenged with DTT (Dias-Gunasekara, 2006). 
 
To distinguish the PDI complexes amongst the ladder of disulphide dependent Ero1β 
interactions, the lysates shown in Fig 4.3B were subjected to immunoblotting and probed with 
αPDI (Figure 4.3C). There was no reproducible change in PDI/Ero1β complexes upon the 
addition of homocysteine to the Ero1βG252S and H254Y transfectants or to the mock. In this 
experiment, there was a change in the wild type where there was a decrease in the PDI 
complex upon homocysteine treatment (Figure 4.3C, lane 4); however this change was not 
reproducible and is likely to be caused by an air bubble whilst transferring the SDS-PA gel onto 
the membrane for western blotting. It is likely that some PDI complexes detected here are 
those interactions with client proteins. Overall, this experiment suggests that homocysteine 
can partially reduce Ero1 and can alleviate oxidative misfolding of the H254Y and G252S 
mutants. 
  













Figure 4.3. The effect of homocysteine on WT, H254Y and G252S Ero1β 
Following mock transfection (M), or transfection with Ero1β WT, H254Y or G252S, HeLa 
cells were treated with 0 or 10 mM homocysteine (HC) for an hour. These cells were then 
lysed in MNT buffer and the resulting cell lysates were subjected to non-reducing (NR), or 
reducing (R) SDS-PAGE and subsequent Western blotting with the αHA (A and B) or αPDI 
(C) antibody. Ero1α monomer oxidation states are labelled OX1, OX2 or reduced (Red). 
PDI-Ero1β complexes (PDI/Ero1 β) and Ero1β-Ero1β complexes (Ero1β/ Ero1β) are labelled. 
Background bands are indicated (*). 
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4.2.3 Further characterisation of the effect of homocysteine on Ero1β in cells transfected with 
mutant Ero1β G252S 
 
To further investigate the shift in migration seen in Ero1β following homocysteine treatment, 
HeLa cells transfected with Ero1 G252S were treated with a wider range of homocysteine 
concentrations, as has been done with Ero1α. The change between oxidation state is not as 
clear as that seen in Ero1α, with a smooth change in molecular weight with the changing 
homocysteine concentrations (Figure 4.4A, lanes 2, 3, 4 and 5). A clear change in the amount 
of complexes was observed when transfectants were treated with a range of homocysteine 
concentrations, with the top band lost at 1 mM homocysteine (Figure 4.4 A, lane 4), and the 
next at 10 mM (Figure 4.4 A, lane 5). There appeared to be fewer complexes at 0 mM 
homocysteine compared to 0.1 mM homocysteine (Figure 4.4 A, lane 2), but this is likely due 
to unequal loading of protein, as the band representing the Ero1β monomer in lane 2 is also 
fainter. All higher molecular weight complexes were broken under reducing conditions when 
DTT was added to the samples (Figure 4.4 A, lanes 6-10), proving that the interactions 
disrupted by homocysteine were disulphide dependant. 
 
The same cell lysates were subjected to western blotting and probed with an αPDI antibody to 
provide a blotting control (Figure 4.4B). 
 
  





Figure 4.4. The effect of homocysteine on the G252S Ero1β mutant 
Following mock transfection (M), or transfection with Ero1β G252S, HeLa cells were treated 
with 0, 0.1, 1 or 10 mM homocysteine (HC) followed by lysis in MNT buffer. The resulting 
cell lysates were subjected to non-reducing (NR), or reducing (R) SDS-PAGE and subsequent 
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4.2.4 The effect of homocysteine on Ero1β in HT1080 cells transfected with the mutant Ero1β 
H254Y and G252S 
 
Despite their limited capacity to be transfected with Ero1, it was possible to transfect HT1080 
cells with the G252S and H254Y Ero1β HA tagged mutants and to detect expression in some 
experiments. This allowed the determination of whether the results seen in HeLa cells could be 
replicated in HT1080 cells, one of the cell lines used to investigate Ero1α in the previous 
chapter. The transfected HT1080 cells were treated plus or minus 10 mM homocysteine and 
the cell lysates were analysed by non-reducing SDS-PAGE and western blotting (Figure 4.5A 
and B). Although not as clear as the results seen in HeLa cells, there was a demonstrable 
change in migration of the monomeric Ero1β FAD mutants, which became more compact with 
homocysteine treatment (Figure 4.5A, lanes 6 and 8). This shift could be seen in both mutants 
(Figure 4.5A, compare lanes 5 and 6, 7 and 8) but not in the wild type, because transfection of 
the wild type was unsuccessful. Compared to the HeLa lysates shown in Figure 4.4, two distinct 
monomeric Ero1β bands could be seen more clearly in this experiment (Figure 4.5), with both 
an oxidized and partially reduced form apparent in the successfully transfected samples (lanes 
5, 6, 7 and 8). The presence of multiple background bands act as loading controls, but make 
the interpretation of the effect of homocysteine on Ero1 mutant misoxidation difficult for 
HT1080 cells. When analysed under reducing conditions, Ero1β was reduced to a single band, 
showing that the change in molecular weight was due to changes in disulphide bonds (Figure 
4.5B).  
 
The HT1080 lysates were immunoblotted and probed with αPDI as a control (Figure 4.5C). 
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Figure 4.5. The effect of homocysteine on H254Y and G252S Ero1β mutants in HT1080 
cells 
Following mock transfection (M), or transfection with Ero1β WT, H254Y or G252S, HT1080 
cells were treated with 0 or 10 mM homocysteine (HC) for 1 hour. They were then lysed in 
MNT buffer. The resulting cell lysates were subjected to non-reducing (NR), or reducing (R) 
SDS-PAGE and subsequent Western blotting with the αHA (A and B) or αPDI (C) antibody. 
Ero1monomer oxidation states are labelled OX1 and OX2 or reduced (Red). Background 








4.2.5 Initial treatment of tissue cells with homocysteine  
 
The results shown in Chapter 3 and the Figures 4.2-5 above demonstrate that both Ero1α and 
Ero1β are pushed into less compact forms upon treatment with homocysteine in immortalized 
cell lines. However, to understand how these proteins behave in vivo, tissues can be used to 
see whether homocysteine acts in the same way on primary cell types. 
 
Single cell suspensions were made from mouse liver and pancreatic tissue, chosen because 
these tissues have high expression of Ero1α and Ero1β, respectively. Liver and pancreas cells 
along with HT1080 cells also in suspension, were treated with homocysteine (Figure 4.6). 
HT1080 cells were used as the effect of homocysteine on these cells is known and will indicate 
whether the different treatment method used here (treatment of cells in suspension) has been 
successful.  HT1080 and liver samples analysed by SDS-PAGE and western blotting were 
probed with the anti-Ero1 mAB 2G4. The pancreas sample was not probed with 2G4 as it 
expresses Ero1α at a much lower level. As found previously, HT1080 samples lost the 2G4 
Ero1α signal at 10 mM homocysteine, when lysates were analysed under both non-reducing 
and reducing conditions (Figure 4.6A, lanes 2 and 6). Actin controls show that there was 
protein in these samples (Figure 4.6B).  The liver sample contained a small amount of 
monomeric Ero1α, but it existed mainly as a complex (*) in untreated cells (Figure 4.6A, lane 3). 
Upon homocysteine treatment, no monomeric Ero1α was visible and other Ero1α complexes 
(**) were formed with a slightly lower molecular weight than that present in the untreated 
cells (Figure 4.6A, lane 4). Under reducing conditions, the fully reduced Ero1α could be 
visualised. Unlike in HT1080, the signal was not lost, meaning that the 2G4 mAB was still able 
to detect the fully reduced form. As no monomeric Ero1α signal was present under non-
reducing conditions, 2G4 may not be able to detect the alkylated OX1 form of Ero1α. To 
4C 
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further investigate this, liver single cell suspensions were treated with DTT as well as 
homocysteine (Figure 4.6C). Again, Ero1α lost its monomer signal upon homocysteine 
treatment under non-reducing conditions, but not reducing conditions. When treated with DTT, 
Ero1α was partially reduced and the complexes were lost. A difference in molecular  weight 
could be seen when comparing the Ero1α under non-reducing and reducing conditions. This 
confirmed that Ero1α was not completely reduced by the DTT treatment. In the liver cells, 2G4 
could still detect the OX1 form of Ero1α, meaning that treatment with 10 mM homocysteine 
pushed all the Ero1α into complexes. As the complex seen in untreated liver cells (*) seemed 
to decrease with homocysteine, and a complex of a slightly lower molecular weight appeared 
(**), the treatment may be encouraging other interactions to occur at the expense of the 
monomer and the heavier complex (Figure 4.6C).  
  











Figure 4.6. Homocysteine  disperses Ero1 complexes in liver cell suspensions  
Liver and HT1080 cells in single cell suspension were treated with 0 or 10 mM 
homocysteine (HC) or with 10 mM DTT. The cells were washed, lysed in MNT buffer and 
were subjected to non-reducing (NR), or reducing (R) SDS-PAGE and subsequent Western 
blotting with the 2G4 (A and C) or αactin (B) antibody. 
Ero1α complexes in liver are labelled (*)(**).Ero1αmonomer oxidation states are labelled 
OX2 or reduced (Red).  
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4.2.6 The effect of homocysteine on Ero1β in pancreatic cells  
 
Ero1β is expressed in the pancreas, with high expression in the islets but lower expression in 
the surrounding enzyme secreting cells. PDI shows the opposite pattern, with lower expression 
in the islets compared to the surrounding cells. The expression of the pancreas specific PDIp is 
only found in the acinar cells. As Ero1β and PDI do not strictly co-localise, PDI may not be the 
primary electron donor for Ero1β in the pancreas (Desilva, 1997; Dias-Gunasekara, 2005). Thus 
the regulation of Ero1β may differ in the pancreas, depending on the relative competition for 
PDI and other electron donors.  
 
When a pancreas cell suspension was lysed and probed for Ero1β using the 4131 antibody, two 
bands appeared with molecular weights of ~50 and ~70 kDa under non-reducing conditions 
(Figure 4.7A, lanes 1, 2, 3 and 4). The heavier band is likely to be the reduced form. Ero1β is 
predicted to be ~ 50kDa (without glycans); the lower band is likely to consist of a background 
band (*) and Ero1β OX2 which is highly expressed, giving it the appearance of being a single 
band. Under reducing conditions the Ero1β OX2 form was reduced, leaving only the 
background band at this molecular weight (lanes 3 and 4). The background band was also 
found in the liver lysates (Figure 4.7A, lanes 5, 6, 7 and 8). To further confirm that the heavier 
molecular weight band in the pancreas was Ero1β, cell lysates were treated with endoH to 
digest immature sugar residues (Figure 4.7 B, compare lanes 1 and 2, 3 and 4). There was a 
decrease in the molecular weight of Ero1β following endoH treatment, consistent with 
published reports that Ero1β is glycosylated. 
 
The cells in this experiment were treated +/- 10 mM homocysteine. No change in apparent 
molecular weight (or signal intensity) of the Ero1 reduced or OX2 bands was observed upon 
6B 
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treatment of the pancreatic cells with homocysteine (Figure 4.7A, lanes 1 and 2). No high 
molecular weight complexes were observed. Although the effectiveness of the 4131 antisera 
at detecting Ero1 complexes remains open to question, this result suggests that Ero1β existed 
mainly as a monomer in the pancreas. In contrast to the pancreas, abundant PDI complexes 
were detected in the liver. These complexes did show a decrease when liver cells were 
incubated with homocysteine (Figure 4.7C, lanes 3 and 4). Taken together, these results 
suggest that the susceptibility of the Ero1-PDI oxidative folding pathway to homocysteine may 
vary between tissues. 
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Figure 4.7. Homocysteine has no detectable effect on pancreatic Ero1β 
Liver and pancreas cells in single cell suspension were treated with 0 or 10 mM 
homocysteine (HC). The cells were lysed in MNT buffer and were directly (A and C), or 
following endoH treatment (B), subjected to non-reducing (NR), or reducing (R) SDS-PAGE 
and subsequent Western blotting with the 4131 (A and B) or αPDI (C) antibody. The Ero1 
monomer oxidation state is labelled OX2, the reduced form is labelled (Red), and the 










 The results of this chapter show that homocysteine has a reducing effect on Ero1β as well as 
on Ero1α when Ero1 is expressed in cell lines (Figures 4.3 and 4.5). As the structural 
differences between Ero1α and Ero1β do not change the effect of homocysteine, it is unlikely 
that the method through which homocysteine takes its effects is through the sites of 
difference. Figure 4.8 shows the differences in cysteine residues between the two homologues, 
but also highlights that most are conserved between the two. It should also be noted that 
there is a difference in the number of N-glycosylation sites. Whilst Ero1α has two glycans, 
Ero1β has four, but there is no evidence to suggest that these affect protein function (Pagani 
et al., 2000).  
 
The occurrence of Ero1β complexes decreased with homocysteine treatment (Figure 4.3 and 
4.4). In both wild type and the Ero1β H254Y mutant, there was a dramatic loss in Ero1β/PDI 
complexes. A loss of homodimers was also observed (Figure 4.3 and 4.4), which could be a 
result of reduction by homocysteine or homocysteine preventing them from binding via post-
translational modifications. It is also possible that Ero1β forms homodimers as a regulatory 
mechanism (Dias-Gunasekara, 2005);  when Ero1β is in what appears to be its active state e.g. 
induced by homocysteine treatment, it may be unable to form homodimers.   





Figure 4.8. Comparison of the disulphide bond arrangements in Ero1α and Ero1β 
Cysteine residues are labelled according to amino acid position. Cysteine residues and 
disulphide bonds conserved between Ero1α and Ero1β are black, whilst those which are 
not are coloured red.  
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A slightly different result was seen in Ero1β G252S with only a loss of the heaviest complex, 
which was not seen in the wild type (Figure 4.3). Homocysteine did not appear to affect the 
formation of homodimers, or the abundance of Ero1β/PDI complexes. These results are similar 
to those seen upon DTT treatment of the Ero1β G252S mutant, where an increase in higher 
molecular weight complexes was seen by Gunasekara et al (2006). Upon treatment with 
homocysteine, a redistribution of the complexes was seen. The results seen with the Ero1 
H254Y mutant are also similar to when treated with DTT, with a decrease, but not complete 
loss of the complex signal (Figure 4.3). This would suggest that the treatment of homocysteine 
is similar to that of DTT in that it is having a reducing effect. The treatment with homocysteine 
may be taking Ero1β out of complexes, thus preventing misoxidation of the FAD mutants. This 
could potentially, in some circumstances, protect Ero1β against stress-induced oxidative 
misfolding. 
 
 It is unlikely that the G252S mutation has a direct effect on the Ero1β-PDI interaction, as this 
interaction occurs at a site unaffected by the mutation. However, as the mutation destabilises 
the binding of the electron acceptor FAD, it may prevent the reoxidation of Ero1β. PDI can act 
as a chaperone as well an electron donor for Ero1. Since the G252S mutation potentially 
confers structural instability to the protein this could require additional chaperone assistance 
from PDI.  
 
During temperature stress both of the Ero1β FAD mutants are known to misoxidise and their 
disulphide-dependent interactions are disrupted. In the Ero1p equivalents of these mutants, 
such stress is lethal, but viability can be restored by oxidising agents like diamide (Frand and 
Kaiser, 1998). It would be interesting to see the effect of such agents in conjunction with 
homocysteine to further characterise homocysteines reducing function. 




By using the known reducing effect of homocysteine on Ero1α, and the accompanying loss of 
signal from the antibody 2G4, it was possible to show that homocysteine also affected cells 
from tissues. The cell line HT1080 showed the same response when in single cell suspension as 
when grown and treated in a monolayer.  
 
The transfection of Ero1β into a cell line represents an overexpressed system where molecular 
interactions can be influenced by non-physiological concentrations of proteins. However, it 
should be noted that the expression of Ero1α in the liver and Ero1β in the pancreas is at least 
as high as that achieved in transfected cells. The pool of Ero1α in liver cells was found to exist 
mostly in complex form (more so than in HT1080 cells). This could be a consequence of a high 
level of expression, or a high activity level, either of which are likely due to the protein 
secretory function of the tissue type. Upon homocysteine treatment, all detectable Ero1α was 
found in complex form, with additional complexes becoming visible. These additional 
complexes may be released from the heavier complexes following modification; alternatively 
homocysteine may cause Ero1α to misoxidise and form unusual intermolecular disulphides. 
Unlike HT1080 cells, liver cells did not completely lose the 2G4 antibody signal with 10 mM 
homocysteine. There was still a 2G4 signal arising from Ero1 associated non-reducing 
complexes. It is likely that the Ero1α monomers were either recruited into complexes upon 
treatment with homocysteine, or Ero1 was released from greater molecular weight 
aggregates into ~ 150kDa complexes (Figure 4.6). It is clear that homocysteine is having an 
effect on liver tissue, but the persistence of the 2G4 signal at 10 mM homocysteine, which has 
not been observed in the other cell lines tested, is likely to mean that any modification which 
prevented the detection of Ero1α by 2G4 is not effective here.  This may be due to the 
modification not occurring in the liver or due to there being a system which buffers the 
modification by higher protein or metabolite concentrations. 




 Treatment of liver cells with DTT reduced all Ero1α complexes, however DTT did not induce a 
change in the molecular weight of the Ero1α monomer, suggesting that in normal  conditions, 
Ero1α exists in an OX1 form (Figure 4.6). When compared to the Ero1α in the HT1080 cell line 
which becomes less mobile, potentially induced to the active state, with homocysteine, 
perhaps Ero1α in a PDI complex represents a more active form which is induced by 
homocysteine.  
 
When Ero1β was observed in pancreas tissue, it was present in two forms under non reducing 
conditions, oxidised and reduced. The presence of the reduced form in non-reducing 
conditions may be due to high expression, the regulatory poise of the pancreas, or because the 
reduced form may have another function e.g as a chaperone. Alternately this could be the OX1 
form of Ero1β running at a molecular weight very similar to that of reduced Ero1β at ~55kDa.  
 
 No change to Ero1β was seen upon homocysteine treatment of pancreas cells, despite having 
seen a change in Ero1β oxidation state in the HT1080 cell line transfected with Ero1β. As 
homocysteine only appears to have an effect on Ero1 in certain cell types there may be other 
factors regulating its behaviour in pancreatic cells.  
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The previous chapters have focussed on the quality control machinery in the ER, characterising 
the function of Ero1α and Ero1β. This chapter will explore the quality control of the client 
protein MHC class II, which assembles in the ER. This involves further characterising the 
stability of the MHC class II dimer, and how its stability is affected by the homocysteine 
induced changes in Ero1α.  
 
5.1.1 Toll-like receptors 
 
Toll-like receptors (TLR) are type 1 transmembrane receptors possessing an extracellular 
leucine-rich repeat domain (Medzhitov et al., 1997), and an intracellular Toll/ Toll-interleukin 1 
(IL-1) receptor domain (Rock et al., 1998). TLRs recognise specific structural patterns of 
microbial components known as pathogen associated molecular patterns (PAMP), and respond 
to these by activating a range of signal transduction pathways which are either specific to the 
activated TLR or shared by all TLRs (Medzhitov et al., 1997). Activation of these pathways 
recruits IL-1 receptor domain-containing adaptor proteins, with each TLR recruiting a different 
combination of the four versions, MyD88, TIRAP, TRIP and TRAM. In all pathways this activates 
the transcription factors NF-kB and AP-1, resulting in inflammatory cytokine and chemokine 
expression. Other TLR specific pathways are also activated, for example the transcription 
factor IRF3, which controls type 1 interferon production, is activated upon TLR3 stimulation 
(Barton and Medzhitov, 2003) (Figure 5.1). Such pathways are also involved in activating the 
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adaptive immune system via the upregulation of cell surface expression of co-stimulatory 
molecules (CD80 and CD86) and MHC class II molecules on antigen presenting cells (Medzhitov 
et al., 1997). 
 
Along with their classical function, MHC class II molecules play a number of other roles in 
immune responses such as maintaining the full activation of the TLR triggered immune 
response. Full TLR activation of innate responses have been shown in the murine system to be 
reliant on MYD88 and TRIF dependant pathways, which are enhanced by interaction with the 
tyrosine kinase Btk (Figure 5.1). Intracellular MHC class II has been shown by 
immunoprecipitation to complex with CD40 which physically associates with and maintains the 
activity of Btk, allowing it to interact with MyD88 and TRIF and promote TLR signalling (Liu et 
al., 2011). When MHC class II is removed from macrophages and dendritic cells by use of 
knockout mice, there is a reduction in TLR prompted production of proinflammatory cytokines 
and type I interferon. 
 
Both TLRs and MHC class II molecules are found mainly on APCs, allowing this non-classical 
relationship to exist. Previous studies have shown that the MHC class II isotypes have different 
requirements for the formation of SDS-stable dimers, with DP4, unlike DR and DQ, able to form 
SDS-stable dimers in the absence of Ii (van Lith, 2010). Given the differences in stability 
between MHC class II isotypes, and the relationship between MHC class II and TLR signalling, it 
is possible that interactions with the TLR signalling machinery could account for the unusual 
stability seen in DP. 
 
 







Figure 5.1. TLR3 Signalling pathway 
Activation of TLR3 leads to the recruitment of the adaptor protein TRIF, which via a 
signal transduction pathway activates the transcription factors NF-kB, AP1 and IRF3 
resulting in inflammatory cytokine expression. High activity of TRIF is maintained by an 
interaction with Btk. MHC class II (MHC II) has been proposed to interact with CD40, 
which binds to, and maintains activity of Btk. 
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5.1.2 Leupeptin/ammonium chloride  
 
The MHC class II pathway of peptide presentation at the cell surface involves the 
endosome/lysosome, where breakdown of the Ii by cathepsin proteases allows processing and 
eventual displacement of the CLIP fragment by antigenic peptides. This pathway can be 
disrupted by leupeptin as well as ammonium chloride. Leupeptin is a cysteine/serine protease 
inhibitor, which prevents the complete degradation of Ii, whilst ammonium chloride 
neutralizes lysosomal pH also preventing endosomal cathepsins from functioning. Without this 
Ii degradation, MHC class class II molecules cannot bind to peptides and accumulate in the 
MIIC (endosomal/lysosomal) compartments (van Lith, 2010). 
  






5.2.1 MHC class II molecules have different levels of stability 
 
MHC class II molecules are stabilised by antigenic peptides or high affinity self-peptides bound 
at the peptide binding site, however before this can happen MHC class II molecules must first 
fold into their native structure and then bind a peptide which will bind stably. The chaperones 
Ii and DM facilitate this process. Differences have been observed between the three classical 
MHC class II molecules, HLA-DR, DP and DQ, in their requirements for these chaperones to 
assist in the formation of SDS-stable MHC class II dimers. Unlike DR and DQ, DP4 is able to 
form SDS-stable dimers in the absence of Ii. This property can be assessed by a stability assay 
(Germain and Margulies, 1993; van Lith, 2010). When lysates from cells expressing DPα and β 
chains are incubated in an SDS-containing buffer at room temperature, a portion of the DP 
molecules remain as a dimer, but when boiled, noncovalent interactions between the heavy 
chains are disrupted, leaving α and β monomers.  
 
To investigate whether, when Ii is present, the stability of DP differs from DR, lysates from the 
model antigen presenting cell line MelJuso, following lysis, were subjected to a range of 
temperatures in an SDS stability assay. These were analysed by SDS-PAGE and western blot 
and probed with conformation independent 1B5 (αDRα) and αDPβ antibodies. Figure 5.2 
shows that DR dimers only resist denaturation at the lowest temperature tested, 20˚C, with no 
band representing DR dimers at 60 or 90˚C (Figure 5.2, compare lanes 1, 2 and 3). As expected, 
the DRα monomer was found at all temperatures tested. Like DR, DP monomers were found at 
all temperatures (Figure 5.2, compare lanes 4,5 and 6), however the amount did not remain 
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constant. This may be a result of the DP antibody being less efficient at detecting the 
monomer.  Unlike DR, some DP dimers remained stable at 60˚C, despite there being less of 
them shown by the reduction in band size compared to the 20˚C band. The DP dimers were 
denatured at 90˚C (Figure 5.2, lane 4). A background band of about 50 kDa, slightly lighter than 
the DP dimer, was detected by the αDP antibody. When this band has previously been 
detected by the antibody, it has not influenced the recovery of stable DP dimers (van Lith, 
2010). 
  





Figure 5.2. HLA –DR and DP have different levels of stability 
MelJuSo cells were lysed in MNT buffer. Cell lysates in sample buffer were heated 
to 20ᵒC, 60ᵒC or 90ᵒC for 5 minutes. Cell lysates were then subjected to non-
reducing (NR) SDS-PAGE and subsequent Western blotting with the αDR (1B5) or 
αDP antibody. Background bands are indicated (*). 
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5.2.2 DP and DR localisation  
 
Differences in the stability of DR and DP in MelJuSo cells could be explained by differential 
localisation within the secretory pathway. Therefore, the cellular distribution of HLA-DP and –
DR were determined using immuno-localisation in MelJuSo cells to determine whether DP and 
DR co-localise. Cells were treated +/- leupeptin and ammonium chloride, which prevent the 
trafficking of DP and DR through the endocytic pathway, to determine if DP has an alternative 
pathway or is found in compartments other than those where DR is located. Alternative DP 
trafficking and localisation could indicate that DP molecules gain access to an unconventional 
peptide pool or interact with as yet unknown accessory proteins that may influence heavy 
chain stability. Following treatment with leupeptin or ammonium chloride, cells were fixed, 
permeabilised and co-stained with DAPI, and stained with a DP or DR antibody. Analysis by 
fluorescence microscopy of mock treated cells showed characteristic ER and punctate staining, 
indicative of endosomal localisation for both DP and DR (Figure 5.3A and 5.4A). This 
localisation did not change after treatment with leupeptin for either DP (Figure 5.3C) or DR 
(Figure 5.4C). When treated with ammonium chloride, DR appeared mainly in the ER (Figure 
5.4B), whilst DP localisation (Figure 5.3B) varied, with a mixture of ER only staining and ER and 
what appears to be endosomal staining in the cells. To assess the lysosmal compartments in 
the presence or absence of ammonium chloride and leupeptin, the experiment and analysis 
was carried out again and the cells incubated with lysosotracker. However, the signal from the 
lysosotracker was not distinct enough to determine whether the lysosomes were enlarged 
following the treatments (data not shown).  
 
  





Figure 5.3. Localisation of HLA –DP in mock, NH4Cl and leupeptin treated MelJuSo cells 
MelJuSo cells were mock treated (A) or treated with NH4Cl (B) or leupeptin (C) and stained 
with DAPI and αDP antibody. Yellow and pink arrows indicate examples of endosomal and 
ER staining, respectively. Red scale bar=10 microns. 
 
DAPI αDP Overlay 





Figure 5.4. Localisation of HLA –DR in mock, NH4Cl and leupeptin treated MelJuSo cells  
MelJuSo cells were mock treated (A) or treated with NH4Cl (B) or leupeptin (C) and stained 
with DAPI and αDR antibody. Yellow and pink arrows indicate examples of endosomal and 
ER staining, respectively. Red scale bar=10 microns. 
 
DAPI αDR Overlay 
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5.2.3 Is TLR3 stabilising DP? 
 
Full TLR3, 4 and 9 activation of innate responses is reliant on MYD88 and TRIF dependant 
pathways, which are enhanced by interaction with the tyrosine kinase Btk. Mouse models have 
shown that Intracellular MHC class II complexes with CD40 in endosomes to maintain the 
activity of Btk (Liu et al., 2011). If such an interaction is present in human cells, it may 
potentially account for the differing stabilities of the HLA isotypes, in particular the unusual 
stability of HLA-DP.  
 
To investigate whether the TLR3 machinery could potentially interact with and stabilise MHC 
class II molecules, a cell line which endogenously expresses TLR3 in the presence or absence of 
MHC class II expression was required. Cells which do not naturally express MHC class II can be 
transfected with these molecules, meaning their assembly, trafficking, interactions and 
chaperone requirements (e.g. for HLA-DM and Ii) can be controlled.   
 
Experimenting with a cell line which naturally expresses MHC class II would not be suitable. 
The transfection of MHC class II molecules would result in the overexpression of MHC class II, 
which in mice does not affect Btk activation, whereas restored expression of MHC class II in 
deficient mice activates Btk (Liu et al., 2011).  
 
In accordance with its role in immune surveillance, TLR3 is highly expressed in tissues in 
contact with the external environment, for example epithelial cells in the lung (Zarember, 
2002). However, there are conflicting views regarding the expression of TLR3, especially in 
leukocytes. There are several reports that it is only expressed in Dendritic cells (DC) (Muzio et 
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al., 2000), whilst others suggest it is expressed in a wider variety of cell types such as T or NK 
cells (Zarember, 2002). 
 
Here, the human monocytic leukemia THP-1, the human melanoma MelJuSo and, the human 
fibrosarcoma HT1080 cell lines were investigated for their expression of TLR3. THP-1 cells are 
an immortalised monocyte-type suspension cell line that can be differentiated into adherent 
macrophages by treatment with mitogens e.g. PMA. RNA was extracted from these cell lines 
and subjected to RT-PCR using primers against TLR3 and β-actin to examine RNA levels. -actin 
acts as an expression and amplification control and was strongly expressed in all 3 cell lines, 
confirming that the RT-PCR had been successful (Figure 5.5, lanes 1, 3, 5 and 7). HT1080 had 
the highest amount of TLR3 RNA (Figure 5.5, lane 8) whereas the MelJuSo cell line showed no 
detectable expression (Figure 5.5, lane 2). Despite published data claiming that TLR3 is not 
expressed in monocytes (Matsumoto and Seya 2008), small amounts were found in the THP-1 
cell line as shown in Figure 5.5, lane 4, as well differentiated THP-1 macrophages as shown in 
Figure 5.5, lane 6.  
 
  





Figure 5.5. TLR3 expression in the MelJuSo, THP-1, HT1080, and macrophage cell lines 
RNA extracted from MelJuSo, THP-1, HT1080 and THP-1 derived macrophage cells was 
converted to cDNA and used to test for the presence of actin and TLR3 expression. 
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Studies show that TLR3 expression is higher in resting macrophages than in monocytes and 
even higher in activated macrophages, so upon differentiation and maturation of the THP-1 
cell line, TLR3 is expected to be upregulated (Heinz et al. 2003). The previous RT-PCR on RNA 
(cDNA) extracted from THP-1 cells showed no difference in TLR3 levels after differentiation 
(Figure 5.5, compare lanes 4 and 6). To verify this, western blotting was used. THP-1 cells were 
treated with PMA and LPS. The differentiated cells were lysed and examined with a TLR3 
antibody following SDS-PAGE. A TLR3 signal appeared in HT1080 and undifferentiated THP1 
cells in similar amounts (Figure 5.6A, lanes 1 and 2). A much fainter band could be seen (Figure 
5.6A, lanes 3 and 4) when THP-1 cells were differentiated (+PMA; Figure 5.6A, lane 3) and 
differentiated and activated (+PMA and LPS; Figure 5.6A, lane 4). Probing these lysates with a 
PDI antibody shows equal loading of the samples (Figure 5.6B, lanes 1-4), demonstrating that 
the changes in the TLR3 signal were not due to differences in overall protein loading. This 
result is inconsistent with the literature; however, the molecular weight of the band 
supposedly representing TLR3 in Figure 5.6A is about 60kDa, and does not correspond to the 
predicted TLR3 molecular weight of 104 kDa. To assess whether the band seen in Figure 5.6A 
was likely to be a genuine TLR3 polypeptide, an endoH digestion experiment was performed. 
TLR3 is highly glycosylated, so upon endoH treatment the migration of this band should 
increase. Following such treatment of the HT1080 and THP1 lysates, no change in molecular 
weight was seen (compare Figure 5.6C, lanes 1 and 3, and lanes 2 and 4). In addition, a mouse 
intestinal lysate run alongside the cell lysates showed a band of about 100 kDa (and some 
higher molecular weight material) and is likely to be TLR3 (Figure 5.6C, lane 5). Probing the 
western blotted lysates with an Ero1α antibody showed that the endoH treatment was 
effective, with a decrease in the molecular weight of Ero1α in both HT1080 and THP-1 cells 
following deglycosylation (Figure 5.6D, compare lanes 1 and 3 and, 2 and 4).  
 




Figure 5.6. Increasing THP-1 TLR3 expression    
THP-1 cells were treated with PMA, PMA and LPS or, mock treated, then, along with 
HT1080 cells, lysed in MNT buffer. Cell lysates were treated +/- endoH (C and D). Cell 
lysates, endoH treated cell lysates and gut lysates were subjected to non-reducing (NR) 
SDS-PAGE and subsequent Western blotting with the αTLR3 (A and C), αPDI (B) or αEro1α 
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Taken together, these experiments suggest that the TLR3 antibody was able to detect TLR3 in 
tissue, but not in the immortalised cell lines, where a non-specific protein was bound. 
 
The experiments shown in Figure 5.5 suggested that TLR3 expression in HT1080, MelJuSo and 
THP-1 cells was too low to allow a putative MHC class II-TLR3 interaction to be investigated. 
Another method of upregulating TLR3 is by ligand stimulation. Treatment of cells with the TLR3 
ligand poly(I:C) should induce such a response (Ritter et al., 2005).  Thus RNA was extracted 
from HT1080 cells treated with 50 or 100 µg/ml poly(I:C) and subjected to RT-PCR using 
primers to amplify TLR3. However, there appeared to be no change in the expression of TLR3 
upon poly(I:C) stimulation of HT1080 cells (Figure 5.7, lanes 1, 2 and 3). 
  





Figure 5.7. TLR3 expression in activated HT1080 cell lines 
RNA extracted from HT1080 cells treated with 0 (-), 50 or 100 µg/ml poly(I:C) was 
reverse transcribed to cDNA and amplified by PCR for the presence of TLR3. 
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For an interaction between HLA-DP and TLR3 to occur they must co-localise. HLA-DP has been 
shown to reside in the ER and endocytic pathway (Ritter et al., 2005). TLR3 is generally thought 
to be found intracellularly, residing at the endosomal membrane, and binding to endosomal 
ligands (Johnsen et al., 2006). This reflects its role in detecting viral dsRNA. However, as with 
the conflicting opinions regarding TLR3 expression, there is debate as to its cellular location. 
These molecules have been found on the cell surface, which is characteristic of many other 
TLRs, in human fibroblast cells (Matsumoto et al. 2002). Such expression would be 
advantageous as it would give cells the ability to detect extracellular, most likely nonviral, 
dsRNA. Johnsen et al. (2006) provide further evidence of TLR3 localisation being dependant on 
cell type. As the HT1080 cell line has the highest TLR3 expression of the cell lines tested, its 
localisation was explored. Cells were fixed, permeabilised and stained with DAPI and a TLR3 
antibody. Fluorescence microscopy was used to visualise the localisation of TLR3 in HT1080 
cells (Figure 5.8). The DAPI stained shows clearly identifiable nuclei, however the pattern of 
staining for TLR3 is indistinct, with the localisation difficult to interpret. Taken together with 
the data in Figure 5.6, the experiments suggest that although TLR3 mRNA is synthesised to 
some extent in HT1080 cells, the level of protein expression is too low to analyse by western 
blotting and immunofluorescence.  
 
  





Figure 5.8. TLR3 expression in HT1080 cells 
HT1080 cells were fixed and immunostained with the αTLR3 antibody. Nuclei were 
stained with DAPI. Red scale bar=10 microns. 
DAPI αTLR Overlay 
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By introducing the HLA isotypes DR and DP into a TLR 3 expressing cell line, their ability to 
complex with CD40, and enhance the activity of TLR3 activated Btk can be tested. This could be 
done by measuring the levels of TNF, IL-6 and IFN-, the production of which increases upon 
TLR3 activation. Expression of both the MHC class II α and β chain are required for 
enhancement of Btk activity, meaning it is important that both the MHC class II α and β chain 
are expressed, together with the components needed for their assembly- DMα, DMβ and Ii. 
The plasmids for these components were transfected in different combinations to determine if 
a stable MHC class II dimer could be expressed. DRβ was transfected either alone, + DRα and Ii 
or +DRα and DMα (Figure 5.9A). The transfected cell lysates were analysed by western blot 
alongside mock transfected HT1080 cells, as well as HLA-DR expressing MelJuSo cell lysates. 
The PVDF membranes were probed using an anti DRβ antibody. The MelJuSo positive control 
shows the monomeric DRβ chain, as well as the heavier DRαβ heterodimer (Figure 5.9A, lane 
1), neither of which were found in the mock transfected HT1080 sample (Figure 5.9A, lane 3). 
DRβ was successfully transfected, as shown by the ~ 30kDa band representing the DRβ chain 
(Figure 5.9, lanes 2 and 4). However the absence of a higher molecular weight band suggests 
that the DRα chain was not expressed in the co-transfectant. As multiple plasmids were being 
transfected here, it is possible that the ratio of DNA to transfection reagent was suboptimal in 
this experiment. To establish if this was the case, all plasmids were transfected into HT1080 
cells, but at varying concentrations (Figure 5.9A, lanes 6, 7, and 8). 0.5 µl DNA was required to 
be able to see expression of the DR chain. However, although the DRβ chain was expressed, 
no DRαβ heterodimer was evident. This suggests that the DRα chain was not successfully 
transfected and expressed. 
 
This experiment was repeated, transfecting just the DRα and DRβ chain to reduce the amount 
of DNA being taken up by the cell. Cell lysates from the transfectants were analysed by SDS-
PAGE and western blotting, as before. Immunoblotting with the anti-DRβ antibody confirmed 
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that DRβ and the DRαβ heterodimer was present in the control MelJuSo sample (Figure 5.9B, 
lane 1). In the HT1080 transfectants, the DRβ construct was successfully transfected, with a 
band representing the DRβ chain, as well as a higher molecular weight band, which is likely to 
be DRhomodimers, as DRα is not present (Figure 5.9B, lane 3 and 5). There was no signal 
when cells were transfected with DRα alone, as expected because the membrane was probed 
with an anti DRβ antibody (Figure 5.9B, lane 4). When both chains were transfected (Figure 
5.9B, lane 5), two bands were seen, the lower being DRβ, the higher being either a DRαβ 
heterodimer or a DRβ homodimer (as seen in Figure 5.9B lane 3). To clarify whether DRα was 
expressed, the same samples were probed with an anti DRα antibody (Figure 5.9C). This 
revealed that the DRα construct was not transfected, with the only signal being in the positive 
control MelJuSo sample (Figure 5.9C, lane 1). From these experiments, it was concluded that it 
would be too challenging to investigate the role of TLR3 in the assembly and stability of HLA-
DR by reconstituting HLA-DR, DM and Ii in HT1080 cells by transfection. 
  





Figure 5.9. Transfection of the MHC class II system 
HT1080 cells were transfected with combinations of DRα, DRβ, Ii, DMα and DMβ or mock 
transfected and lysed in MNT buffer. Along with MelJuSo lysates, the HT1080 lysates were 
then subjected to non-reducing (NR) SDS-PAGE and subsequent Western blotting with the 
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5.2.4 Effect of homocysteine on MHC class II stability 
 
The previous chapters have shown that homocysteine increases the amount of OX1 Ero1α and 
may thus influence its activity, with implications for the oxidative protein folding and quality 
control of “client” proteins in the ER. Here, MHC class II is used to explore how the 
homocysteine-induced change in Ero1, and other potential changes in the ER may affect ER 
“client” proteins. As the stability of MHC class II is known to be temperature sensitive, with DR 
losing its dimer at 60 ⁰C, MelJuSo cells were treated with homocysteine to determine if this is 
another factor which causes changes in MHC class II stability (Figure 5.10). The cell lysates 
were analysed under boiling and non-boiling conditions; this means that they were subjected 
to boiling for 5 minutes following lysis. This acts as a control, confirming that the heavier band 
seen is the dimer.  
 
Although MHC class II heterodimers do not have inter-molecular disulphide-bonds, their 
assembly is still dependent on the correct formation of intra-molecular disulphide bonds. 
However, the stability of MHC class II dimers did not appear to change upon homocysteine 
treatment (Figure 5.10A and B, lanes 1, 2, 3 and 4). This result suggests that changes to the 
homocysteine-induced Ero1 oxidation state do not impact the stability of the overall MHC class 
II pool. It remains to be seen whether the ER redox state or Ero1 activity are required for the 
early stages of MHC class II monomer folding.   
 
Although there were no gross homocysteine-induced changed, the amount of MHC class II 
monomer (DR) increased slightly with homocysteine treatment under non-reducing conditions, 
with no, or very little monomer in untreated cells (Figure 5.10 A, lanes 1, 2, 3 and 4). Under 
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reducing conditions, the recovery of DR monomers was greater than that obtained under non-
reducing conditions. Lysates were probed with an αactin antibody as a control (Figure 5.10 C). 
 
Although the overall pool of stable DR heterodimers did not appear to be influenced by 
homocysteine, it remains possible that the peptide loading of DP and DQ allelic variants are 
influenced by homocysteine, and this may be worthy of further investigation in the future. 
 
  











Figure 5.10. Homocysteine does not affect the stability of the HLA-DR pool in MelJuso 
cells 
MelJuSo cells were treated with 0, 0.1, 1 or 10 mM HC for 1 hour then lysed in MNT 
buffer. Prior to analysis by non-reducing (NR) or reducing (R) SDS-PAGE and subsequent 
Western blotting, the lysates were boiled (+), or left at room temperature (-) for 5 
minutes. The antibodies 1B5 (A and B) or αactin (C) were used on the western blot. DR 
monomers (M) and dimers (D) are labelled.  
 




5.3 Discussion  
 
The MHC class II molecules, HLA-DR, DP, and DQ have different requirements for assembly, 
with DP able to form SDS-stable dimers in the absence of Ii (van Lith, 2010). The work in this 
chapter further builds upon this observation.  Here HLA-DR and DP are shown to have different 
stability thresholds not only, as previously shown, in the absence of Ii, but in its presence, with 
DP able to resist being denatured at a higher temperature than DR (Figure 5.2). DP and DR 
alleles on average show ~70% similarity to each other, so whether the differences in stability 
are due to structural differences between the molecules or a consequence of another factor 
stabilising the dimer remains open to question. 
 
Despite the requirement for Ii for targeting MHC class II molecules to the endosomal-
lysosomal compartments, without it some αβ complexes are folded and able to leave the ER. 
By comparing the localisation of the DP and DR molecules when the breakdown of Ii is 
inhibited, it would be possible to see how this occurs, and whether DP has an alternative 
pathway which may help account for its differential stability. The localisation of both DR and 
DP appeared similar, and further investigation into the lysosomal morphology also did not 
show any clear differences in the distribution of DR and DP (Figure 5.3 and 5.4). However these 
results do confirm the expected endosomal localisation of MHC class II molecules in general.  
 
There are conflicting views regarding the expression of TLR3, with it being suggested that TLR3 
is only found in DCs by some whilst others propose a much wider expression (Muzio et al., 
2000; Zarember, 2002). This is investigated in this chapter by testing four different cell types 
(Figure 5.5), none of which are DCs. With 3 out of 4 cell lines weakly expressing TLR3, 
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expression of this molecule may be wider than originally proposed, and it is not solely 
expressed in antigen presenting cells. This allows for exploration of the TLR-MHC class II 
interaction by transfecting MHC class II into cells where it is not endogenously expressed. 
Given a cell line which endogenously expresses both TLR3 and MHC class II it would have 
interesting to stain for these to see the co-localisation. It would also have been interesting to 
co-stain for TLR3, HLA-DP/DR and Ii in DC subtypes obtained from tissues, to see if and where 
the MHC class II molecules exist independently of Ii.  
 
The cell lines tested here only had low levels of TLR3 expression which most likely would not 
have been high enough to functionally analyse if the presence of MHC class II had an impact on 
the cells response to a foreign peptide. The expression of TLR3 failed to increase upon 
differentiation of immortalised THP1 monocytes to macrophages and ligand stimulation with 
LPS or Poly(I:C). Had the experiment proceeded, TLR3 could have been transfected into one of 
the cell lines tested here, or a higher expressing cell line could have been used for the 
experiment.   
 
In order to test whether the presence of TLR has an effect on MHC class II, a MHC class II 
transfected cell line was to be used. Although the transfection of all components necessary for 
a stably bound MHC class II dimer has been achieved in the past (van Lith, 2010), this was 
challenging for some cell lines and it was not possible here. This may be due to too many 
plasmids being co-transfected. It would not have been effective to transfect individual alleles 
into a cell line which naturally expresses MHC class II. This is because the transfection of MHC 
class II molecules would result in the overexpression of MHC class II, and because tagging the 
MHC class II molecule can adversely affect its localisation. It may however have been possible 
to use fibroblasts with knocked out MHC class II expression, providing these cells expressed 
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functional levels of DM and Ii. Another potential solution would have been to use a retroviral 
system to introduce the necessary genes into a cell line which does not express MHC class II. 
 
MHC class II has been shown to interact with a number of other molecules which can mediate 
its signalling at the cell membrane and intracellularly. An example of this is tetraspanins which 
associate with MHC class II at different cellular locations (Engering and Pieters, 2001). As MHC 
class II lacks any signalling motifs in its cytoplasmic tail it has been suggested that interactions 
with these molecules are used to initiate signalling (Hassan and Mourad, 2011). Little is known 
about how and where MHC class II molecules interact with other molecules to control 
signalling. It would therefore be interesting to investigate whether any of these signalling 
molecules preferentially interacted with different MHC class II isotypes or had stabilising or 
localising effects on MHC class II (Al-Daccak et al., 2004). 
 
An increasing amount of cross-talk between TLR and MHC class II is becoming apparent, with 
the TLR trafficking chaperone UNC93B1 shown to interfere with the MHC class II presentation 
pathway, and more recently, Ii shown to interact with, and negatively regulate TLR7 signalling 
(Manoury, 2015). How such a relationship affects its binding to MHC class II may be of note, 
but more importantly the increasing number of nodes between the pathways may have 
implications for MHC class II stability and trafficking.  
 
HLA-DP has been shown to present some ER protein-derived peptides on the cell surface; 
whether these peptides are loaded in the ER or are obtained at the cell surface, or during 
recycling is yet to be determined, and again may have implications for DP stability (Diaz et al., 
2005).   




The stability of the MHC class II dimer is indirectly reliant on disulphide bonds, as shown by the 
presence of dimers under both reducing and non-reducing conditions when samples are non-
boiled (Figure 5.10 A and B). However, intramolecular molecular disulphides are present. 
Under non-reducing, non-boiling conditions no, or very little monomer was seen in untreated 
cells (Figure 5.10 A lane 1), whereas it was clearly present in reducing conditions (Figure 5.10B, 
lane 1). The increase in MHC class II monomer seen with homocysteine treatment under non-
boiling, non-reducing conditions, suggests that disulphide bonds might be being broken. This 
may be because homocysteine is acting as a reducing agent, or it may be due to the change in 
OX1 of Ero1α. This could be further investigated with the use of an MHC class II antibody to 
detect if the change in MHC class II monomer concentration is due to a conformational change. 
The use of a constitutively active or dominant negative Ero1mutants may also help 
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6. Final Discussion  
 
Previous studies have shown a link between homocysteine and Ero1, with treatment of 
mammalian cells with homocysteine leading to an increase in the Ero1 OX1 form (Battle et al., 
2013). These experiments were carried out using the oesophageal cell line, OE33, which has 
high levels of Ero1α expression and are derived from a cellular location in which the cells will 
have been exposed to, and may respond to, fluctuating dietary factors by changing the poise 
of the oxidative folding machinery. This thesis has further characterised the relationship 
between homocysteine and Ero1 proteins, finding that the effect of homocysteine is not 
restricted to Ero1α in the OE33 cell line. Millimolar concentrations of homocysteine were 
found to have the same effect of increasing the amount of “OX1-like” Ero1β when cell lines are 
transfected with Ero1β (Figures 4.3 and 4.5), but not in pancreatic cells. 
 
Ero1α with mutated cysteine residues, namely those which form structural or functional 
disulphide bonds, were also used to explore where in the Ero1α redox cycle homocysteine was 
having its reducing effect, and if OX1 still increased when regulatory disulphides were removed. 
Despite the mutants existing in different OX1:OX2 ratios when untreated all, except the 
constituently active C104A/C131A, are pushed into a lower mobility state following 
homocysteine treatment. As some of the other mutants tested (C391A, C394A/C397A and 
C391A/C394A/C397A) may lack certain structures or may lack active site cysteines, these 
results show that the effect of homocysteine is not reliant on the complete 3D structure of 
Ero1α, nor on the complete transfer of electrons. As the increase in OX1 is not impaired by the 
loss of these cysteine residues, it is likely that homocysteine is not having a direct reducing 
effect on them. The effect is likely to be indirect, as supported by experiments in which 
incubation of purified Ero1α protein with mM concentrations of homocysteine showed no 
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change in Ero1α activity (unpublished work, personal communication, Bulleid laboratory). Thus 
homocysteine is likely to work through an intermediate, or indirect, pathway. 
 
Although GSH is a poor substrate for Ero1, an equilibrium is maintained between the redox 
states of Ero1 and GSH, with GSH maintaining the redox state of PDI to ensure efficient 
isomerization of non-native disulphide bonds (Chakravarthi and Bulleid, 2004; Molteni et al., 
2004). Homocysteine could act through GSH by altering its levels, thus causing a redox 
imbalance with Ero1. It would be interesting to measure any change in GSSG:GSH ratio upon 
homocysteine treatment to determine if it is buffering the effects of the active Ero1, or if 
Ero1 is responding to changes in the redox environment. 
 
This study also provides evidence that homocysteine stimulates a modification of Ero1. When 
cells are treated with homocysteine, the monoclonal antibody 2G4 is unable to detect Ero1α 
(Figure 3.3-3.5). This cannot be due to the changes in disulphide bonds stimulated by 
homocysteine treatment, as whilst the 2G4 detects Ero1α when fully reduced, it does not 
when Ero1α has been treated with 10 mM homocysteine. Therefore a modification to the 
antibody epitope is likely to be preventing the binding of 2G4. The modification to Ero1α by 
homocysteine was observed in the HT1080, HeLa and OE33 cell lines, however not in the liver 
tissue (Figure 3.3, 3.14 and 4.6). It is difficult to be certain what the modification could be as 
the 2G4 antibody epitope, whose signal is lost upon homocysteine treatment, has not been 
mapped. Given this information, or by using truncation mutants to map the epitope, it would 
be possible to identify where the modification is happening, which may give clues as to the 
type of modification and whether it is a direct effect of homocysteine, whether it is through 
another molecule (e.g glutathionylation or nitrosylation) or whether is it caused by changes in 
the ER, for example changes in the redox equilibrium. With this information it may also be 
possible to determine if the same modification occurs in Ero1β. If so, it may be possible to 
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understand the structural basis of the homocysteine modified form and whether it is the same 
as the active OX1 form. It is possible that the modification affects Ero1 function. This could be 
tested by site-directed mutagenesis of the modified residue, comparing the changes in 
oxidative folding capacity upon ER redox and ER stress induction in Ero1 transfectants and in 
the activity of purified Ero1 mutant proteins in vitro.  
 
Induction of Ero1α OX1 by homocysteine was observed in multiple cell lines. In some of these 
experiments, Ero1α was strongly expressed by transfection, which has the potential to 
increase the production of ROS (Harding et al., 2003). This can be counteracted by activation of 
the UPR resulting in increased glutathione synthesis and thus higher antioxidant capacity 
(Appenzeller-Herzog et al., 2008), however the expression levels of Ero1α and Ero1β in some 
tissues are as high, or higher, than those in the transfectants. To check whether the 
transfections result in UPR, RT-PCR could be utilised to see if XBP1 is activated, or whether 
stress chaperones like BiP are induced.  
 
The OX1:OX2 ratio differs between cell lines, as does their folding capacity and ability to 
respond to cellular stress; for example, Ero1α exists almost entirely in the OX2 form in the 
HT1080 cell line, whereas in the THP-1 cell line, although there is still a higher proportion of 
OX2, a significant amount of OX1 exists (Benham et al., 2013). However, these differences 
between cell lines do not appear to affect the ability of homocysteine to increase the amount 
of Ero1α OX1. To understand how Eros behaved in a system more representative of the in vivo 
environment, tissue derived cells were used (Figures 4.6 and 4.7). Ero1OX1-like induction by 
homocysteine was seen in liver cells, however the same was not seen in Ero1β from pancreatic 
tissue cells. This may suggest that certain cells have a different redox poise, regulatory 
environment or different levels of Ero1 control to protect them from homocysteine. As Ero1β 
is not induced by hypoxia, this may indicate that it is not as vulnerable as Ero1α to changes in 
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the redox environment of the ER. To test if Ero1β would be more vulnerable to homocysteine 
when there are larger changes in the redox environment, the pancreas cells could be exposed 
to hypoxic conditions in a hypoxia chamber, or treated with peroxide, prior to homocysteine 
treatment.   
 
As the pancreas has a high level of Ero1β expression and a high secretory output, greater levels 
of homocysteine may be needed to influence Ero1β and the redox conditions. The high 
expression may also indicate that although Ero1 is physiologically required in cells with high 
secretory output, it may not solely function as a UPR responsive gene. Why do some cells 
possess high levels of inactive Ero1 (e.g. pancreas) and Ero1 (e.g. liver) when, under stress, 
cells respond by increasing transcription of these genes rather than activating the protein pool? 
Perhaps a high threshold of protein concentration is needed for it to be pushed into the active 
version, but it has also been suggested that inactive Ero1 may possess another function as a 
chaperone complex or client protein complex (Dias-Gunasekara, 2005). 
 
The proposed looser regulation of Ero1 (Wang et al., 2011) may also explain to the lack of 
change in Ero1β in tissue derived pancreas cells. With looser regulation, and thus being more 
active, Ero1β would be expected to produce more ROS than Ero1α. The main off setters of ROS 
production are GPx8 and PrxIV, however there is some evidence that GPx8 is functionally 
coupled to Ero1α and knock down of PrxIV does not cause the same elevation of the UPR as 
with GPx8 knockdown suggesting functional separation (Ramming et al., 2014). Little is known 
about the differences in how H2O2 produced by Ero1α and Ero1β are offset, and whether 
Ero1β is coupled in the same way. If H2O2 production is also increased by homocysteine 
treatment, there may be differences in the ability of Ero1α and Ero1β to deal with it, perhaps 
through differences in the interactions with the GPx/PrdxIV detoxification machinery. 




Ero1β expression has not been detected in any immortalised cell lines. Ero1β is constitutively 
expressed in pancreatic cells, however the pancreas is composed of a number of specialised 
cell types with specialist secretory functions and of these, Ero1β expression has been shown in 
islet cells. Ero1β expression is not found in the pancreatic cell line PANC1. This could be 
because the cell line is epithelial thus its main function is not secretion, or because in vivo 
factors required for the induction of Ero1β expression are absent in cell culture. Nevertheless, 
transfection of Ero1β into pancreas-derived cell such as PANC1 and the insulin secreting rat 
INS-1 line may help determine whether the lack of homocysteine effect in pancreatic tissue is 
due to pancreas-specific factors, or the metabolic environment. 
 
High levels of homocysteine have been reported to induce oxidative stress and increase 
generation of ROS, with increased levels of ATF6, XBP-1 and PERK (Yang, 2014). This study also 
shows that this stress is mediated, at least in part, by Ero1α, with the UPR response attenuated 
with over expression of Ero1α and increased when Ero1α is knocked out. When these results 
are compared with the homocysteine induced increase in Ero1α OX1 seen in this thesis, it 
seems that the increase in OX1 may be a response to the increase oxidative stress. However 
these experiments would need to be tied together and could be done by a pulse-chase 
metabolic labelling experiment to see if homocysteine treatment results in changes in UPR-
induced protein translation.  
 
It would also be interesting to see how other chemical inducers of ER oxidative stress change 
the Ero1 OX1:OX2 balance. If they do not induce the same increase in OX1, yet homocysteine 
treatment results increased OX1 and a UPR, then it is possible that homocysteine is not 
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increasing OX1 via a stress response, but the increase in OX1 results in a stress response. This 
would be similar to the UPR induced by the constitutively active Ero1α mutant (Hansen, 2012). 
 
The UPR described as a result of homocysteine would be expected to increase Ero1 expression. 
It is difficult to say if such a change is seen in this study; a more suitable method for 
quantifying expression, such as quantitative RT-PCR, would be required to determine this. 
Whether the increased Ero1 expression would impact the Ero1 OX1:OX2 ratio is unknown.  
 
The OX1:OX2 ratio of Ero1 present in the ER is generally determined by the redox equilibrium 
of the ER, whereas stress, for example UPR and hypoxia, causes changes in transcription. Thus 
it would seem that homocysteine increases OX1 by causing changes in the redox equilibrium.  
Alternatively, homocysteine could directly push the ER redox balance towards a more reducing 
state. PDI could potentially directly oxidise homocysteine into its oxidised form, homocystine, 
pushing Ero1 into its OX1 form. This may also provide an explanation as to why homocysteine 
does not affect Ero1 in all cells, as seen with Ero1β in pancreatic cells. As Ero1β interacts with 
different PDI family members, for example in the pancreas Ero1 interacts with PDIp (Fu et al., 
2009), certain partners of Ero1β may not be as sensitive to homocysteine. If homocysteine 
were oxidised by PDI, and different PDI family members differed in their sensitivity to 
homocysteine, there could be knock on effects on Ero1β. 
 
Patients with hyperhomocysteinemia and homocystinuria have defects in their homocysteine 
metabolism pathways which leads to a build-up of plasma homocysteine, and results in 
millimolar concentrations of circulating homocysteine (Faraci and Lentz, 2004). The 
detrimental effects of homocysteine can be reduced by increasing the amount of vitamin B in 
the diet (Elanchezhian et al., 2012), however further characterisation of how metabolic defects 
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of homocysteine metabolism influence the regulation of disulphide bond formation in diseases 
with a redox imbalance is required. Such studies may provide further information about 
targets for drug development and biomarkers for diseases with an oxidative folding 
component. 
 
Having looked at the Ero1 PDI partnership, a client protein was looked at in chapter 5. 
Following the investigation of the effect of homocysteine on Ero1, here homocysteine was 
shown not to have a direct effect on MHC class II molecules (Figure 5.10). Despite this, further 
experiments are required to determine whether homocysteine has any subtle effects. A pulse 
chase analysis of MHC class II with and without homocysteine would establish whether 
homocysteine has an impact of MHC class II assembly.  
 
MHC class II was further investigated, finding that the DP dimer is able to resist being 
denatured at higher temperatures than DR, despite appearing to have the same localisation 
(Figure 5.2-5.4). This builds upon previous studies showing that the MHC haplotypes DR, DP 
and DQ have different requirements to form stable dimers (van Lith, 2010). 
 
It was not possible to determine whether the TLR pathway influences the hetero-dimerisation 
or stability of a specific MHC class II isotype (Figure 5.4-5.9, Chapter 5).  The interaction 
between MHC class II and TLR3 via CD40 has been shown in mice (Liu et al., 2011) but is 
relatively uncharacterised and many other questions remain unanswered, such as whether 
CD40 binds to MHC class II directly in humans, as well as how CD40 is trafficked to the 
endosomes; this could be dependent on its binding to MHC class II. A stable interaction 
between MHC class II and CD40 has also been found in other cells or subcellular compartments, 
for example in tonsillar B cells where they associate after stimulation of either molecule, which 
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could provide another system in which the interaction could also be investigated (Leveille et al., 
1999). 
 
 Homocysteine does not seem to affect MHC class II stability (Figure 5.10), however further 
knowledge as to how homocysteine affects the clients of the oxidative folding machinery, as 
well as the impact of an increased Ero1 OX1 level, is required to predict how other proteins, 
including PDI substrates, respond to homocysteine. Oxidative folding is important for the 
folding of MHC class II molecules, with the β chain containing two long range disulphides and 
the α chain containing one. Although it is known that MHC class II molecules interact with the 
ER resident chaperones calnexin, ERp72 and GRP94 during early folding and assembly 
(Anderson 1994, Arunachalam 1995, Schaiff 1992), less is known about the formation of the 
disulphides. In HLA-DM, the individual chains direct the oxidation of the partner chain, with 
DMα preventing misoxidation of DMβ whose own disulphides are required for correct 
oxidation of DMα (Van Lith, 2006). With these intrinsic properties determining oxidative 
folding, rather than the ER oxidation machinery, and with high sequence homology between 
the MHC class II family members, this may have implications for the folding of the classical 
MHC class II molecules, with the potential of oxidative folding redundancy here too. The DM 
folding mechanism, and the presence of an extra disulphide that allows DM to form a stable 
heterodimer able to leave the ER without a bound peptide, which is required by the classical 
molecules (van Lith and Benham, 2006), may make it more susceptible to changes in the 
oxidative folding environment. DPβ contains an extra cysteine residue, and a disulphide linked 
DPαβ has been shown to exist. Although the extra disulphide bond does not account for its 
stability (van Lith, 2010), it may have implications for its folding mechanism; whether DP 
alleles perform more like DM, with its extra disulphide, or whether the free cysteine allows for 
an interaction with oxidoreductases remains to be established.  
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Ero1α has been shown to be important in the folding of MHC class I, with Ero1α binding non-
covalently to calnexin, which has an association with the MHC class I heavy chain. PDI has been 
suggested to mediate the formation of disulphides in the MHC class I heavy chain (Cho et al., 
2011; Kukita et al., 2015). When Ero1α is overexpressed, the amount of oxidized MHC class I 
heavy chain increases (Kukita et al., 2015). This has implications for cancers where Ero1α 
expression is increased during hypoxia, and studies show that low MHC class I is associated 
with poor prognosis of osteosarcoma (Tsukahara et al., 2006).  
 
Although little is known about how disulphide bonds are formed, and which oxidoreductases 
are involved in the early stages of the MHC class II pathway, more is known about the later 
stages.  Gamma-interferon-inducible lysosomal thiol reductase (GILT), the only thiol reductase 
known to exist in the lysosome and able to function at low pH, is related to the thioredoxin 
family of oxidoreductases (Arunachalam et al., 2000). GILT reduces disulphide containing 
antigens, allowing their presentation by MHC class II (Maric et al., 2001). GILT also regulates 
the function of cathepsin S, one of the proteases that cleaves Ii and large polypeptides for 
MHC class II presentation. GILT has been shown to both assist the degradation of cathepsin S 
and maintain its proteolytic activity. These roles seem to oppose each other, so more needs to 
be known regarding these how these processes function, and how the outcome is determined, 
before it is possible to say how they affect antigen presentation (Balce et al., 2014; Phipps-
Yonas et al., 2013). GILT levels are another factor believed to relate to cancer prognosis, with 
low levels associated with poor survival in patients with diffuse large B-cell lymphoma (DLBCL). 
Antigen processing is vital for producing tumour-specific epitopes, which can be presented by 
MHC class II, thus a decreased GILT expression diminishes presentation of tumour antigens and 
the resulting T cell mediated anti-tumour response. The loss of GILT expression in patients with 
DLBCL may represent a form of immune evasion (Phipps-Yonas et al., 2013). The known 
functions of GILT are becoming more diverse. One recent development is GILTs involvement in 
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the regulation of the cellular redox state. In the absence of GILT the proportion of oxidised 
GSH increases resulting in oxidative stress (Chiang and Maric, 2011). 
 
DP could be interacting with one of a number of molecules, and as DP is found at the cell 
surface with ER protein derived peptides, it is clear that DP is able to bind peptides in the ER, 
with the possibility that these are stabilising DP. With a peptide binding motif which is 
different to that of ER loaded MHC class I molecules, MHC class I and DP will not compete for 
the same peptides, but it is unclear whether these DP binding ER peptides are competing with 
Ii (Diaz et al., 2005). 
 
Whilst there is still much to be discovered about the oxidative folding of MHC class II 
molecules, there is potential for differences in folding pathways to exist between the isotypes, 
as well as interactions between these molecules and oxidoreductases. The interaction 
between MHC class II and CD40 recently described in the literature also presents another 
potential stabilising relationship, which has been studied here and provides a groundwork for 
further investigation. 
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